



Beyond Medications and Diet: Alternative Approaches to Lowering Blood Pressure: A Scientific Statement From the American Heart Association Robert D. Brook, Lawrence J. Appel, Melvyn Rubenfire, Gbenga Ogedegbe, John D.

Bisognano, William J. Elliott, Flavio D. Fuchs, Joel W. Hughes, Daniel T. Lackland, Beth A. Staffileno, Raymond R. Townsend and Sanjay Rajagopalan on behalf of the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity and Metabolism

 Hypertension. 2013;61:1360-1383; originally published online April 22, 2013; doi: 10.1161/HYP.0b013e318293645f
 Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2013 American Heart Association, Inc. All rights reserved. Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://hyper.ahajournals.org/content/61/6/1360

Data Supplement (unedited) at:

http://hyper.ahajournals.org/content/suppl/2013/04/22/HYP.0b013e318293645f.DC1.html http://hyper.ahajournals.org/content/suppl/2013/04/22/HYP.0b013e318293645f.DC2.html

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at: http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Hypertension* is online at: http://hyper.ahajournals.org//subscriptions/

Beyond Medications and Diet: Alternative Approaches to Lowering Blood Pressure

A Scientific Statement From the American Heart Association

Robert D. Brook, MD, Chair; Lawrence J. Appel, MD, MPH, FAHA, Co-Chair; Melvyn Rubenfire, MD, FAHA; Gbenga Ogedegbe, MD, MPH; John D. Bisognano, MD, PhD; William J. Elliott, MD, PhD, FAHA; Flavio D. Fuchs, MD, PhD; Joel W. Hughes, PhD; Daniel T. Lackland, DrPH, MSPH, FAHA; Beth A. Staffileno, PhD, FAHA; Raymond R. Townsend, MD, FAHA; Sanjay Rajagopalan, MD; on behalf of the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity and Metabolism

Abstract—Many antihypertensive medications and lifestyle changes are proven to reduce blood pressure. Over the past few decades, numerous additional modalities have been evaluated in regard to their potential blood pressure-lowering abilities. However, these nondietary, nondrug treatments, collectively called alternative approaches, have generally undergone fewer and less rigorous trials. This American Heart Association scientific statement aims to summarize the blood pressure-lowering efficacy of several alternative approaches and to provide a class of recommendation for their implementation in clinical practice based on the available level of evidence from the published literature. Among behavioral therapies, Transcendental Meditation (Class IIB, Level of Evidence B), other meditation techniques (Class III, Level of Evidence C), yoga (Class III, Level of Evidence C), other relaxation therapies (Class III, Level of Evidence B), and biofeedback approaches (Class IIB, Level of Evidence B) generally had modest, mixed, or no consistent evidence demonstrating their efficacy. Between the noninvasive procedures and devices evaluated, device-guided breathing (Class IIA, Level of Evidence B) had greater support than acupuncture (Class III, Level of Evidence B). Exercise-based regimens, including aerobic (Class I, Level of Evidence A), dynamic resistance (Class IIA, Level of Evidence B), and isometric handgrip (Class IIB, Level of Evidence C) modalities, had relatively stronger supporting evidence. It is the consensus of the writing group that it is reasonable for all individuals with blood pressure levels >120/80 mmHg to consider trials of alternative approaches as adjuvant methods to help lower blood pressure when clinically appropriate. A suggested management algorithm is provided, along with recommendations for prioritizing the use of the individual approaches in clinical practice based on their level of evidence for blood pressure lowering, risk-to-benefit ratio, potential ancillary health benefits, and practicality in a real-world setting. Finally, recommendations for future research priorities are outlined. (Hypertension. 2013;61:1360-1383.)

Key Words: AHA Scientific Statement ■ blood pressure ■ cardiovascular diseases ■ complementary therapies ■ hypertension ■ prehypertension ■ preventive medicine

Hypertension is available at http://hyper.ahajournals.org

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on March 1, 2013. A copy of the document is available at http://my.americanheart.org/statements by selecting either the "By Topic" link or the "By Publication Date" link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, Fuchs FD, Hughes JW, Lackland DT, Staffileno BA, Townsend RR, Rajagopalan S; on behalf of the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity and Metabolism. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. *Hypertension*. 2013;61:1360–1383.

The online-only Data Supplement—Methods and Results is available with this article at http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYP.0b013e318293645f/-/DC1.

The online-only Data Supplement—References is available with this article at http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYP.0b013e318293645f/-/DC2.

Expert peer review of AHA Scientific Statements is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit http://my.americanheart.org/statements and select the "Policies and Development" link.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright-Permission-Guidelines_UCM_300404_Article.jsp. A link to the "Copyright Permissions Request Form" appears on the right side of the page.

^{© 2013} American Heart Association, Inc.

Hypertension is one of the most common disorders, affecting $\approx 26.4\%$ of the adult population worldwide. It ranks as the leading chronic risk factor for mortality, accounting for 13.5% of all deaths.^{1,2} Moreover, its prevalence is projected to grow to affect >1.5 billion people by 2025.^{1,2} Half of all strokes and ischemic heart disease events are attributable to high blood pressure (BP).^{1,2} Given the monotonic relationship between cardiovascular events and BP even down to optimal levels (115/75 mmHg), the global hypertension-related public health burden is enormous.³

An important component of the overall strategy to prevent the adverse health consequences of hypertension is the recommendation promulgated by formal guidelines for individuals to adopt lifestyle changes that reduce BP.4-6 Proven approaches promoted by the guidelines include weight loss, reduced sodium intake, adoption of a Dietary Approaches to Lower Hypertension-style eating pattern, aerobic exercise for 30 minutes on most days per week, and moderation of alcohol intake.7-10 In this regard, the American Heart Association (AHA) published a scientific statement in 2006 outlining these dietary approaches to treat and prevent hypertension.¹¹ These strategies were later endorsed by the American Society of Hypertension.¹² Given the high prevalence of BP levels above optimal¹³ and the 90% lifetime risk for developing hypertension among middle-aged adults with normal blood pressure,14 these dietary recommendations apply not only to individuals with hypertension but also to individuals with prehypertension and to a large portion of the general populace.

Aims and Rationale

Beyond dietary strategies, certain additional nonpharmacological treatments may have the capacity to lower BP.9,15,16 For the purposes of this scientific statement, these therapies are called alternative approaches and are broadly classified into 3 categories: behavioral therapies, noninvasive procedures or devices, and exercise-based regimens. There are several reasons why these strategies are likely to become increasingly important and commonly used tools in the management of high BP. First, adherence to dietary strategies has often been shown to be difficult to maintain.^{13,17} Some of the alternative approaches outlined in this document may in theory be more readily adopted and thus serve as practical adjuvants to help lower BP. However, it is recognized that long-term effectiveness and adherence have not been established for most of these approaches, and the degree to which they are adopted when recommended by physicians will likely vary among individuals and approaches.18 Second, many of these alternative approaches may represent viable methods to help treat prehypertension. There is growing evidence that prehypertension not only predicts an increased risk for the development of hypertension but also confers an increased risk for cardiovascular events.^{19,20} Given the paucity of evidence supporting the cost-effectiveness of pharmacological therapy,^{21,22} these approaches may represent practical options for some individuals with prehypertension. Third, in accordance with guidelines, healthcare providers may offer a trial of nonpharmacological interventions (including alternative modalities) as part of the initial treatment of stage I hypertension among individuals wishing to avoid or delay drug therapy when clinically appropriate.⁴ Fourth, there is an increasing prevalence of resistant hypertension.²³ Combination strategies incorporating these alternative approaches might be helpful to achieve BP control among individuals with resistant hypertension. Fifth, most of the reviewed alternative approaches pose little to no side effects and could thus represent acceptable options for individuals with multiple medication intolerances. Finally, despite numerous efforts for the nationwide promulgation of healthy lifestyles, the number of individuals with hypertension in the United States continues to grow, most recently estimated at 29% of adults.¹³ Alternative approaches represent adjuvant nonpharmacological modalities to help combat this prevalent and expensive disorder.

At present, most of these benefits remain hypothetical because they have yet to be directly tested. Furthermore, many of the published studies assessing alternative approaches have been observational in nature. Even among published randomized trials, methodological weaknesses, including inadequate randomization methods and the inclusion of suboptimal control groups, small sample sizes, and brief follow-up durations (eg, 3-6 months), are common. Other prevalent limitations include selection, proficiency, compliance, and cointervention biases. The lack of inclusion of home or ambulatory BP monitoring (ABPM) outcomes in many studies is also a significant shortcoming. Finally, with few exceptions, there is a paucity of outcome trials demonstrating that these alternative approaches are capable of reducing hard cardiovascular events. On the other hand, most currently recommended nonpharmacological interventions (eg, exercise, smoking cessation) have not undergone rigorous testing among outcome trials; hence, this may be an unrealistic standard before the use of alternative approaches is recommended specifically for BP lowering, provided that they are efficacious in this regard and generally safe.

Regardless of these limitations, the major justification for this review is the plausibility that these treatments could offer substantive public health benefits provided that they indeed effectively reduce BP. BP lowering per se is acknowledged as an accepted surrogate marker that reliably predicts the cardiovascular health benefits of an intervention so long as it is not offset by other treatment-related risks.^{24,25} Apart from the small risk of developing worse hypertension by delaying medical treatment as seen in a few trials, most alternative approaches pose little direct health risks. Therefore, the principal objective of this scientific statement is to provide an up-to-date assessment of the evidence supporting the BP-lowering efficacy of several alternative approaches. Although some of these treatments have been reviewed on an individual basis, our aim is to provide a comprehensive summary for healthcare providers within a single document. Although some of the therapies (eg, exercise, yoga, meditation, and acupuncture) also have the potential to provide health or psychological benefits beyond BP lowering, these outcomes are beyond the scope of this document. The second goal is to provide practical recommendations for incorporating these modalities into clinical practice on the basis of the currently available published trial evidence. Finally, suggested future research priorities are outlined.

Methods and Evidence Review

An initial online review of the English language literature was performed with PubMed that included alternative BP-lowering approaches and excluded orally active agents such as dietary changes, complementary therapies, herbs, and novel medications. The writing group then classified the approaches into 3 broad categories: behavioral therapies, including meditation techniques, yoga, biofeedback, and relaxation or stress-reduction programs; noninvasive procedures or devices, including device-guided breathing modulation and acupuncture; and exercise-based regimens, including aerobic, resistance, and isometric exercise methods. The initial search identified a meta-analysis or comprehensive review for each topic that was published within the past 6 years. A systematic literature search limited to human studies and the English language was next performed in PubMed for publications between January 1, 2006, and October 31, 2011, for each of the above methodologies in relation to BP. These systematic searches were done to identify important studies published shortly before or after the most recent meta-analyses or review. This yielded 124, 105, and 773 publications for behavioral therapies, noninvasive procedures and devices, and exercise-based regimens, respectively. The complete list of publications is available

	CLASS I Benefit >>> Risk Procedure/Treatment SHOULD be performed/ administered	CLASS IIa Benefit >> Risk Additional studies with focused objectives needed IT IS REASONABLE to per- form procedure/administer treatment	CLASS IIb Benefit ≥ Risk Additional studies with broad objectives needed; additional registry data would be helpful Procedure/Treatment MAY BE CONSIDERED		arm dure/ Treatment No Proven Benefit s Cost Harmful enefit to Patients
LEVEL A Multiple populations evaluated* Data derived from multiple randomized clinical trials or meta-analyses	 Recommendation that procedure or treatment is useful/effective Sufficient evidence from multiple randomized trials or meta-analyses 	 Recommendation in favor of treatment or procedure being useful/effective Some conflicting evidence from multiple randomized trials or meta-analyses 	Recommendation's usefulness/efficacy less well established Greater conflicting evidence from multiple randomized trials or meta-analyses	 Recommendation that procedure or treatment is not useful/effective and may be harmful Sufficient evidence from multiple randomized trials or meta-analyses Recommendation that procedure or treatment is not useful/effective and may be harmful Evidence from single randomized trial or nonrandomized studies 	
LEVEL B Limited populations evaluated* Data derived from a single randomized trial or nonrandomized studies	 Recommendation that procedure or treatment is useful/effective Evidence from single randomized trial or nonrandomized studies 	 Recommendation in favor of treatment or procedure being useful/effective Some conflicting evidence from single randomized trial or nonrandomized studies 	 Recommendation's usefulness/efficacy less well established Greater conflicting evidence from single randomized trial or nonrandomized studies 		
LEVEL C Very limited populations evaluated* Only consensus opinion of experts, case studies, or standard of care	 Recommendation that procedure or treatment is useful/effective Only expert opinion, case studies, or standard of care 	 Recommendation in favor of treatment or procedure being useful/effective Only diverging expert opinion, case studies, or standard of care 	 Recommendation's usefulness/efficacy less well established Only diverging expert opinion, case studies, or standard of care 	 Recommendation that procedure or treatment is not useful/effective and may be harmful Only expert opinion, case studies, or standard of care 	
Suggested phrases for writing recommendations	should is recommended is indicated is useful/effective/beneficial	is reasonable can be useful/effective/beneficial is probably recommended or indicated	may/might be considered may/might be reasonable usefulness/effectiveness is unknown/unclear/uncertain or not well established	COR III: No Benefit is not recommended is not indicated	COR III: Harm potentially harmful causes harm
Comparative effectiveness phrases*	treatment/strategy A is recommended/indicated in preference to treatment B treatment A should be chosen over treatment B	treatment/strategy A is probably recommended/indicated in preference to treatment B it is reasonable to choose treatment A over treatment B		should not be performed/ administered/ other is not useful/ beneficial/	associated wi excess morbi ity/mortality should not be performed/ administered/

Table 1. Applying Classification of Recommendations and Level of Evidence

A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.

*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use.

+For comparative effectiveness recommendations (Class I and Ila; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.

in the online-only Data Supplement-References. Each systematic search was conducted with the assistance of a medical librarian and used relevant keywords and medical subject headings. The details of the search strategies and terms are available in the online-only Data Supplement— Methods and Results. Some studies published in 2012 and/ or identified from the references of other publications were added during the process of writing the scientific statement. All identified publications were then reviewed by members of the writing committee. Each treatment approach was evaluated in terms of its BP-lowering efficacy as the main outcome. The safety of each methodology and the efficacy within specific subgroups (eg, individuals with prehypertension) were also evaluated when germane information was available. The individual approaches were then assigned an official level of evidence (LOE) and class of recommendation (COR) per AHA guideline criteria based on the expert opinion of the writing group members (http://www.heart. org/HEARTORG/) (Table 1).26 During this decision process, emphasis was given to the findings from the most recent high-quality systematic meta-analyses, which also included studies published before the start date of the systematic review. Next, identified studies published after the latest meta-analysis were individually assessed. Their findings were evaluated to assess whether they substantially added to the overall level of data supporting the efficacy of each approach. Randomized, controlled clinical trials in which outcomes were assessed in a blinded fashion were given the most weight in the decision processes.

Organization of the Writing Group

Writing group members were nominated so that the writing group could comprise healthcare providers and scientists with a breadth of expertise in the fields of clinical hypertension, cardiology, exercise physiology, cardiac rehabilitation, and dietary-lifestyle treatments for cardiovascular disease prevention and hypertension management. The members were selected by the co-chairs of the writing group and by the AHA Manuscript Oversight Committee. The Manuscript Oversight Committee also provided formal approval of the final roster and of the scientific statement outline.

Scope of the Guidelines

This scientific statement does not represent a meta-analysis of all published studies for each alternative BP-lowering modality. Rather, the focus is to perform a review of the evidence supporting the BP-lowering efficacy of each treatment and to provide an LOE and a COR for each approach.²⁶ A secondary goal is to provide expert opinion–based recommendations for the implementation of these approaches within clinical practice for the management of high BP. A systemic review of the numerous additional alternative approaches, including dietary treatments (eg, herbs, nutraceuticals), is beyond the scope of this document. Procedures that are currently experimental and treatments that apply only to select subgroups of individuals underwent an abbreviated nonsystematic review.

Behavioral Therapies

Several alternative approaches can be categorized within the framework of behavioral therapies. Although these methods vary considerably, the techniques included in this scientific statement have been studied in terms of their BP-lowering potential either as a primary trial outcome or as an ancillary health benefit. An intrinsic difficulty in interpreting the results of behavioral interventions is that many represent a combination of several individual approaches (eg, relaxation plus meditation and/or deep breathing). Thus, the separation of these techniques into individual methods is somewhat artificial and must be recognized as a limitation. We have, whenever possible, included techniques that were the predominant intervention and acknowledged whether they included additional methods when relevant. Another limitation of some of the randomized studies is the difficulty in assigning an appropriate control intervention.

Meditation Techniques

Meditation has been part of human societies in various forms for thousands of years. The optimal manner to categorize the myriad techniques is open to opinion. It should be emphasized that their origins typically relate to endeavors to improve awareness or consciousness and have little to do with the treatment of hypertension. In the limited context of this review, we have divided practices into focused attention (ie, mantra and training awareness); Transcendental Meditation (TM), a technique to transcend thought and to experience pure awareness, typically by employing specific mantras; and contemplative forms (eg, Zen and mindfulness), including the Mindfulness-Based Stress Reduction (MBSR) program.²⁷⁻³⁰ Further details are found in the **online-only Data Supplement—Methods and Results**.

Meta-Analyses or Reviews

The Healthcare Research and Quality report published an evidence-based document on meditation practices for health in 2007.³¹ The University of Alberta Evidence-Based Practice Center was commissioned to prepare the report. It was requested and funded by the National Center for Complementary and Alternative Medicine and included published studies through 2005. For hypertension, 5 trials of TM, 2 trials of Zen meditation, and 2 other trials of meditation without a clear description (which were not included in the meta-analysis) were reviewed. Only 2 trials (both of TM) were considered to be of high methodological quality. The studies of TM had sample sizes ranging from 37 to 106 and were medium- to long-term interventions (≥ 3 months). TM was found to be superior to progressive muscle relaxation with respect to reductions in systolic (-4.30 mmHg; 95% confidence interval [CI], -6.02 to -0.57) and diastolic (-3.11 mmHg; 95% CI, -5.00 to -1.22) BP but not to health education (systolic BP, -1.10 mm Hg; 95% CI, -5.24 to 3.04; diastolic BP, -0.58 mmHg; 95% CI, -4.22 to 3.06). Compared with repeated measurement of BP ("BP checks"), Zen meditation was found to produce reductions in diastolic BP (-6.08 mmHg; 95% CI, -11.68 to -0.48) but not systolic BP (-3.67 mm Hg; 95% CI, -9.04 to 1.70). For healthy individuals, 3 studies of TM were found for inclusion in a meta-analysis of TM compared

with no treatment. TM was not associated with greater systolic (0.93 mmHg; 95% CI, -9.53 to 11.39) or diastolic (-1.63 mmHg; 95% CI, -8.01 to 4.75) BP reductions.

Since the Healthcare Research and Quality report, 2 additional meta-analyses evaluating the effects of TM on BP have been published.32,33 They criticized the Healthcare Research and Quality report on several methodological grounds. Many of the studies included in both meta-analyses overlapped. In addition, numerous individual studies were ultimately not included in the final statistical analyses because of poor quality. The meta-analysis published in 2007 comparing TM with attention control included 6 randomized, controlled trials of at least 8 weeks' duration that were thought to be well designed with a total of 449 individuals. TM was associated with significant reductions in both systolic (-5 mmHg; 95% CI, -7.6 to 2.3) and diastolic (-2.8 mm Hg; 95% CI, -5.0 to -0.5) BP.33 A separate meta-analysis published in 2008 included 9 randomized, controlled trials suitable for analysis (367 individuals in active and 344 in control groups). It compared TM with health education (7 studies), relaxation (1 study), or no treatment (1 study).³² The studies varied in duration from 8 to 52 weeks (median, 15 weeks) and included individuals with normal blood pressure (n=3), with prehypertension (n=2), and with overt hypertension (n=4). For all studies, the outcomes were clinic-measured BP averages. TM was associated with significant reductions in both systolic (-4.7 mmHg; 95% CI, -1.9 to -7.4) and diastolic (-3.2 mm Hg; 95% CI, -1.3 to -5.4) BP compared with control arms. Similar reductions were reported for individuals with hypertension and individuals with normal blood pressure.

Recent Trials

A recent trial of TM randomized 298 university students with normal blood pressure to TM or wait-list control. The trial was a single-blind study; the primary outcome was clinic BP. Students randomized to TM did not have a reduction in BP unless they were deemed to be at high risk for hypertension (ie, body mass index >25 kg/m², BP >130/85 mm Hg, and/or a self-reported family history of hypertension).³⁴ The effect of TM versus health education was also recently assessed in a randomized, controlled trial for the secondary prevention of cardiovascular disease among 201 blacks.³⁵ During an average follow-up of 5.4 years, the primary end point (composite of all-cause mortality, myocardial infarctions, or stroke) was significantly reduced by 48% (hazard ratio, 0.52; 95%) CI, 0.29-0.92) in the TM group. Compared with the control group, systolic BP was 4.9 mmHg lower (95% CI, -8.3 to -1.5) at the end of the trial among those randomized to TM. However, this net difference was attributable to an increase in systolic BP in the control group (4.9 mmHg) rather than a significant reduction induced by TM treatment (0.02 mmHg). In this regard, TM may have played a role in preventing agingrelated BP progression over half a decade. More long-term follow-up research is required.

Recent studies have also evaluated the effectiveness of contemplative forms of meditation, including mindfulness meditation and MBSR.^{36–42} Two trials were conducted in children and randomized participants in groups (eg, by class). One randomized trial compared breathing awareness meditation with life skills training and health education in 166 black ninth grade students with elevated resting systolic BPs.⁴⁰ Interventions were conducted by teachers in health education classrooms for 1 semester (ie, 3 months). Breathing awareness meditation produced a greater decrease in 24-hour systolic BP (3.1 ± 1.0 mmHg) compared with the other treatments and a 2.0 ± 0.8 -mmHg decrease in diastolic BP compared with life skills training. The other trial compared 3 months of daily mindfulness meditation with health education in 73 seventh grade students with normal blood pressure.³⁶ Meditation produced a larger decrease in resting systolic BP (-2.7 mmHg) compared with the increase (1.1 mmHg) observed in the health education.

Three small, randomized trials evaluated the effects of slightly different forms of meditation, 2 in individuals with normal blood pressure that did not demonstrate any effects on BP^{39,41} and 1 in individuals treated for hypertension.⁴² The first 2 trials involved 4 weeks of body-scan meditation or mindfulness meditation in university students with normal blood pressure and were compared with no intervention or guided imagery, respectively.43 Both trials did not demonstrate differences in BP compared with control interventions. The trial in nonmedicated individuals with hypertension involved randomization to 8 weeks of meditation or no intervention.42 Reductions in resting clinic systolic BP (median, -15 mm Hg) and in ambulatory systolic and diastolic BPs were reported in the meditation group. Finally, 2 nonrandomized studies evaluated the effects of completing an 8-week MBSR program on BP in individuals with cancer. The first was a preinterventionversus-postintervention comparison of BP in 59 individuals with cancer at 6 time points (for up to 12 months).⁴⁴ A small decrease in systolic BP (2.1 mmHg) was observed from pretesting to postintervention assessments. The second study was a wait-list controlled study comparing the MBSR program and no treatment in 76 women with cancer.37 MBSR was not associated with reduced BP by the end of the 8-week intervention, although subgroup analyses suggested that MBSR may have reduced systolic BP in women who initially had higher levels.

Finally, the results of a well-designed trial randomizing 101 untreated adults with stage I hypertension to an MBSR program versus a wait-list control were recently presented.⁴⁵ After 12 weeks, the BP differences between groups measured by ambulatory monitoring were not different $(0.0\pm7.2/0.4\pm4.7 \text{ mmHg})$. The investigators noted that prior studies reporting positive findings were conducted among individuals treated for hypertension and that the benefits related to an MBSR intervention may have been derived from superior medication adherence. Nonetheless, these important findings do not support a direct BP-lowering effect of an MBSR program over a 3-month time period.

Mechanisms of BP Lowering

The mechanism whereby meditation techniques lower BP when it occurs remains unclear. It has been suggested that the mechanisms may lead to reductions in stress and physiological arousal, thereby producing favorable effects on the autonomic nervous system balance.^{32,33} Further studies are needed to clarify the importance of this and other possible biological pathways.

Summary and Clinical Recommendations

The overall evidence supports that TM modestly lowers BP. It is not certain whether it is truly superior to other meditation techniques in terms of BP lowering because there are few head-to-head studies. As a result of the paucity of data, we are unable to recommend a specific method of practice when TM is used for the treatment of high BP. However, TM (or meditation techniques in general) does not appear to pose significant health risks.³² Additional and higher-quality studies are required to provide conclusions on the BP-lowering efficacy of meditation forms other than TM.

The writing group conferred to TM a *Class IIB, Level of Evidence B* recommendation in regard to BP-lowering efficacy. TM may be considered in clinical practice to lower BP. Because of many negative studies or mixed results and a paucity of available trials, all other meditation techniques (including MBSR) received a *Class III, no benefit, Level of Evidence C* recommendation Thus, other meditation techniques are not recommended in clinical practice to lower BP at this time.

Biofeedback Techniques

Biofeedback for the management of hypertension involves the use of nonpharmacological methodologies that provide information feedback to the individual associated with the lowering of BP.⁴⁶ Techniques that may be used include cognitive behavioral therapy, relaxation therapy, guided imagery, and psychological education. The methods of biofeedback include direct BP measurement and indirect indicators such as thermal biofeedback, galvanic skin response, heart rate. and electromyographic activity. Individuals receive feedback on parameters through the use of 1 of a variety of different methodologies. When the end point (BP in these studies) reaches a prespecified level, the individual receives a feedback signal to identify thoughts and activities at that time. The individual then repeats the thoughts and activity sequences associated with this lower BP in an effort to capture the benefit associated with that scenario. Numerous clinical trials have been implemented to test the effects of biofeedback on BP reduction.47 Biofeedback procedures have also been used in conjunction with other stress reduction techniques to have larger effects.⁴⁸

Meta-Analyses or Reviews

Several meta-analyses and reviews of biofeedback therapy were published between 2003 and 2010.33,47,49 These analyses acknowledged the shortcomings of biofeedback investigations in hypertension (short duration, small sample sizes, difficulties with blinding, and significant heterogeneity when trial data were combined). In addition, a number of the meta-analyses combined multiple complementary medicine techniques in their analyses, thus rendering the effects related specifically to biofeedback alone difficult to assess. The use of different methodologies to assess BP may have also affected the ability to discern small changes. Both of the most recent meta-analyses did not report statistically significant overall BP reductions with biofeedback.^{33,47} For example, in a 2007 meta-analysis, use of biofeedback techniques alone produced small nonsignificant decreases in systolic (-0.8 mm Hg; 95% CI, -4 to 2.6) and diastolic (-2.0 mm Hg; 95% CI, -5.1 to 1.2) BPs among 6 trials including 141 individuals in total.33

As further testament to the difficulty of performing overviews of the antihypertensive efficacy of biofeedback, 2 systematic reviews assessing biofeedback in hypertension reached different conclusions. A 2003 review identified biofeedback as more effective than nonintervention (sham or nonspecific behavioral intervention) when combined with relaxation.⁴⁹ This review was limited in multiple respects, including a pooling of results that was weak in justification. On the other hand, a systematic review done in 2010 that included strict study inclusion assessment found no evidence for the effectiveness of biofeedback in regard to hypertension control compared with placebo, no intervention, pharmacotherapy, and/or behavioral therapy.⁴⁷ As with most interventions, there has been a wide range of reported individual patient- and trial-specific BP responses. The spread of systolic BP reductions among trials using biofeedback in the literature spans values ranging from none to $\approx 15 \text{ mm Hg.}^{50}$

Recent Trials

In a small randomized trial using ABPM, a significant –8/–5– mmHg reduction in individuals randomized to biofeedback compared with controls was reported.⁵¹ This difference, however, was not evident with office BP measurements. As outlined in the earlier meta-analysis by the same first author,⁵⁰ treatment effects of biofeedback may be dependent on the starting BP values, being larger in those with untreated hypertension (>140/>90 mmHg) with smaller reductions noted among individuals with normal blood pressure or individuals taking antihypertensive medications.

In a recently published trial, 65 individuals with hypertension were randomized to biofeedback training combined with behavioral relaxation (behavioral neurocardiac training) versus active control consisting of autogenic training (repetitive visualizations to induce a state of relaxation) over 2 months.52 Training in behavioral neurocardiac training and in the control was supplemented by 20-minute audiotaped exercises for daily home practice. Behavioral neurocardiac training reduced daytime and 24-hour systolic BP levels (-2.4±0.9 mmHg, P=0.009, and -2.1±0.9 mmHg, P=0.03, respectively). No effects were observed in individuals in the control group. Behavioral neurocardiac training also increased RR high-frequency power (0.15 to 0.40 Hz; P=0.01) and RR interval (P<0.001) during cognitive tasks. Among individuals in the control group, high-frequency power was unchanged (P=0.29) and RR interval decreased (P=0.03). Neither intervention altered spontaneous baroreflex sensitivity (*P*>0.10).

Patient factors responsible for achieving a \geq 5-mmHg systolic BP reduction through biofeedback-assisted relaxation have also been assessed. Being medically untreated and having the lowest finger temperatures, the smallest standard deviations of BP during ABPM, and the lowest scores on a psychological test were the best predictors of BP responsiveness.⁵³

Mechanisms of BP Lowering

The mechanisms responsible for the BP lowering induced by biofeedback when it occurs are incompletely described. There is some evidence that favorable alterations in autonomic nervous system balance may be involved.^{47,52} Additional studies

are required to determine the precise pathways responsible when biofeedback produces a reduction in BP.

Summary and Clinical Recommendations

Although meta-analyses results are mixed, some recent trials have shown that certain biofeedback techniques can reduce BP.^{51,52} It is plausible that some techniques may be more effective than others⁵²; however, a paucity of data precludes making recommendations for implementing a specific methodology to treat high BP in clinical practice. On the other hand, no significant health risks were reported among the trials.^{47,52}

The writing group conferred to biofeedback techniques in general a *Class IIB, Level of Evidence B* recommendation in regard to BP-lowering efficacy. Biofeedback may be considered in clinical practice to lower BP.

Yoga

The term yoga (Sanskrit meaning union) has many connotations. It originated in ancient India as primarily a word to describe a contemplative state with the aim of cessation of mental activity and attainment of a state of superior consciousness. Its many complexities and various forms are briefly outlined in the online-only Data Supplement—Methods and Results.

Meta-Analyses or Reviews

As far as we are aware, no formal meta-analysis of the effects of yoga on BP has been performed. Two literature reviews have been published since 2007.^{54,55} Most studies were small and executed outside North America or Europe. The majority were uncontrolled case series or small cohort studies with significant methodological limitations. The published randomized trials often suffered from small sample sizes, inadequate control groups, or a lack of control for many other factors.^{38,56–59} The effect of yoga intervention per se was commonly difficult to assess because concomitant lifestyle changes were frequently undertaken. Finally, BP was rarely the primary outcome of interest, with ABPM used in only a few studies.

A recent 2012 review qualitatively discussed studies published between 2006 and 2011.⁵⁵ The authors stated that BP was lowered by yoga in 8 of the 9 studies evaluated. An earlier review in 2007 discussed the effects of yoga on multiple cardiovascular risk factors in studies published from 1980 to 2007.⁵⁴ A total of 32 articles were reviewed. Reductions in BP were noted in 25 studies; however, it was not clear whether BP was unchanged or not measured in the other 7 studies. As previously outlined, there were significant methodological and reporting limitations in many of the individual studies.

Recent Trials

There have been a limited number of reports published in the past few years attesting to the effects of various yoga programs on BP. Two small randomized studies of hatha yoga–type practices evaluated BP as an outcome since 2007.^{60,61} A third small trial assessed the impact of a variation of pranayama on a background of hatha yoga practice. In a randomized, controlled clinical trial, yoga-naïve adults with stage I hypertension were randomized to 12 weeks of Iyengar yoga or control arms (enhanced usual care emphasizing diet).⁶⁰ In total, 26

and 31 individuals in the yoga and control arms, respectively, completed the study. In the control group, 24-hour systolic, diastolic, and mean arterial pressure BPs decreased significantly by 5, 3, and 3 mm Hg, respectively, from baseline to 6 weeks (P<0.05 versus baseline) and 4, 2, and 2 mm Hg at 12 weeks (P=NS versus baseline). In the yoga group, 24-hour systolic, diastolic, and mean arterial BPs were unchanged compared with baseline at 6 weeks but were reduced by 6, 5, and 5 mm Hg, respectively, at 12 weeks (P=0.05 versus baseline). No differences were observed in catecholamine or cortisol metabolism. In this small study, although there were no differences between the 2 interventions, the reductions seen at 12 weeks with yoga were comparable to what is typically observed with other lifestyle changes.

In the second randomized trial, HIV-infected adults (n=60) with mild to moderate cardiovascular risk were assigned to 20 weeks of supervised Ashtanga Vinyasa yoga or standard of care treatment.⁶¹ Baseline and week 20 measures included BP and 2-hour oral glucose tolerance testing with insulin monitoring, body composition, fasting serum lipid/lipoprotein profile, and quality-of-life measures. Resting systolic and diastolic BP levels improved more (P=0.04) in the yoga group (-5±2 and -3±1 mmHg, respectively) than in the standard of care group (1±2 and 2±2 mmHg, respectively) without improvement in other measures noted.

In a trial performed in Brazil, 76 elderly individuals were randomized to a variation of yogic pranayama breathing called Bhastrika on a background of hatha yoga.⁶² Pulmonary function, heart rate, and BP variability for spontaneous baroreflex determination were measured at baseline and after 4 months. In the yoga group, there were significant decreases in the low-frequency component heart rate variability (a marker of cardiac sympathetic modulation), along with the low-frequency/high-frequency ratio, a marker of sympathetic-vagal balance (P<0.001). Spontaneous baroreflex sensitivity did not change and quality of life only marginally increased in the yoga group.

Mechanisms of BP Lowering

Few studies have evaluated the possible mechanisms whereby yoga might alter BP. The limited evidence suggests that it might be capable of favorably altering autonomic balance.⁶² Whether additional pathways are involved requires future investigation.

Summary and Clinical Recommendations

There are limited data from high-quality, randomized, controlled trials pertaining to the potential BP-lowering efficacy of yoga in and of itself. Additional larger and higher-quality trials are needed. Therefore, a specific technique cannot be recommended. On the other hand, beyond the potential for musculoskeletal injuries, there are few ostensible cardiovascular health risks posed by yoga practice, and no adverse events have been reported in the few completed trials.

Because of the scarcity of reliable study results and the mixed findings from randomized, controlled studies, no firm conclusions can be drawn; thus, the writing group ascribed to yoga a *Class III, no benefit, Level of Evidence C* recommendation for BP-lowering efficacy. Yoga techniques are not recommended in clinical practice to lower BP at this time.

Other Relaxation Techniques

Relaxation and stress-reduction programs can be heterogeneous in nature and often comprise a multitude of approaches used in conjunction. This makes a uniform assessment of the treatment-associated BP-lowering responses difficult. There may also be overlap in the methods used to elicit a relaxation response with the approaches previously reviewed (eg, meditation).

Meta-Analyses or Reviews

Whether relaxation and stress reduction reduce BP has been studied for >40 years. In 1988, the Hypertension Intervention Pooling Project integrated data from 12 randomized, controlled trials and concluded that relaxation provided a small treatment effect for diastolic but not systolic BP among individuals with hypertension not taking medication.⁶³ After this report, a review performed in 1991 concluded that the effects of relaxation seemed to depend on the study design.⁶⁴ Individuals with higher initial BP levels appeared to benefit more. Studies incorporating multiple pretreatment baseline BP values among individuals demonstrated a smaller effect, suggesting the possibility of regression to the mean and a habituation effect as individuals acclimate to repeated BP measurements.

In the case of stress management treatments for hypertension, 2 early meta-analyses reported varying effects. A review performed in 1993 reported that single-component therapies (eg, relaxation alone) did not provide greater BP reductions than appropriate controls or self-monitoring of BP.⁶⁵ However, multicomponent stress management treatments were associated with reductions of 13.5 and 3.4 mmHg for systolic and diastolic BPs, respectively, compared with sham treatments. Another review published in 1994 also reported that multicomponent stress management therapies were more effective in reducing BP than single-component relaxation-based therapies.⁶⁶

The most recent meta-analysis is the Cochrane Review published in 2008. It evaluated the results from 25 trials including several different types of "relaxation therapies" that were used for ≥8 weeks' duration among 1198 individuals not taking antihypertensive medications with BP levels $\geq 140/85$ mmHg.67 Techniques evaluated included cognitive or behavior therapy, progressive muscle relaxation, and autogenic training. Some control groups used sham therapy; other trials compared active treatment with no intervention alone. Given these limitations and after the exclusion of 1 poor trial, relaxation treatments as a heterogeneous group produced small decreases in systolic (-4.6 mm Hg; 95% CI, -6.9 to -2.2) and diastolic (-2.9 mm Hg; 95% CI, -4.5 to -1.3) BPs. However, results from sensitivity analyses and the findings limited to specific subgroups were less compelling. For example, results from trials with blinded outcomes (-3.2 mmHg; 95% CI, -7.7 to 1.4) or those that included sham control groups (-3.5mmHg; 95% CI, -7.1 to 0.2) were not statistically significant.

In terms of specific techniques, this meta-analysis also demonstrated modest but significant BP-lowering effects of cognitive behavioral therapy (11 trials) and progressive muscle relaxation (16 trials) but not autogenic training (6 trials). Relaxation studies with cognitive behavior therapy lowered systolic (-6.3 mmHg; 95% CI, -11.7 to -0.8) and diastolic (-4.1 mmHg; 95% CI, -8.0 to -1.1) BP. Relaxation trials using progressive muscle relaxation lowered systolic (-4.8 mmHg; 95% CI, -7.3 to -2.4) and diastolic (-2.8 mmHg; 95% CI, -4.8 to -0.9) BPs. However, when reviewing their overall findings, the authors felt that the evidence supporting the BP-lowering efficacy of relaxation therapies was weak because of the poor quality of most trials. In addition, the BP-lowering effects were not significant among all the methods when a sham control group was included. Relaxation therapies were also associated with a small risk for worsening or uncontrolled hypertension resulting from delaying medical treatment in the trials.⁶⁷ In light of these limitations, it was suggested that further higher-quality studies are required to conclude that relaxation techniques effectively and safely lower BP. In agreement with this conclusion, a previous metaanalysis reported nonsignificant decreases in BP by relaxation therapy using progressive muscle relaxation (-1.9/-1.4)mmHg; 2 trials) and stress management (-2.3/-1.3 mmHg; 5 trials) programs.³²

Recent Trials

A recent stress management trial compared the effects of 12 sessions of listening to 12 minutes of an audio relaxation program or music (Mozart) among 41 older adults.⁶⁸ The reduction in systolic BP was greater in the audio relaxation program. However, the BP levels at 1 and 3 months were not significantly lower than the initial measurements. In another randomized trial, relaxation response training was compared with lifestyle modification in 122 elderly adults with isolated systolic hypertension.⁶⁹ After 8 weeks, the degree of systolic BP reduction was not significantly different between groups. However, the authors noted that the relaxation group was significantly more likely to successfully eliminate the use of a BP-lowering medication while maintaining similar BP control. Another recent trial failed to demonstrate the effectiveness of individualized behavioral psychotherapy or selfhelp psychotherapy for BP lowering measured by ABPM after 12 weeks.70

Mechanisms of BP Lowering

It has been speculated that relaxation techniques may favorably alter autonomic nervous system balance and/or the hypothalamic-pituitary-adrenal axis.⁶⁷ The precise pathways responsible when relaxation therapies produce a decrease in BP require clarification.

Summary and Clinical Recommendations

Given the variety of methods used in the relaxation trials, the heterogeneity of results, the overall poor quality of most studies, and the frequent lack of appropriate control groups, it is difficult to conclude whether specific techniques or relaxation therapies as a general group lower BP. The meta-analysis findings also suggest that there is a small risk for worsening hypertension while medical treatment is delayed.⁶⁷ However, there was no reported direct cardiovascular harm imparted by using relaxation treatments per se.

As a result of the large number of trials with mixed results and numerous limitations, the writing group ascribed to relaxation techniques (as a group) a *Class III, no benefit, Level* *of Evidence B* recommendation for BP-lowering efficacy. Relaxation techniques are not recommended in clinical practice to reduce BP at this time.

Noninvasive Procedures and Devices

Acupuncture

Acupuncture has been postulated to lower BP for a number of decades. A 1996 report from the World Health Organization indicated that acupuncture is a suitable treatment for early hypertension.⁷¹ There are 2 basic forms of acupuncture, known as manual acupuncture and electroacupuncture.

Meta-Analyses or Reviews

To date, 2 systematic reviews and meta-analyses have evaluated the BP-lowering responses imparted by acupuncture. The first review, published in 2009, evaluated the results of 11 randomized, controlled trials⁷²; the second more recent review, published in 2010, included the results from 20 randomized, controlled trials.⁷³

In the first meta-analysis,⁷² 3 sham-controlled trials were pooled. The systolic BP reduction was not significant (-5 mmHg; 95% CI, -12 to 1), whereas the decrease in diastolic BP was marginal (-3 mmHg; 95% CI, -6 to 0). However, significant heterogeneity among the studies was noted. In the second meta-analysis,73 the overall findings suggested modest BP lowering for both systolic (-4.23 mm Hg; 95% CI, -6.47 to -1.99) and diastolic (-2.53 mmHg; 95% CI, -3.99 to -1.08) BPs. Similarly, heterogeneity among the studies was found. BP was significantly lowered in the 2 high-quality studies compared with sham controls among individuals taking BP medications. Nevertheless, the authors of both meta-analyses summarized that their overall findings were inconclusive in terms of the benefit of acupuncture for BP lowering among individuals with hypertension. It is important to note the important limitations of the available studies, including methodological and design heterogeneity, small sample sizes, inconsistent inclusion of effect modulators, and differences in BP-related end points.

Major Trials Included in the Meta-Analyses

There are 3 individual studies of reasonable quality determined by an Oxford scale of ≥ 4 (maximum, 5) or a score of ≥ 6 on the 11-point scale developed by the Cochrane Review Group. The first study, conducted in Germany, was a singleblind, randomized, controlled trial that compared the effect of a 6-week traditional Chinese acupuncture (n=83) and sham acupuncture (identical needling at nonacupoints; n=77) on 24-hour ambulatory BP reduction among individuals treated for hypertension.⁷⁴ After the 22-session treatment, individuals in the active arm experienced significantly lower mean 24-hour ambulatory BP compared with those in the sham acupuncture arm (difference, 6.4 mmHg [95% CI, 3.5-9.2] and 3.7 mm Hg [95% CI, 1.6–5.8] in 24-hour systolic and diastolic BPs, respectively); however, the effect disappeared and BP returned to pretreatment levels 3 and 6 months after cessation of acupuncture therapy. The second high-quality study, conducted in South Korea, was a double-blind, randomized, controlled trial that compared the effect of acupuncture as an add-on to antihypertensive medication or lifestyle changes

compared with sham acupuncture (nonpenetrating needles at the same acupoints) among 41 individuals with hypertension and prehypertension.⁷⁵ Thirty individuals with hypertension being treated with antihypertensive medication completed the trial with a significant BP reduction noted with the active acupuncture after 8 weeks of intervention from 136.8/83.7 to 122.1/76.8 mm Hg. Finally, the third and largest study, the Stop Hypertension With the Acupuncture Research Program (SHARP), was conducted in the United States and included 192 individuals with untreated hypertension.⁷⁶ Study participants were randomly assigned to 1 of 3 treatment groups: traditional Chinese acupuncture (standardized), acupuncture at preselected points (individualized), or invasive sham acupuncture. The primary outcome of BP reduction from baseline to 10 weeks was not significantly different between the active arms (standardized and individualized treatment) and the sham acupuncture arm.

Mechanisms of BP Lowering

In the manual form of acupuncture, the mechanism of effect appears to be through sensory mechanoreceptor and nociceptor stimulation induced by connective tissues being wound around the needle and activated by mechanotransduction.77 In the case of electroacupuncture, the effects appear to additionally involve the stimulation of peripheral nerve fibers, including vagal afferents, that in turn activate central opioid (and other) receptors or anti-inflammatory reflex pathways.⁷⁸ Reflex increases in sympathetic activity may also be reduced by electroacupuncture. The role of mechanoreceptor stimulation in the BP reductions in animal models is supported by the ability to attenuate this effect by gadolinium, which blocks stretch-activated channels.⁷⁹ Both forms of acupuncture have similar central nervous system effects, although electroacupuncture tends to have a greater intensity of effect as determined by functional magnetic resonance imaging studies in humans.80 In a study of 50 untreated individuals with hypertension, manual acupuncture (which reduced BP in that study) lowered plasma renin activity from 1.7 to 1.1 ng·mL⁻¹·h⁻¹ over a 30-minute period with no change in vasopressin or cortisol concentrations.⁸¹ An extensive review of the BP-reducing effects of electroacupuncture indicates predominantly sympathetic nervous system attenuation involving alterations in glutamate, acetylcholine, nociceptin, opioid, GABA, serotonin, and endocannibinoid neurotransmitter modulation.82

Summary and Clinical Recommendations

Although several studies of acupuncture have demonstrated positive effects on BP among individuals with hypertension and prehypertension, the quality of the studies is limited, so at present definite conclusions cannot be reached. It is also important to note that most studies were completed in Asian countries where acupuncture is readily available from qualified and trained medical professionals. Such training is extensive, time-consuming, and expensive, and a substantial modification in medical education and training would be required to make acupuncture accessible and available for the management of hypertension in many regions of the world. In addition to logistical difficulties in the real-world setting, metaanalyses have reported a small risk of developing uncontrolled hypertension while deferring active medical treatment and the rare potential for minor adverse events, including pain and bleeding at needle sites.⁷² Given the paucity of data, no specific acupuncture technique can be recommended over another at this time.

Because of the overall mixed study and meta-analyses results coupled with the negative findings from recent large, randomized trials, the writing group ascribed to acupuncture a *Class III, no benefit, Level of Evidence B* recommendation for BP-lowering efficacy. Acupuncture is not recommended in clinical practice to reduce BP at this time.

Device-Guided Slow Breathing

Slow deep breathing, as practiced by meditation, yoga, and several relaxation techniques, has long been thought capable of favorably affecting BP.^{83–86} A short period of deep breathing (6 breaths in 30 seconds) has been shown to reduce systolic BP by 3.4 to 3.9 mm Hg within minutes in a clinic setting compared with quiet rest.⁸⁷ Beyond the short term, it has been postulated that using deep-breathing techniques over weeks to months may additionally yield long-term reductions in BP.^{83,85,86}

Several methods to help achieve slow breathing have been promoted. One device has received US Food and Drug Administration approval for over-the-counter distribution "for use in stress reduction and adjunctive treatment to reduce blood pressure" (http://www.resperate.com).⁸⁸ This interactive system uses a belt around the thorax to monitor breathing rate, which feeds real-time data into a small battery-operated controller box, which in turn generates musical tones into headphones, corresponding to inspiration and expiration. Studies support that most people find it easy to use the device and experience a prompt and effortless reduction in respiratory rate as they match their breathing pattern to the musical notes.⁸⁹

Meta-analysis, Reviews, and Recent Trials for BP Lowering The BP-lowering effects associated with this specific Food and Drug Administration-approved device-guided slow breathing device have been evaluated in 13 clinical trials of various sizes (total number of individuals ranged from 11 to 149) and quality, sometimes compared against a control intervention (3 none, 1 usual care, 3 relaxing music, 3 home BP monitoring, or a combination thereof), typically for 8 or 9 weeks. The most appropriate control intervention is controversial, as are many issues related to study design and statistical power.⁹⁰ The pooled study population consists of 608 individuals, 55% men, average age of 57 years, 77% medicated, with an initial office BP of 150/89 mm Hg (9% with BP <140/90 mm Hg and 23% with BP \geq 160/100 mmHg). Twelve studies have now been published in peer-reviewed journals⁹⁰⁻¹⁰¹; 2 are still in abstract form.^{102,103} With 3 exceptions,^{90,95,101} the trials were funded by the manufacturer and reported significant BP-lowering results (at least in per-protocol analyses). All of the trials that were independent of the manufacturer found lower office BP levels in those who used the device compared with baseline. However, no significant differences were seen across randomized groups using either 24-hour ABPM in a 4-week study of 40 individuals with prehypertension or stage 1 hypertension⁹⁰ or office BP values in 30 individuals with hypertension and diabetes mellitus95 or 30 individuals with hypertension.90

In a meta-analysis of all 13 available studies performed for the purposes of this scientific statement, the weighted average reduction in office BP at 8 to 9 weeks compared with baseline with the use of the device was 13/7 versus 9/4 mmHg for control interventions (10 studies; both P < 0.01). Hence, the net reduction in BP induced by device-guided breathing is on the order of 4/3 mmHg, accounting for the placebo effect in the control groups. Subgroup analyses of these overall results are confounded by small numbers of observations, cross-trial heterogeneity, and lack of patient-specific data. Nonetheless, the existing data suggest that the BP-lowering effect was independent of age, sex, and antihypertensive medication status. Both in the aggregated data and in the largest study,⁹² a graded relationship was noted between the total time spent in slow breathing during the exercise and the BP-lowering effect. A threshold effect on BP lowering was seen at ≈15 minutes of use of the device (or ≈6-7 minutes of actual slow breathing) daily, consistent with the manufacturer's recommendations. Studies that measured home BP in those who use the device showed that home BP levels began to decrease after ≈1 to 2 weeks of daily use.¹⁰² Typical of all treatments, a larger BP-lowering effect was seen among those with higher initial BP values.

A separate meta-analysis published in 2012 evaluated the BP-lowering efficacy of the device in 8 trials.¹⁰⁴ Overall, device use significantly lowered clinic-measured systolic (-3.67; 95% CI, -5.99 to -1.39) and diastolic (-2.51; 95% CI, -4.15 to 0.87) BPs among the 494 adults included in the analyses. Home BP levels were also significantly lowered when the results from 4 trials were pooled. The authors of this study were concerned about the potential for bias in the trials sponsored by the device manufacturer. Among the 3 remaining trials, BP was nonsignificantly lowered. The authors concluded that there is evidence that use of this device-guided breathing technique may lower BP; however, independent and larger studies are required to provide definitive evidence.

Mechanism of BP Lowering

The mechanism underlying the BP-lowering effect is complicated.^{88,89,102} One hypothesis holds that autonomic imbalance plays a major role in the origin of hypertension.103,105,106 Relative overactivity of the sympathetic nervous system eventually desensitizes cardiopulmonary and arterial baroreflex/chemoreflex receptors, leading to a resetting of threshold BP values at which regulatory signals are triggered.¹⁰⁷ Paced breathing with prolonged breath cycles may favorably alter (ie, reduce) chemoreceptor sensitivity, thereby decreasing arterial baroreceptor inertia and sympathetic outflow.¹⁰⁸ Another possible mechanism involves the fact that augmentation of tidal volume activates the Hering-Breuer reflex mediated by pulmonary stretch receptors.¹⁰⁹ This reduces chemoreflex sensitivity, in turn upregulating baroreflex receptor sensitivity and thereby decreasing arterial BP. It has also been suggested that paced slow breathing entrains central nervous system nuclei in which respiratory and cardiovascular centers crosstalk, thus favorably altering rhythmic sympathetic outflow to the vasculature. Small mechanistic studies suggest that the reduction in BP occurs mainly via a reduction in systemic

vascular resistance and total arterial compliance.^{88,89,110,111} However, the overall biological mechanisms and the precise or integrated neural pathways involved in lowering BP by slow deep breathing remain to be fully elucidated.

Summary and Clinical Recommendations

The overall evidence from clinical trials and meta-analyses suggests that device-guided slow breathing can significantly lower BP. There are no known contraindications to the use of the device, and no adverse effects have been noted.¹⁰⁴ Unfortunately, the device currently costs in excess of \$200 in the United States; however, it has recently been included on the British National Health Service's Drug Tariff (Part IX), which makes its cost reimbursable if prescribed by a physician. Specific recommendations for use are outlined elsewhere¹¹⁰ and by the manufacturer (http://www.resperate. com). Another limitation is that device-guided slow breathing has not been directly compared with other forms of regulated breathing such as pranayama. Hence, it remains unknown whether paced slow breathing can be taught and effectively used to lower BP over the long term without the use of a device.

According to trial evidence, 15-minute sessions of deviceguided slow breathing need to be performed at least 3 to 4 times per week to reduce BP. It has been suggested that more frequent use may lead to greater BP lowering; however further evidence is required in this regard. There have been no trials longer than 8 to 9 weeks' duration; hence, the efficacy of longterm use is unclear. Longer and larger studies are also required to demonstrate the patient populations most likely to benefit from this technology.^{88,89,110,111}

The writing group conferred to device-guided breathing a *Class IIA*, *Level of Evidence B* recommendation for BP-lowering efficacy. Device-guided breathing is reasonable to perform in clinical practice to reduce BP. Should additional studies in larger and broader populations corroborate its effectiveness thus far demonstrated, it is conceivable that this technique may merit even stronger recommendations in the future.

Exercise-Based Regimens

Numerous studies have evaluated the effects of various exercise modalities on BP. For the purposes of this review, exercise is characterized as predominantly dynamic aerobic, dynamic resistance, and isometric resistance. Dynamic (isotonic) refers to the regular, purposeful movement of joints and large muscle groups compared with isometric exercise, which involves static contraction of muscles without joint movement. Aerobic versus anaerobic describes the availability of oxygen for energy production during contraction and is typically a function of the relative intensity of exercise. Most activities involve a combination of many of these factors. Classification is typically done by the dominant characteristics of the exercise. Some trials have used single exercise types, and others have investigated the effects of combination regimens. Although the writing group acknowledges this complexity and the large variations among published studies, the BP-lowering actions of exercise are reviewed in the context of the dominant regimen type used in the studies.

It is important to emphasize that exercise regimens, in particular resistance training,¹¹² are contraindicated by existing guidelines in unstable cardiovascular conditions including the presence of uncontrolled severe hypertension (BP \geq 180/110 mmHg)^{112,113} at least partially because of the transient incremental elevation in BP. Individuals with stage II hypertension (160–180/100–110 mmHg) require assessment of their cardiovascular risk before beginning exercise training, as well as careful follow-up.^{112–114} Additional recommended scenarios for performing stress testing before starting exercise programs have been outlined previously.¹¹³

Dynamic Aerobic (Endurance) Exercise

Aerobic training refers to exercise that is the dynamic regular and purposeful movement of large muscle groups in moderate and/or vigorous activity that places stress on the cardiovascular system. Usual examples of aerobic training exercises include speed walking, jogging, running, dancing, cycling, swimming, and using elliptical machines. The amount of aerobic exercise is measured as the intensity compared with rest, conveyed in metabolic equivalents (METs), equal to 3.5 mL O₂·kg⁻¹·min⁻¹ (eg, walking at 3 miles/h=3.5 METs, jogging at a 14-min/mile pace=6 METs, and jogging at a 10-min/ mile pace=10 METs); duration (minutes per session); and frequency (number of sessions per week). The total amount of dynamic aerobic activity can be expressed as "exercise volume," which is the product of average METs multiplied by the number of minutes per week, with the goal of reaching 500 to 1000 MET·min/wk.

The general recommendations for exercise to improve health have been outlined in detail elsewhere.¹¹⁵ They are not provided specifically for the treatment of hypertension but are suggestions on how to prescribe an exercise program according to an individual's habitual physical activity, physical function, and health status. An earlier position stand published in 2004 by the American College of Sports Medicine provided guidelines specifically on an exercise prescription plan for the treatment of hypertension.¹¹⁴ The guidelines recommended \geq 30 minutes of accumulated physical activity per day on most days per week. Moderate endurance physical activity at 40% to 60% maximum capacity was promoted with resistance exercise added as a supplement.

Meta-Analyses or Reviews

Physical fitness has been recommended for managing hypertension for >40 years.¹¹⁶ Numerous individual studies have been performed, with the overall evidence supporting a clinically meaningful BP-lowering action of dynamic aerobic exercise. The most recent meta-analysis of endurance training (walking, jogging, running, cycling) published in 2007 involved 72 trials and 105 study groups with an average of 40 participants in the trials. The median age of participants was 47 years (57% male). On average, the participants were relatively fit, with a baseline peak energy expenditure of 9.6 METs, which increased by \approx 1 MET after training. The median training consisted of 40-minute episodes performed 3 times per week over 16 weeks at an average intensity of 65% of heart rate reserve (maximal minus resting heart rate). After adjustment for the number of trained participants, exercise

induced significant net reductions in resting clinic (3.0/2.4 mmHg; P<0.001) and daytime ambulatory (3.3/3.5 mmHg; P<0.01) BPs.¹¹⁷ The reduction in resting clinic BP was more pronounced among the 30 individuals with hypertension (-6.9/-4.9 mmHg) compared with the individuals without hypertension (-1.9/-1.6 mmHg; P<0.001). Overall, there was no observed effect of several exercise-related variables, including training frequency, intensity, and mode, as well as time per session, on the magnitude of BP response; however, the individual studies were not specifically designed in most instances to assess the effect of these factors.

A review published in 2010 evaluated the effects of regular aerobic exercise on BP levels assessed throughout the full 24-hour period measured by ABPM.¹¹⁸ The overall findings were consistent with the previous meta-analyses of clinic-based BP measurements. Aerobic training was shown to reduce most ambulatory BP outcomes among individuals with hypertension in most studies. Nevertheless, it was noted that the responses were highly variable among individuals.

The effect of walking programs on BP was recently reviewed in 2010.¹¹⁹ Nine of 27 trials (34% of the total participants) reported significant reductions in systolic or diastolic BP. It was noted by the authors that the trials that demonstrated a significant effect tended to be larger and used more intense and frequent (36.5-minute sessions performed 4.4 d/wk) exercise regimens for longer durations (19 weeks). Among the positive studies, the overall mean reduction in BP between the intervention and control groups from the baseline to the end of the follow-up ranged from 5.2 to 11.0 mm Hg and from 3.8 to 7.7 mm Hg for systolic and diastolic BPs, respectively. However, it was also noted that, as a result of heterogeneity and the limitations of the published studies, further high-quality trials are required to provide firm conclusions on the efficacy of walking programs.

Finally, in 2011, another systematic review evaluated the effectiveness of lifestyle interventions among women 18 to 44 years of age, with 5 studies examining the effects of exercise alone on BP.¹²⁰ The modes of exercise included aerobic interval training (AIT) and walking for 6 to 24 weeks' duration. Overall, there were nonsignificant changes in BP. As with so many exercise-based interventions, the sample sizes for these studies were relatively small (range, 21–53 women).

Recent Trials, Specific Patient Populations, and Different Exercise Programs

Many of the more recently published studies have investigated the effect of specific aspects of (eg, intensity) or variations in (eg, combined exercise approaches) the exercise regimen on the BP response after training. Additionally, the efficacy of aerobic exercise among several subgroups, including women, the elderly, and individuals with prehypertension, diabetes mellitus, metabolic syndrome, and kidney disease, has been reported.

The effect of exercise intensity on the resting and BP response to exercise after endurance training was recently reported among sedentary persons at least 55 years of age (22 individuals with normal blood pressure, 12 with prehypertension, and 5 with stage 1 hypertension). The study was

a randomized crossover trial including lower-intensity (33% of heart rate reserve) and higher-intensity (66% of heart rate reserve) regimens, each performed for 10 weeks with an intermediary sedentary period. The exercise regimens consisted of 50-minute sessions performed 3 times per week. After training, systolic BP measured in the clinic decreased significantly and to a similar degree in both treatment arms: from 126.2±1.8 to 121.3 ± 1.6 mmHg after lower-intensity training (P<0.05) and from 125.4±1.8 to 119.7±1.5 mmHg after higher-intensity training (P<0.001). Diastolic BP was reduced from 75.4±1.4 to 73.5±1.3 mmHg and from 76.4±1.4 to 71.9±1.3 mmHg after lower-intensity and higher-intensity training, respectively. The reduction in diastolic BP was significant only after higher-intensity training. BP decreased by 5.4/4.0 mmHg in the 22 participants with normal BP at baseline and by 7.6/6.5 mmHg in the 17 participants with high-normal BP or stage 1 hypertension (P < 0.01). There was a similar reduction in systolic BP during submaximal exercise in both groups. However, mean day and nighttime ambulatory BP levels were not significantly altered after training, regardless of exercise intensity.121 In contrast, in a study designed to assess the effect of exercise intensity in men with elevated ambulatory BP (mean, 145/85mmHg), there was a graded additive BP-lowering effect on postexercise BP of more intense exercise. Over the course of the next 9 hours, compared with individuals in the control group, mean ambulatory systolic BP decreased 2.8±1.6 mmHg after low-intensity (40% of peak Vo₂), 5.4±1.4 mmHg after moderate-intensity (60% of peak Vo₂), and 11.7±1.5 mm Hg after vigorous (100% Vo₂ peak) exercise (P<0.001).122

Combining intermittent high-intensity (>80%-90% of maximal heart rate) with moderate-intensity (>60% maximal heart rate) aerobic training, known as AIT, has been shown to enhance fitness and weight loss and has been safely incorporated into cardiac rehabilitation in appropriate individuals. In 65 men and women with controlled hypertension, continuous and interval training performed in 40-minute sessions 2 times a week had a similar effect on ambulatory BP, but interval training decreased BP more than continuous training in those with 24-hour BP levels above the median at baseline (126/80 mmHg). In addition, only higher-intensity interval training reduced arterial stiffness.123 In a similar study, AIT was more effective than continuous training in stage 1 hypertension (mean ambulatory BP, 153/93mmHg). After medication washout, 88 men and women were randomized to AIT or isocaloric continuous training for \approx 40-minute sessions 3 times per week for 12 weeks. Ambulatory systolic BP was reduced by 12 mmHg (*P*<0.001) by AIT and 4.5 mmHg (*P*=0.05) by continuous training. Ambulatory diastolic BP was reduced by 8 mmHg (P<0.001) by AIT and 3.5 mmHg (P=0.02) by continuous training. Improved endothelial function as measured by flow-mediated dilation was observed only in the AIT group.¹²⁴

Upper-limb aerobic exercise has also been shown to provide significant hemodynamic benefits among individuals with hypertension who are limited by orthopedic or vascular occlusive diseases. Twelve weeks of upper-limb cycling 3 times per week with progressive duration and intensity resulted in a significant decrease in systolic $(134.0\pm20.0 \text{ to } 127.0\pm$

16.4 mmHg; P=0.03) and diastolic (73.0±21.6 to 67.1±8.2 mmHg; P=0.02) BPs, with no change among individuals in the control group. Arm exercise was associated with a significant improvement in small-artery compliance and endothe-lium-dependent vasodilation, each of which may help explain the decrease in BP.¹²⁵

Aerobic exercise may also positively affect BP and left ventricular mass among individuals with borderline hypertension. In a recent controlled study of 52 middle-aged men with highnormal or mildly elevated BP, 16 weeks of stationary cycling 3 times per week for ≈45 minutes at 60% to 80% of maximum heart rate resulted in a highly significant reduction in resting BP (-12/-6.5 mmHg) compared with individuals in the control group (-3/-1.1 mmHg).¹²⁶ Most impressive was the marked reduction in postexercise BP among the exercise group after training (-29.2/-7.5 mmHg) compared with the control group (-1/-1 mmHg). Left ventricular mass also decreased significantly in the exercise group (-43.2 ± 18.6 g), whereas there was no change among individuals in the control group (3.4 ± 6.8 g; P<0.05).

The effect of brief bouts of exercise on ambulatory BP among individuals with prehypertension was evaluated in a randomized, crossover design in 21 men and women (mean age, 47.2±2.92 years).¹²⁷ There were 3 groups: accumulated physical activity of 10 min/h over a 4-hour period, 1 continuous 40-minute session (both at 50% of peak oxygen consumption), and a nonexercising control. Systolic and diastolic BPs were reduced for ≈10 hours after accumulated 40 minutes of exercise and for 7 hours after continuous exercise (P<0.05 for both). There were significant reductions in systolic (5.6±1.6 mmHg; P=0.002) and diastolic (3.1±0.2 mmHg; P=0.020) BPs in the group with accumulated physical activity, which was more effective in reducing systolic BP than a single continuous session (P=0.045).

There is some evidence that individuals with diabetes mellitus and/or chronic kidney disease can also achieve a reduction in BP from regular aerobic exercise. A randomized, controlled study involving participants with diabetes mellitus and chronic kidney disease compared aerobic exercise plus optimal medical management with medical management alone.¹²⁸ The exercise group underwent 6 weeks of supervised aerobic training 3 times weekly, followed by 18 weeks of unsupervised home-based exercise. After 24 weeks, exercise training resulted in increased exercise duration during treadmill testing and a decrease in resting systolic BP, although the decrease was not statistically significant, likely related to the small sample size (n=7). Another randomized, controlled study designed to assess the effect of exercise on a standard 6-minute walk test in end-stage renal disease compared the effects of 6 months of supervised intradialytic exercise training with home-based exercise training or usual care in individuals undergoing hemodialysis.129 There were no statistically significant differences between intradialytic and home-based exercise or usual care for either the 6-mile walk or BP parameters. However, the sample size of the study was underpowered to attain statistical significance for the BP outcomes. Despite this limitation, the results supported a trend toward a reduction in BP by aerobic exercise among individuals undergoing dialysis.

In a recent study, 43 men and women (mean age, 50.2 years) with metabolic syndrome were randomized to 4 groups: AIT for 43 minutes 3 times per week with intervals of 70% to 95% at peak heart rate, multiple muscle group strength training for 40 to 50 minutes 3 times per week with resistance set at 60% of the participant's maximal weight for a given muscle group, a combination of AIT (twice per week) and strength training (once per week), or control (no change in dietary or physical activity patterns). A training effect on BP was noted in the AIT group (systolic and diastolic BPs reduced by 5.5 mm Hg [95% CI, -11.4 to 0.4] and 4.1 mm Hg [95% CI, -8.3 to 0.12], respectively, from baseline) but did not research significance in the 11 individuals.¹³⁰

On the other hand, a modest increase in activity level may not be effective in lowering BP compared with dietary advice alone among individuals with diabetes mellitus. In the relatively large Early Activity in Type 2 Diabetes (ACTID) randomized trial of 593 newly diagnosed diabetics, individuals randomized to a pedometer-based program plus intense dietary counseling did not have significant reductions in systolic or diastolic BP after 6 to 12 months compared with those receiving standard or intense dietary advice alone.¹³¹ The lack of BP lowering occurred despite increases in activity in the pedometer group (17% increase in mean steps taken daily). It was speculated that the exercise may have been of insufficient intensity or type (ie, did not also involve resistance training) to have improved BP.

In a randomized study, the effects of aerobic versus resistance exercise in men and postmenopausal women with prehypertension or stage 1 essential hypertension were evaluated.¹³² Aerobic exercise was performed at 65% maximal oxygen consumption peak for 30 minutes 3 days per week, and resistance exercise comprised 3 sets of 10 repetitions at 65% of maximum 3 days per week. Among woman, there were greater BP reductions after resistance compared with aerobic exercise. Men, on the other hand, had comparable BP effects after either exercise mode. These data confirm the beneficial effects of both types of exercise for men and women and the potential need for tailoring nonpharmacological treatment plans for men and women with hypertension.¹³²

In a large epidemiological study involving older male veterans (age, 65–92 years) with an 8-year median follow-up, an inverse and graded association between impaired exercise capacity (in METs) and all-cause mortality was noted.¹³³ Fitness categories were formed using the lowest 20th percentile of METs for this cohort (\leq 4 METs) followed by 1-MET increments for increases in exercise capacity (eg, 4.1–5, 5.1–6, and up to >9 METs). Mortality risk was 12% lower for every 1-MET increase in exercise capacity, regardless of age. Mortality risk was similar between least-fit individuals (\leq 4 METs) and those who achieved the next fitness category (4.1–5 METs), but thereafter, the risk declined significantly for the remaining fitness categories (*P* for trend <0.001). Importantly, systolic BP was significantly lower at higher fitness categories (*P*<0.001).

Further supporting the BP-lowering effects of aerobic exercise in older adults with hypertension is a trial conducted in 2010 involving men and women 76±8 years of age with stage I isolated systolic hypertension.¹³⁴ Participants were randomized to 16 weeks of exercise consisting of aerobic training (progressive 40%–85% heart rate reserve) or strength training (resistance) 3 times per week or to passive control. Participants in the exercise groups had a significant decrease in diastolic (3 mmHg; *P*<0.05) but not systolic BP.

Finally, a recent article published in 2012 has provided some of the first evidence that aerobic exercise training can effectively lower BP even among individuals with resistant hypertension, defined as a BP \geq 140/90 mm Hg on 3 medications or a BP controlled by \geq 4 medications.¹³⁵ Fifty individuals were randomized in a parallel-design study to participate (or not participate) in an 8- to 12-week treadmill exercise program 3 times per week. Aerobic activity was considered to be at a moderate level. Compared with individuals in the control group, 24-hour systolic (-5.4±12.2 versus 2.3±7.3 mm Hg; *P*=0.03) and diastolic (-2.8±5.9 versus 0.9±4.1 mm Hg; *P*=0.01) BP levels were significantly reduced by aerobic training.

Mechanisms of BP Lowering

Mechanistic studies provided evidence that the hypotensive effect of endurance aerobic training is probably mediated at least in part through a reduction in systemic vascular resistance via decreased activities of the sympathetic and the reninangiotensin systems and improved insulin sensitivity. Many other factors, including improved endothelium-dependent vasodilatation, enhanced baroreceptor sensitivity, and arterial compliance, may also be involved.¹¹⁷

Summary and Clinical Recommendations

The majority of studies that have evaluated the effect of aerobic exercise training on BP have been limited by small sample sizes. There have been wide ranges of participant characteristics, basal fitness and BP levels, and exercise regimens investigated. Nonetheless, the overall available evidence and the results from the most recent meta-analyses support that moderate-intensity dynamic aerobic regimens are capable of significantly lowering BP among most individuals within a few months. The general health recommendation to perform moderate- or high-intensity exercise (>40%-60% maximum) for at least 30 minutes on most days per week to achieve a total of at least 150 minutes per week likely also applies to BP lowering.^{115,117} Indeed, these guidelines agree with the American College of Sports Medicine position stand on exercise and hypertension.¹¹⁴ In addition to the potential risks for musculoskeletal injuries, there is a small absolute short-term increase in cardiovascular risk induced by aerobic exercise, particularly after high-intensity episodes among unconditioned individuals and individuals with preexisting cardiovascular disease. The risk-to-benefit ratio and suggestions for performing exercise testing before endurance training is prescribed should be carefully considered as outlined in detail elsewhere.^{113,114} Finally, further studies are required to elucidate the optimal mode, training frequency, intensity, and duration of exercise, as well as patient predictors of responses, that achieve maximal BP lowering. Therefore, we recommend following existing Joint National Committee guidelines to perform aerobic physical activity at least 30 minutes per day most days of the week.4

Because of the positive findings from the majority of trials and the meta-analyses, the writing group ascribed to dynamic aerobic exercise a *Class I, Level of Evidence A* recommendation for BP-lowering efficacy. Dynamic aerobic exercise should be performed by most individuals to reduce BP if clinically appropriate and not contraindicated.

Dynamic Resistance Exercise

Dynamic resistance exercises are forms of exercise in which effort is performed against an opposing force accompanied by purposeful movement of joints and large muscle groups. Dynamic resistance exercise involves concentric or eccentric contraction (shortening) of muscles. Common types include weight lifting and circuit training, often with the use of exercise equipment such as Nautilus-type exercise machines. These types of exercise are typically performed with a goal of progressively increasing muscle strength. However, such exercises might also have cardiometabolic benefits, including reduced BP.

Meta-Analyses or Reviews

The most recent meta-analysis of the effect of resistance training on BP was conducted in 2011.136 The authors identified 25 trials (30 different interventions) that tested at least 1 dynamic resistance intervention. Of these 30 interventions, 12 were tested in individuals with optimal BP, 14 in those with prehypertension, and 4 in individuals with hypertension. The sample size of the trials ranged from 15 to 143 participants, with a total of 1043 adults across all studies. In general, trial reporting was of poor quality. For example, just 19 trials reported that outcome assessment was performed in a blinded fashion. Twenty-seven intervention arms used weight or training machines, 2 interventions used Dyna-Bands, and 1 trial did not report the type of exercise. The median duration of the interventions was 8 weeks (range, 6-52 weeks). The median frequency of exercise was 3 sessions per week (range, 2-3 sessions per week). In most trials, the exercise was performed in a supervised setting. Across all 30 groups, net mean changes in systolic and diastolic BPs were -2.7 mm Hg (95% CI, -4.6 to -0.78) and -2.9 mm Hg (95% CI, -4.1 to -1.7), respectively, with a random-effects model. There were no significant differences in the effects of the interventions stratified by baseline BP level. There were also no BP-lowering differences observed across various subgroups of individuals, nor was a relationship between training intensity and BP found. The authors recognized many limitations of their meta-analysis, including the overall paucity of trials and the poor quality of many of the individuals trials. Importantly, no detrimental effects on BP control or triggering of acute cardiovascular events was reported to be induced by resistance training.

It was later emphasized that BP was not the primary end point of interest in many of the studies included in the meta-analysis.¹³⁷ A separate meta-analysis of 9 studies with 11 treatment groups was presented. Resistance training yielded smaller BP-lowering effects (1.08/1.03 mm Hg) that were not statistically significant. In response, the authors supported their original findings, stating that there was no evidence of publication bias or serious inconsistency across the studies.¹³⁶ They reanalyzed their data to include only studies reporting BP changes as the primary outcome. In 11 randomized trials (13 study groups), a smaller but still significant reduction was reported for systolic (-2.7 mm Hg; 95% CI, -4.8 to -0.54) and diastolic (-1.9 mm Hg; 95% CI, -3.3 to -0.54) BPs. There was no difference between studies measuring BP as a primary or secondary outcome.

Recent Trials

After publication of the meta-analysis, 2 relevant studies were published. One nonrandomized study assessed the effects of resistance exercise training on the occurrence of postexercise hypotension.¹³⁸ Findings from this study suggest that training might reduce the occurrence of such hypotensive episodes. Another study was a randomized trial that tested the effects of 2 doses of resistance training on BP and other outcomes in individuals in cardiac rehabilitation units who were concomitantly receiving aerobic training.¹³⁹ There were modest significant reductions in BP at the end of the intervention period; however, there was no control group. Hence, it is unclear if the interventions had any specific effect on BP.

Mechanisms of BP Lowering

The underlying pathway whereby resistance training reduces BP has received little attention. The few studies do not support consistent improvements in endothelial function,^{140,141} arterial compliance,^{140,142} sympathetic activity,^{140,143} or changes in cardiac heart rate variability.¹⁴⁴ Some studies have even observed a worsening of arterial elasticity and aortic wave reflections.¹⁴⁵ Sex differences have been reported, with improved endothelial function without adverse changes in arterial stiffness after resistance exercise among women but not men.¹³² Hence, the complex mechanisms linking dynamic resistance training to a small reduction in BP remain to be fully elucidated.

Summary and Clinical Recommendations

The overall evidence suggests that dynamic resistance exercise can lower arterial BP by a modest degree. The evidence base is notable for a lack of trials in individuals with hypertension. There are additional methodological limitations of the relatively few available studies. However, there is no evidence of harm, an acute triggering of cardiovascular events during exercise, or a chronic worsening of BP by dynamic resistance exercise from the available shortterm studies. Hence, there is no rationale to contraindicate resistance training for most individuals with mild stage I hypertension.

As a result of the positive findings from the majority of trials and the meta-analyses, the writing group conferred to dynamic resistance exercises a *Class IIA*, *Level of Evidence B* recommendation for BP-lowering efficacy. Dynamic resistance exercise is reasonable to perform in clinical practice to reduce BP. Should additional studies in larger and broader populations corroborate its effectiveness thus far demonstrated, it is conceivable that resistance exercise may merit even stronger recommendations in the future.

Isometric (Resistance) Exercise

Isometric resistance exercise involves sustained contraction of muscles with no change in the length of the involved muscle groups. Most of the studies on isometric resistance were of short duration and enrolled relatively few participants. Nonetheless, a clear yet relatively small cardiovascular benefit of resistance training has emerged, including modest improvements in BP.¹¹²

Meta-Analyses or Reviews

There have been a few meta-analyses on the BP-lowering effects of isometric exercise. In 1 review published in 2010, the effect of isometric handgrip exercise training lasting at least 4 weeks was evaluated.146 The main outcome showed an ≈10% decrease in both systolic and diastolic BPs (pooled from 3 studies including 42 and 39 individuals in the exercise and control arms, respectively). The exercise minus control group reductions in systolic and diastolic BP levels were -13.4 and -7.8 mmHg, respectively. Although this change in BP was impressive, it is important to note that this analysis included only 3 studies and a small number of total participants. A more recent meta-analysis published in 2011 also evaluated the impact of several different resistance training modalities.¹³⁶ A subgroup analysis of isometric handgrip exercise alone showed larger decreases in systolic (-13.5 mmHg; 95% CI, -16.5 to -10.5) and diastolic (-7.8 mmHg; 95% CI, -16.4 to 0.62) BPs using random-effects analyses in the 3 included studies compared with dynamic resistance training (-2.7/-2.9 mmHg). On the other hand, dynamic resistance exercise provided additional health benefits not observed in isometric exercise, including improved peak oxygen consumption, body fat, and blood triglycerides. However, this meta-analysis must be taken in the proper context given the heterogeneity of isometric training methods evaluated and the small number of individuals included in the studies. In this limited context, however, it provides support for the efficacy of isometric exercises, particularly handgrip, for lowering BP.

A few additional reviews of the BP-lowering efficacy of isometric handgrip exercises were published from 2008 to 2010.147,148 Some studies not included in the previous metaanalyses for various trial quality reasons were also evaluated.136,146 The overall conclusions of these reviews accorded with the findings of the meta-analyses. Many of the trials used a commercially available automated handheld dynamometer. However, a similar BP-lowering efficacy has been demonstrated by the use of an inexpensive spring-loaded handgrip device after 8 weeks of training in at least 1 randomized, controlled study of 49 individuals with normal blood pressure.149 It was also noted that most of the protocols involving isometric handgrip necessitated less time commitment to produce effective reduction in BP (≈33 min/wk total) compared with other exercise modalities (eg, typically 150 min/wk with aerobic dynamic exercise).

Recent Trials

Several additional small studies have evaluated the BP-lowering efficacy of isometric exercise. In a study conducted in 2010, it was demonstrated that bilateral leg

Alternative Treatments	LOE	COR
Behavioral therapies	·	
Transcendental Meditation	В	IIB
Other meditation techniques	С	III (no benefit)
Biofeedback approaches	В	IIB
Yoga	С	III (no benefit)
Other relaxation techniques	В	III (no benefit)
Noninvasive procedures or devices		
Acupuncture	В	III (no benefit)
Device-guided breathing	В	IIA
Exercise-based regimens		
Dynamic aerobic exercise	А	Ι
Dynamic resistance exercise	В	IIA
lsometric handgrip exercise	С	IIB

 Table 2. Class of Recommendation and Level of Evidence for

 Blood Pressure Lowering

COR indicates class of recommendation; and LOE, level of evidence.

isometric training can reduce resting BP.¹⁵⁰ In this study, 13 participants sat in a dynamometer that ensured a reproducible isometric exercise that allowed a 90° flexion of the hip while individuals sat in an upright position. Participants performed 4 bouts of 2-minute-long exercises separated by 3 minutes of rest, and great care was taken to have the participants exercise in a uniform fashion. Both systolic (-4.9 ± 5.8 mm Hg) and diastolic (-2.8 ± 3.2 mm Hg) BP levels were significantly reduced after 4 weeks of training.

In a similar study, individuals were randomized to a high- or low-intensity leg isometric regimen (≈10% and 20% maximum voluntary contraction, respectively) or to a control group.¹⁵¹ This trial was carefully done but, again, included a relatively small cohort of only 33 healthy young male individuals. Exercise regimens consisted of 4 repeated 2-minute-long bouts performed 3 times weekly. Significant decreases in systolic, diastolic, and mean arterial BPs were seen at 8 weeks among both exercise groups. Although not statistically significant, the BP-lowering effects were slightly greater in the high- versus low-intensity exercise group (-5.2±4.0/-2.6±2.9 versus -3.7±3.7/-2.5±4.8 mm Hg, respectively). There were no significant changes in BP at the 4-week intermediate time point, which is different from the results in the previous study.¹⁵⁰ Although there was no effect of isometric exercise intensity on the degree of BP reduction, the difference in maximum voluntary contraction was small between groups.

Because of the paucity of clinical trials, numerous issues remain unresolved in terms of using isometric exercise training to maximize BP lowering, including the optimal intensities, muscle groups exercised, duration of therapy, number of static contraction bouts per session, and effect of training with bilateral versus unilateral muscle contractions. The effects across broader ranges of patient characteristics and initial BP values also require further investigation. Finally, the safety of using various isometric exercises and intensities among individuals with hypertension needs to be better evaluated. In particular, the cardiovascular health risks associated with the transient elevation in BP that occurs during muscle contractions need to be more clearly established. Few studies have investigated the magnitude of this BP surge among individuals with hypertension.¹⁵² The available data suggest that the brief rise in BP can be quite pronounced, depending on the isometric exercise used (eg, percent maximal effort, size of muscle groups involved). On the other hand, the response is transient (ie, resolves within a few minutes), and there is no evidence from the few available published studies that it is associated with an increase in risk for acute cardiovascular events.112,136,148 Nonetheless, isometric exercises have not been studied in very-high-risk or unstable cardiovascular patients or individuals with more severe levels of hypertension (eg, stage II). Careful and prudent restrictions on prescribing any type of exercise apply to individuals with uncontrolled BP. Current recommendations state that isometric exercise should be avoided among individuals with BP levels >180/110 mm Hg until their hypertension is better controlled.¹¹²

Mechanisms of BP Lowering

Isometric exercise causes an acute stimulation of the metaboreflex in a physiological attempt to restore muscle blood flow. This and other responses may produce reductions in tissue oxidative stress, improved vascular endothelial function, and favorable changes in baroreflex sensitivity, as well as autonomic balance over the long-term. The available studies provide mixed findings; thus, the responsible mechanistic pathways have not been fully clarified.¹⁴⁸

Summary and Clinical Recommendations

The overall evidence suggests that isometric, particularly handgrip, exercises produce significant reductions in BP. However, caution is required at this point because only a few relatively small studies have been published. Results from larger-scale high-quality studies are necessary to draw firm conclusions. This would be of great benefit to the field because there may still be a concern among healthcare providers that isometric exercise is contraindicated because it acutely raises BP. The optimal methods of exercise also require further investigations. For the time being, following a program with published evidence that it can effectively lower BP is reasonable. In regard to isometric handgrip, this consists of several intermittent bouts of handgrip contractions at 30% maximal strength lasting 2 minutes each for a total of 12 to 15 minutes per session. This should be performed at least 3 times per week over 8 to 12 weeks.147 Although no adverse events have thus far been reported (keeping in mind that most studies have used relatively low-intensity isometric exercises),^{112,136,148} more data are needed to establish the safety of this modality.




Figure. Algorithm for implementing alternative approaches in clinical practice. Target-organ disease is end-organ damage related to high BP (eg, left ventricular hypertrophy, chronic kidney disease, or albuminuria). See text for a detailed discussion of using this treatment algorithm in clinical practice. BP indicates blood pressure; CV, cardiovascular; HTN, hypertension; JNC, Joint National Committee VII on High Blood Pressure Management; and SE, side effect. *Start/assure compliance with dietary + lifestyle therapy. Individualize alternative approach with selection guided by Table 2. †Earlier medication therapy should be started (or added to existing therapy) if BP levels increase to >20/10 mm Hg above goals during this period. ‡Target BP depending on comorbidities per JNC guidelines.

On the basis of the review, the writing group ascribed to isometric handgrip exercises a *Class IIB, Level of Evidence C* recommendation for BP-lowering efficacy. Isometric handgrip exercise may be considered in practice to reduce BP. Should additional studies in larger and broader populations corroborate its effectiveness thus far demonstrated, it is conceivable that this technique may merit even stronger recommendations in the future.

Additional Alternative Approaches

During the past few decades, a wide variety of other nonpharmacological methods for lowering BP have been reported. Several promising approaches include endovascular radiofrequency renal nerve ablation,^{153,154} baroreceptor activation therapy with carotid baroreceptor pacing,^{155,156} and continuous positive airway pressure for individuals with sleep apnea.^{157,158} Numerous additional approaches and complementary therapies have also been described.^{16,159} These treatments are outlined in the **online-only Data Supplement—Methods and Results**. However, they were not systematically reviewed, and official CORs are not provided in this scientific statement because of the paucity of high-quality clinical trials, because of the investigational nature of the procedures, because they were considered a dietary approach (eg, nutraceuticals), or because the method pertains only to a selected set of individuals (eg, continuous positive airway pressure).

Clinical Practice Considerations

A summary of the ascribed LOE and COR values in relation to the BP-lowering efficacy of each modality is provided in Table 2. Dynamic aerobic exercise has a high LOE for BP lowering and the greatest potential for improving other cardiovascular health parameters (eg, lipids, glucose).¹⁶⁰ Numerous observational cohorts also suggest that it may reduce cardiovascular risk in a dose-dependent manner.161,162 Therefore, aerobic exercise should be considered the primary alternative modality to help reduce BP. This recommendation accords with existing guidelines on using lifestyle modifications to treat prehypertension and stage I hypertension.⁴ Resistance exercise also has a high LOE for BP lowering, has been associated with additional cardiovascular health benefits,¹¹² and is therefore also highly recommended by our review. The writing group endorses that most individuals should start with aerobic or resistance exercise (alone or together) as the first alternative approach unless contraindicated or they are unwilling or unable to exercise. This recommendation to incorporate resistance exercise training for most individuals expands on existing BP guidelines that only explicitly promote aerobic activity.4 However, the simple advice to individuals to adopt an exercise regimen is often met with modest and variable success.¹⁸ A different or additional alternative modality may be used if BP proves unresponsive, if further treatment is needed to achieve goals, or if there is a lack of adherence to exercise. Among the approaches, it is the opinion of the writing group to next consider the use of device-guided breathing or isometric handgrip exercise. These modalities are recommended with a higher priority in the order of preference over the remaining options on the basis of the larger weight of evidence supporting their BP-lowering efficacy or their greater practicality to use in the real-world setting compared with the other techniques with a Class IIB recommendation (ie, TM and biofeedback).

General Role in BP Management

A large but variable body of evidence documents the ability of alternative therapies to lower BP, as reviewed in this scientific statement. We did not identify any consistently proven health risks posed by any of these treatments per se when used in a responsible manner and when BP levels are monitored appropriately. The exception to this rule is for clinicians to use caution when recommending exercisebased modalities for individuals with stage II hypertension and to proscribe them among individuals with severely elevated levels (>180/110 mm Hg) or unstable cardiovascular syndromes (eg, class III-IV angina) because of the associated transient increase in BP and cardiovascular risk, particularly during isometric and resistance exercises among unconditioned individuals.^{18,112,113} It is also important to highlight that there is little to no evidence from randomized, controlled clinical trials that these therapies as a group can prevent hard cardiovascular events. Hence, the writing group believes that these alternative modalities should be considered adjunctive therapies to standard treatments (diet and medications) for high BP. Our recommended approach mirrors previous expert opinions for implementing dietary modifications among individuals with hypertension¹⁰⁻¹² and accords with the management principles for when and how to use nonpharmacological therapies in general as promulgated by nation-level guidelines.⁴⁻⁶

In summary, it is the consensus of the writing group that it is reasonable for all individuals with BP levels >120/80 mm Hg to consider a trial of alternative approaches as adjuvant methods to help lower BP. In light of the fact that there is little evidence that any alternative modality can reliably lower BP by \geq 20/10 mm Hg, individuals requiring this magnitude of BP reduction (including untreated individuals with stage II hypertension) should use alternative approaches only after they are first treated with appropriate pharmacologic strategies. Individuals with an indicated medication per guidelines (eg, target-organ damage, underlying comorbidities) should also use these approaches only as supplements to the required drug therapy regardless of BP level.⁴⁻⁶ It should also be emphasized that most alternative approaches reduce systolic BP by only 2 to 10 mm Hg. Hence, only a minority of individuals will be successful in reaching goals with these treatment modalities alone when BP is $\geq 10/5$ mmHg above target.

The choice of the specific alternative approach can be made on an individual-level basis. However, we recommend that this selection be guided by the evidence as outlined in Table 2. Moreover, it is critical that individuals are adequately educated by their healthcare provider on how to correctly adopt and implement their selected approach. For example, some modalities require practice and have been shown to be ineffective if not performed appropriately (eg, device-guided breathing).92 In cases requiring special expertise (eg, exercise or meditation techniques, stress management) referrals should be made to providers with appropriate credentials or proficiency whenever possible. An overview of the recommended methods of how to use each alternative approach for BP lowering is addressed within each individual section (when available evidence exists). Individuals should also be clearly informed that unlike pharmacologically based treatments there is currently little to no evidence that these alternative approaches, besides exercise regimens, can prevent cardiovascular events to avoid engendering a false sense of security in this regard. Finally, there is no ostensible reason why >1 approach could not be carefully tried together; however, unlike the proven additive efficacy of lifestyle interventions (eg, Dietary Approaches to Lower Hypertension diet plus salt restriction or weight loss), whether combination alternative therapy yields incremental reductions in BP remains untested.162

BP Management Algorithm

A general approach for using alternative treatments is outlined in the Figure. In all circumstances, individuals should also be strongly encouraged at all visits to adhere to the dietary changes proven to lower BP.¹⁰⁻¹² There are several clinical scenarios likely well suited for using these alternative modalities. Individuals with prehypertension (ie, BP 120-139/80-89 mmHg) are excellent candidates to help lower BP and possibly prevent the transition to overt hypertension.^{19,20} Low-risk individuals with stage I hypertension (ie, BP 140-159/90-99 mm Hg with no target-organ disease [eg, proteinuria, left ventricular hypertrophy] or guideline indication for drug therapy for a specific comorbidity [eg, heart failure]) who wish to avoid medications are also reasonable candidates.⁴⁻⁶ An alternative modality could be started in these groups after a trial of diet has proven inadequate, or they could be started concomitantly with dietary approaches initially. Among individuals already taking antihypertensive drugs, an adjuvant alternative treatment can be considered if clinically appropriate (eg. rapid BP reduction is not urgently required and if BP is <20/10 mm Hg above goal) to help avoid adding further medications. Other reasonable candidates include individuals who have controlled hypertension seeking to step-down or stop existing drug therapy,¹⁶³ individuals with persistent BP elevations despite maximal medical therapy (ie, refractory hypertension),¹⁶⁴ and those who have exhausted viable pharmacological options because of multiple drug intolerances.

The appropriate duration of treatment before assessing the final adequacy of BP response after initiating any alternative approach is not well established and depends on the individual situation. However, 3 months' duration is a reasonable time frame given that most of the approaches reduced BP among the studies within this period when shown to be effective. If the BP does not respond or reach target goals, a different alternative approach could thereafter be attempted if still appropriate for the clinical scenario. On the basis of guidelines, individuals with prehypertension can undertake nonpharmacological therapy (which should include these alternative modalities) indefinitely as long as their BP is followed up annually and does not progress to overt hypertension.⁴⁻⁶ Individuals with stage I hypertension on initial assessment can consider trials for up to 6 months (individuals with other cardiovascular risk factors) or as long as 12 months (individuals without other cardiovascular risk factors).⁴⁻⁶ If BP rises to levels consistently >20/10 mmHg above goal during this treatment period or if individuals develop evidence of target-organ damage and/or an indication for a specific medication, appropriate pharmacological therapy should be started at that time. After the appropriate trial durations outlined above, if BP remains >140/90 mmHg, most individuals should begin medication therapy. A final caveat to this algorithm is that most alternative treatments do not commonly reduce BP by >10/5 mm Hg. Close follow-up is warranted for individuals with BP levels this magnitude above target.

Research Recommendations

There are several shortcomings in our present knowledge of the merits of alternative BP-lowering modalities. These include a paucity of well-designed, high-quality cardiovascular outcome trials in appropriate populations with hypertension with adequate control intervention groups for a number of nonpharmacological interventions. The current scarcity of clinical trial evidence demonstrating that the typically modest reduction in BP associated with these approaches translates into a reduction in hard cardiovascular events is a major shortcoming. However, it must be acknowledged that event-based trials are unlikely to be conducted because of the prohibitive sample size required to demonstrate a benefit with small reductions in BP in relatively healthy individuals with mild hypertension. In the absence of such trials, one may have to rely on BP lowering per se as a widely accepted surrogate marker that reliably predicts the cardiovascular health benefits of a medical intervention.^{1,25} Even small decreases in BP within a large population can translate into substantial public health benefits.⁴⁻⁶ We therefore believe that the risk-to-benefit ratio favors reasonable recommendations for individuals to use these alternative approaches as long as they are used under appropriate circumstances and guidance by a healthcare provider. It is also important to re-emphasize that many of the reviewed alternative therapies (eg, resistance and aerobic exercise, yoga, meditation, acupuncture) may provide a range of health or psychological benefits beyond BP lowering or cardiovascular risk reduction.

The writing group has formulated additional specific recommendations for future studies to help better elucidate the potential clinical role of these methods. Given the enormous population of individuals with high BP levels above ideal who may be appropriate candidates for these treatments,^{1,2} these issues warrant consideration. Future trials should assess BP changes by including home and/or ambulatory BP responses, which are known to be less variable, are associated with no (or a smaller) placebo effect, and are superior cardiovascular risk predictors than clinic readings alone. In addition, many of the modalities might appear spuriously effective when used briefly before measurement of BP in the clinic. On the other hand, modest reductions detected over a 24-hour period might be obfuscated by relying solely on clinic readings. The BP-lowering efficacy during longterm treatment (ie, ≥ 1 year) and the long-term compliance associated with these regimens remain largely unknown. Many nonpharmacological alternative regimens require significant motivation and perseverance for continued efficacy. The comparative BP-lowering efficacy across the various nonpharmacological regimens is another area that should be investigated, preferably within the same population to directly assess their relative effectiveness and tolerability. Whether certain characteristics (eg, demographics, biomarkers, or hemodynamic parameters) predict the degree of responses to the various treatments also remains unclear. The ability to optimally tailor specific modalities to match certain patient subtypes has not been explored. The effectiveness of combining alternative approaches together or with other dietary/lifestyle approaches is another important question yet to be adequately assessed. The capacity for these techniques to change the typically progressive course of BP elevations over time among individuals with mild stages or prehypertension has not been studied.²⁰ Special subgroups within the population, in particular the elderly, have generally been underrepresented in previous trials. Finally, the cost-effectiveness of using these modalities in clinical practice, particularly compared with dietary or medical approaches, in individuals with mild stages of hypertension or prehypertension remains to be determined.

Conclusions

Numerous alternative approaches for lowering BP have been evaluated during the past few decades. The strongest evidence supports the effectiveness of using aerobic and/or dynamic resistance exercise for the adjuvant treatment of high BP. Biofeedback techniques, isometric handgrip, and deviceguided breathing methods are also likely effective treatments. There is insufficient or inconclusive evidence at the present time to recommend the use of the other techniques reviewed in this scientific statement for the purposes of treating overt hypertension or prehypertension.

Acknowledgments

We would like to thank Robert Bard Consulting for assisting with manuscript review and reference management and Whitney Townsend, MLIS, for assistance with the literature searches.

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/ Honoraria	Expert Witness	Ownership Interest	Consultant/ Advisory Board	Other
Robert D. Brook	University of Michigan	None	None	None	None	None	None	None
Lawrence J. Appel	Johns Hopkins Medical Institutions	None	None	None	None	None	None	None
John D. Bisognano	University of Rochester Medical Center	CVRx†	None	None	None	None	CVRx*	None
William J. Elliott	Pacific Northwest University of Health Sciences	None	None	None	None	None	None	None
Flavio D. Fuchs	Federal University of Rio Grande do Sul	None	None	None	None	None	None	None
Joel W. Hughes	Kent State University	NIH†	None	None	None	None	None	None
Daniel T. Lackland	Medical University of South Carolina	None	None	None	None	None	None	None
Gbenga Ogedegbe	New York University School of Medicine	None	None	None	None	None	None	None
Sanjay Rajagopalan	Ohio State University	None	None	None	None	None	None	None
Melvyn Rubenfire	University of Michigan	None	None	None	None	None	None	None
Beth A. Staffileno	Rush University Medical Center	None	None	None	None	None	None	None
Raymond R. Townsend	University of Pennsylvania	NIH/NIDDK†	None	None	None	None	Medtronic*; Novartis*; Pfizer*	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition. *Modest.

+Significant.

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
George Bakris	University of Chicago	None	None	None	None	None	Abbott*; Takeda*; Johnson & Johnson*; Daiichi-Sankyo*; Relapsya*; Medtronic*	None
Brent M. Egan	Medical University of South Carolina	None	None	None	None	None	None	None
Clive Rosendorff	Mt. Sinai School of Medicine and the James J. Peters VA Medical Center	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10,000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10,000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition. *Modest.

References

- Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet*. 2005;365:217–223.
- Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. *Lancet*. 2008;371:1513–1518.
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure

to vascular mortality: a meta-analysis of individuals data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903–1913.

4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289:2560–2572.

- National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. August 2011. http:// www.nice.org.uk/guidance/CG127. Accessed April 8, 2013.
- 6. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–2158.
- Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344:3–10.
- Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, Stevens VJ, Vollmer WM, Lin PH, Svetkey LP, Stedman SW, Young DR; Writing Group of the PREMIER Collaborative Research Group. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083–2093.
- Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, Williams B, Ford GA. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens*. 2006;24:215–233.
- Sacks FM, Campos H. Dietary therapy in hypertension. N Engl J Med. 2010;362:2102–2112.
- Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM; American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. *Hypertension*. 2006;47:296–308.
- Appel LJ; American Society of Hypertension Writing Group. ASH position paper: dietary approaches to lower blood pressure. J Am Soc Hypertens. 2009;3:321–331.
- Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010; 303:2043–2050.
- Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003–1010.
- Chobanian AV. Shattuck Lecture: the hypertension paradox: more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361:878–887.
- Woolf KJ, Bisognano JD. Nondrug interventions for treatment of hypertension. J Clin Hypertens (Greenwich). 2011;13:829–835.
- Gao SK, Fitzpatrick AL, Psaty B, Jiang R, Post W, Cutler J, Maciejewski ML. Suboptimal nutritional intake for hypertension control in 4 ethnic groups. *Arch Intern Med.* 2009;169:702–707.
- Lin JS, O'Connor E, Whitlock EP, Beil TL. Behavioral counseling to promote physical activity and a healthful diet to prevent cardiovascular disease in adults: a systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2010;153:736–750.
- Pimenta E, Oparil S. Prehypertension: epidemiology, consequences and treatment. Nat Rev Nephrol. 2010;6:21–30.
- Selassie A, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM. Progression is accelerated from prehypertension to hypertension in blacks. *Hypertension*. 2011;58:579–587.
- McInnes GT. Drug treatment of prehypertension: not now, not ever? Blood Press. 2009;18:304–307.
- Svetkey LP. Management of prehypertension. *Hypertension*. 2005;45: 1056–1061.
- Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. *Circulation*. 2011;124:1046–1058.
- Feig PU, Roy S, Cody RJ. Antihypertensive drug development: current challenges and future opportunities. JAm Soc Hypertens. 2010;4:163–173.
- Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ*. 2009;338:b1665.
- Gibbons RJ, Smith S, Antman E; American College of Cardiology; American Heart Association. American College of Cardiology/American Heart Association clinical practice guidelines, part I: where do they come from? *Circulation*. 2003;107:2979–2986.

- Birnbaum L, Birnbaum A. In search of inner wisdom: guided mindfulness meditation in the context of suicide. *ScientificWorldJournal*. 2004;4:216–227.
- Brown KW, Ryan RM. The benefits of being present: mindfulness and its role in psychological well-being. J Pers Soc Psychol. 2003;84:822–848.
- Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: theoretical considerations and preliminary results. *Gen Hosp Psychiatry*. 1982;4:33–47.
- Kabat-Zinn J, Kabat-Zinn C. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness. New York, NY: Delta Trade Paperbacks; 2005.
- Ospina MB, Bond K, Karkhaneh M, Tjosvold L, Vandermeer B, Liang Y, Bialy L, Hooton N, Buscemi N, Dryden DM, Klassen TP. Meditation practices for health: state of the research. *Evid Rep Technol Assess (Full Rep)*. 2007:1–263.
- Anderson JW, Liu C, Kryscio RJ. Blood pressure response to Transcendental Meditation: a meta-analysis. *Am J Hypertens*. 2008;21:310–316.
- Rainforth MV, Schneider RH, Nidich SI, Gaylord-King C, Salerno JW, Anderson JW. Stress reduction programs in patients with elevated blood pressure: a systematic review and meta-analysis. *Curr Hypertens Rep.* 2007;9:520–528.
- 34. Nidich SI, Rainforth MV, Haaga DA, Hagelin J, Salerno JW, Travis F, Tanner M, Gaylord-King C, Grosswald S, Schneider RH. A randomized controlled trial on effects of the Transcendental Meditation program on blood pressure, psychological distress, and coping in young adults. *Am J Hypertens*. 2009;22:1326–1331.
- 35. Schneider RH, Grim CE, Rainforth MV, Kotchen T, Nidich SI, Gaylord-King C, Salerno JW, Kotchen JM, Alexander CN. Stress reduction in the secondary prevention of cardiovascular disease: randomized, controlled trial of Transcendental Meditation and health education in blacks. *Circ Cardiovasc Qual Outcomes*. 2012;5:750–758.
- Barnes VA, Davis HC, Murzynowski JB, Treiber FA. Impact of meditation on resting and ambulatory blood pressure and heart rate in youth. *Psychosom Med.* 2004;66:909–914.
- Campbell TS, Labelle LE, Bacon SL, Faris P, Carlson LE. Impact of Mindfulness-Based Stress Reduction (MBSR) on attention, rumination and resting blood pressure in women with cancer: a waitlist-controlled study. J Behav Med. 2012;35:262–271.
- Carlson LE, Speca M, Faris P, Patel KD. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. *Brain Behav Immun*. 2007;21:1038–1049.
- Ditto B, Eclache M, Goldman N. Short-term autonomic and cardiovascular effects of mindfulness body scan meditation. *Ann Behav Med.* 2006;32: 227–234.
- Gregoski MJ, Barnes VA, Tingen MS, Harshfield GA, Treiber FA. Breathing awareness meditation and LifeSkills Training programs influence upon ambulatory blood pressure and sodium excretion among African American adolescents. J Adolesc Health. 2011;48:59–64.
- Kingston J, Chadwick P, Meron D, Skinner TC. A pilot randomized control trial investigating the effect of mindfulness practice on pain tolerance, psychological well-being, and physiological activity. J Psychosom Res. 2007;62:297–300.
- 42. Manikonda JP, Störk S, Tögel S, Lobmüller A, Grünberg I, Bedel S, Schardt F, Angermann CE, Jahns R, Voelker W. Contemplative meditation reduces ambulatory blood pressure and stress-induced hypertension: a randomized pilot trial. *J Hum Hypertens*. 2008;22:138–140.
- Ditto B, Eclache M, Goldman N. Short-term autonomic and cardiovascular effects of mindfulness body scan meditation. *Ann Behav Med*. 2006;32:227–234.
- 44. Carlson LE, Speca M, Faris P, Patel KD. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. *Brain Behav Immun.* 2007;21:1038–1049.
- 45. Blom K, How M, Dai M, Baker B, Irvine J, Abbey S, Abramson BL, Myers M, Perkins N, Tobe SW. Hypertension Analysis of stress Reduction using Mindfulness meditatiON and Yoga (The HARMONY Study): study protocol of a randomised control trial. *BMJ Open*. 2012;2:e000848.
- Schwartz MS, Andrasik F. Biofeedback: A Practitioner's Guide. New York, NY: Guilford Press; 2005.
- Greenhalgh J, Dickson R, Dundar Y. Biofeedback for hypertension: a systematic review. J Hypertens. 2010;28:644–652.
- McCraty R, Atkinson M, Tomasino D. Impact of a workplace stress reduction program on blood pressure and emotional health in hypertensive employees. J Altern Complement Med. 2003;9:355–369.

- Nakao M, Yano E, Nomura S, Kuboki T. Blood pressure-lowering effects of biofeedback treatment in hypertension: a meta-analysis of randomized controlled trials. *Hypertens Res.* 2003;26:37–46.
- Linden W, Moseley JV. The efficacy of behavioral treatments for hypertension. Appl Psychophysiol Biofeedback. 2006;31:51–63.
- Linden W, Lenz JW, Con AH. Individualized stress management for primary hypertension: a randomized trial. Arch Intern Med. 2001;161:1071–1080.
- Nolan RP, Floras JS, Harvey PJ, Kamath MV, Picton PE, Chessex C, Hiscock N, Powell J, Catt M, Hendrickx H, Talbot D, Chen MH. Behavioral neurocardiac training in hypertension: a randomized, controlled trial. *Hypertension*. 2010;55:1033–1039.
- Yucha CB, Tsai PS, Calderon KS, Tian L. Biofeedback-assisted relaxation training for essential hypertension: who is most likely to benefit? J Cardiovasc Nurs. 2005;20:198–205.
- Yang K. A review of yoga programs for four leading risk factors of chronic diseases. *Evid Based Complement Alternat Med.* 2007;4:487–491.
- Okonta NR. Does yoga therapy reduce blood pressure in patients with hypertension? An integrative review. *Holist Nurs Pract*. 2012;26:137–141.
- Khatri D, Mathur KC, Gahlot S, Jain S, Agrawal RP. Effects of yoga and meditation on clinical and biochemical parameters of metabolic syndrome. *Diabetes Res Clin Pract.* 2007;78:e9–e10.
- Thomley BS, Ray SH, Cha SS, Bauer BA. Effects of a brief, comprehensive, yoga-based program on quality of life and biometric measures in an employee population: a pilot study. *Explore (NY)*. 2011;7:27–29.
- Parshad O, Richards A, Asnani M. Impact of yoga on haemodynamic function in healthy medical students. West Indian Med J. 2011;60:148–152.
- Murugesan R, Govindarajulu N, Bera TK. Effect of selected yogic practices on the management of hypertension. *Indian J Physiol Pharmacol*. 2000;44:207–210.
- 60. Cohen DL, Bloedon LT, Rothman RL, Farrar JT, Galantino ML, Volger S, Mayor C, Szapary PO, Townsend RR. Iyengar yoga versus enhanced usual care on blood pressure in patients with prehypertension to stage I hypertension: a randomized controlled trial. *Evid Based Complement Alternat Med.* 2009;2011:546428.
- Cade WT, Reeds DN, Mondy KE, Overton ET, Grassino J, Tucker S, Bopp C, Laciny E, Hubert S, Lassa-Claxton S, Yarasheski KE. Yoga lifestyle intervention reduces blood pressure in HIV-infected adults with cardiovascular disease risk factors. *HIV Med*. 2010;11:379–388.
- Santaella DF, Araújo EA, Ortega KC, Tinucci T, Mion D Jr, Negrão CE, de Moraes Forjaz CL. Aftereffects of exercise and relaxation on blood pressure. *Clin J Sport Med.* 2006;16:341–347.
- Kaufmann PG, Jacob RG, Ewart CK, Chesney MA, Muenz LR, Doub N, Mercer W. Hypertension Intervention Pooling Project. *Health Psychol*. 1988;7(suppl):209–224.
- Jacob R, Chesney M, Williams D, Ding Y. Relaxation therapy for hypertension: design effects and treatment effects. *Ann Behav Med.* 1991;13:5–7.
- Eisenberg DM, Delbanco TL, Berkey CS, Kaptchuk TJ, Kupelnick B, Kuhl J, Chalmers TC. Cognitive behavioral techniques for hypertension: are they effective? *Ann Intern Med.* 1993;118:964–972.
- Linden W, Chambers L. Clinical effectiveness of non-drug treatment for hypertension. Ann Behav Med. 1994;16:35–45.
- Dickinson H, Campbell F, Beyer F, Nicolson DJ, Cook J, Ford G, Mason J. Relaxation therapies for the management of primary hypertension in adults: a Cochrane review. *J Hum Hypertens*. 2008;22:809–820.
- Tang HY, Harms V, Speck SM, Vezeau T, Jesurum JT. Effects of audio relaxation programs for blood pressure reduction in older adults. *Eur J Cardiovasc Nurs.* 2009;8:329–336.
- 69. Dusek JA, Hibberd PL, Buczynski B, Chang BH, Dusek KC, Johnston JM, Wohlhueter AL, Benson H, Zusman RM. Stress management versus lifestyle modification on systolic hypertension and medication elimination: a randomized trial. *J Altern Complement Med.* 2008;14:129–138.
- Perez MI, Linden W, Perry T Jr, Puil LJ, Wright JM. Failure of psychological interventions to lower blood pressure: a randomized controlled trial. *Open Med.* 2009;3:e92–e100.
- World Health Organization. Acupuncture: review and analysis of reports on controlled clinical trials. 1996. http://whqlibdoc.who.int/publications/ 2002/9241545437.pdf. Accessed April 8, 2013.
- Lee H, Kim SY, Park J, Kim YJ, Lee H, Park HJ. Acupuncture for lowering blood pressure: systematic review and meta-analysis. *Am J Hypertens*. 2009;22:122–128.
- Kim LW, Zhu J. Acupuncture for essential hypertension. *Altern Ther Health Med.* 2010;16:18–29.
- Flachskampf FA, Gallasch J, Gefeller O, Gan J, Mao J, Pfahlberg AB, Wortmann A, Klinghammer L, Pflederer W, Daniel WG. Randomized trial of acupuncture to lower blood pressure. *Circulation*. 2007;115:3121–3129.

- Yin C, Seo B, Park HJ, Cho M, Jung W, Choue R, Kim C, Park HK, Lee H, Koh H. Acupuncture, a promising adjunctive therapy for essential hypertension: a double-blind, randomized, controlled trial. *Neurol Res.* 2007;29(suppl 1):S98–S103.
- Macklin EA, Wayne PM, Kalish LA, Valaskatgis P, Thompson J, Pian-Smith MC, Zhang Q, Stevens S, Goertz C, Prineas RJ, Buczynski B, Zusman RM. Stop Hypertension with the Acupuncture Research Program (SHARP): results of a randomized, controlled clinical trial. *Hypertension*. 2006;48:838–845.
- Langevin HM, Churchill DL, Cipolla MJ. Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture. *FASEB J.* 2001;15:2275–2282.
- Chao DM, Shen LL, Tjen-A-Looi S, Pitsillides KF, Li P, Longhurst JC. Naloxone reverses inhibitory effect of electroacupuncture on sympathetic cardiovascular reflex responses. *Am J Physiol*. 1999;276(pt 2):H2127–H2134.
- Yamamoto H, Kawada T, Kamiya A, Miyazaki S, Sugimachi M. Involvement of the mechanoreceptors in the sensory mechanisms of manual and electrical acupuncture. *Auton Neurosci.* 2011;160:27–31.
- Napadow V, Makris N, Liu J, Kettner NW, Kwong KK, Hui KK. Effects of electroacupuncture versus manual acupuncture on the human brain as measured by fMRI. *Hum Brain Mapp.* 2005;24:193–205.
- Chiu YJ, Chi A, Reid IA. Cardiovascular and endocrine effects of acupuncture in hypertensive patients. *Clin Exp Hypertens*. 1997;19:1047–1063.
- Li P, Longhurst JC. Neural mechanism of electroacupuncture's hypotensive effects. *Auton Neurosci*. 2010;157:24–30.
- Benson H, Rosner BA, Marzetta BR, Klemchuk HM. Decreased bloodpressure in pharmacologically treated hypertensive patients who regularly elicited the relaxation response. *Lancet*. 1974;1:289–291.
- Bernardi L, Sleight P, Bandinelli G, Cencetti S, Fattorini L, Wdowczyc-Szulc J, Lagi A. Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study. *BMJ*. 2001;323:1446–1449.
- Irvine MJ, Johnston DW, Jenner DA, Marie GV. Relaxation and stress management in the treatment of essential hypertension. *J Psychosom Res.* 1986;30:437–450.
- Patel C. 12-Month follow-up of yoga and bio-feedback in the management of hypertension. *Lancet*. 1975;1:62–64.
- Mori H, Yamamoto H, Kuwashima M, Saito S, Ukai H, Hirao K, Yamauchi M, Umemura S. How does deep breathing affect office blood pressure and pulse rate? *Hypertens Res.* 2005;28:499–504.
- 88. Resperate for hypertension. Med Lett Drugs Ther. 2007;49:55-56.
- Elliott WJ, Izzo JL Jr. Device-guided breathing to lower blood pressure: case report and clinical overview. *MedGenMed*. 2006;8:23.
- Altena MR, Kleefstra N, Logtenberg SJ, Groenier KH, Houweling ST, Bilo HJ. Effect of device-guided breathing exercises on blood pressure in patients with hypertension: a randomized controlled trial. *Blood Press*. 2009;18:273–279.
- Anderson DE, McNeely JD, Windham BG. Regular slow-breathing exercise effects on blood pressure and breathing patterns at rest. J Hum Hypertens. 2010;24:807–813.
- Elliot WJ, Izzo JL Jr, White WB, Rosing DR, Snyder CS, Alter A, Gavish B, Black HR. Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing. J Clin Hypertens (Greenwich). 2004;6:553–559; quiz 560–561.
- Grossman E, Grossman A, Schein MH, Zimlichman R, Gavish B. Breathing-control lowers blood pressure. J Hum Hypertens. 2001;15: 263–269.
- Bae JH, Kim JH, Choe K-H, Hong SP, Ko JK, Kim CH, et al. Effect of device-guided breathing exercise on blood pressure control: Korean multi-center study. *Korean Hypertens J*. 2006;25:241–246.
- Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Bilo HJ. Effect of device-guided breathing exercises on blood pressure in hypertensive patients with type 2 diabetes mellitus: a randomized controlled trial. J Hypertens. 2007;25:241–246.
- Meles E, Giannattasio C, Failla M, Gentile G, Capra A, Mancia G. Nonpharmacologic treatment of hypertension by respiratory exercise in the home setting. *Am J Hypertens*. 2004;17:370–374.
- Rosenthal T, Alter A, Peleg E, Gavish B. Device-guided breathing exercises reduce blood pressure: ambulatory and home measurements. *Am J Hypertens*. 2001;14:74–76.
- Schein MH, Gavish B, Herz M, Rosner-Kahana D, Naveh P, Knishkowy B, Zlotnikov E, Ben-Zvi N, Melmed RN. Treating hypertension with a device that slows and regularises breathing: a randomised, double-blind controlled study. *J Hum Hypertens*. 2001;15:271–278.
- Viskoper R, Shapira I, Priluck R, Mindlin R, Chornia L, Laszt A, Dicker D, Gavish B, Alter A. Nonpharmacologic treatment of resistant

hypertensives by device-guided slow breathing exercises. *Am J Hypertens*. 2003;16:484–487.

- 100. Schein MH, Gavish B, Baevsky T, Kaufman M, Levine S, Nessing A, Alter A. Treating hypertension in type II diabetic patients with device-guided breathing: a randomized controlled trial. *J Hum Hypertens*. 2009;23:325–331.
- 101. Bertisch SM, Schomer A, Kelly EE, Baloa LA, Hueser LE, Pittman SD, Malhotra A. Device-guided paced respiration as an adjunctive therapy for hypertension in obstructive sleep apnea: a pilot feasibility study. *Appl Psychophysiol Biofeedback*. 2011;36:173–179.
- Gavish B. Device-guided breathing in the home setting: technology, performance and clinical outcomes. *Biol Psychol.* 2010;84:150–156.
- Pagani M, Somers V, Furlan R, Dell'Orto S, Conway J, Baselli G, Cerutti S, Sleight P, Malliani A. Changes in autonomic regulation induced by physical training in mild hypertension. *Hypertension*. 1988;12:600–610.
- Mahtani KR, Nunan D, Heneghan CJ. Device-guided breathing exercises in the control of human blood pressure: systematic review and meta-analysis. J Hypertens. 2012;30:852–860.
- Brook RD, Julius S. Autonomic imbalance, hypertension, and cardiovascular risk. Am J Hypertens. 2000;13(pt 2):112S–122S.
- Mancia G. Björn Folkow Award Lecture: the sympathetic nervous system in hypertension. J Hypertens. 1997;15(pt 2):1553–1565.
- 107. Radaelli A, Bernardi L, Valle F, Leuzzi S, Salvucci F, Pedrotti L, Marchesi E, Finardi G, Sleight P. Cardiovascular autonomic modulation in essential hypertension: effect of tilting. *Hypertension*. 1994;24:556–563.
- Oneda B, Ortega KC, Gusmão JL, Araújo TG, Mion D Jr. Sympathetic nerve activity is decreased during device-guided slow breathing. *Hypertens Res.* 2010;33:708–712.
- Schelegle ES, Green JF. An overview of the anatomy and physiology of slowly adapting pulmonary stretch receptors. *Respir Physiol.* 2001;125:17–31.
- Sharma M, Frishman WH, Gandhi K. RESPeRATE: nonpharmacological treatment of hypertension. *Cardiol Rev.* 2011;19:47–51.
- Sica DA. Device-guided breathing and hypertension: a yet to be determined positioning. *Cardiol Rev.* 2011;19:45–46.
- 112. Williams MA, Haskell WL, Ades PA, Amsterdam EA, Bittner V, Franklin BA, Gulanick M, Laing ST, Stewart KJ. Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. *Circulation*. 2007;116:572–584.
- 113. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, Fulton JE, Gordon NF, Haskell WL, Link MS, Maron BJ, Mittleman MA, Pelliccia A, Wenger NK, Willich SN, Costa F. Exercise and acute cardiovascular events: placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. *Circulation*. 2007;115:2358–2368.
- 114. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA; American College of Sports Medicine. American College of Sports Medicine position stand: exercise and hypertension. *Med Sci Sports Exerc.* 2004;36:533–553.
- 115. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP; American College of Sports Medicine. American College of Sports Medicine position stand: quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc.* 2011;43:1334–1359.
- Rudd JL, Day WC. A physical fitness program for patients with hypertension. J Am Geriatr Soc. 1967;15:373–379.
- 117. Fagard RH, Cornelissen VA. Effect of exercise on blood pressure control in hypertensive patients. *Eur J Cardiovasc Prev Rehabil.* 2007;14:12–17.
- Cardoso CG Jr, Gomides RS, Queiroz AC, Pinto LG, da Silveira Lobo F, Tinucci T, Mion D Jr, de Moraes Forjaz CL. Acute and chronic effects of aerobic and resistance exercise on ambulatory blood pressure. *Clinics* (*Sao Paulo*). 2010;65:317–325.
- Lee LL, Watson MC, Mulvaney CA, Tsai CC, Lo SF. The effect of walking intervention on blood pressure control: a systematic review. *Int J Nurs Stud.* 2010;47:1545–1561.
- 120. Robbins CL, Dietz PM, Bombard J, Tregear M, Schmidt SM, Tregear SJ. Lifestyle interventions for hypertension and dyslipidemia among women of reproductive age. *Prev Chronic Dis.* 2011;8:A123.
- 121. Cornelissen VA, Arnout J, Holvoet P, Fagard RH. Influence of exercise at lower and higher intensity on blood pressure and cardiovascular risk factors at older age. J Hypertens. 2009;27:753–762.

- 122. Eicher JD, Maresh CM, Tsongalis GJ, Thompson PD, Pescatello LS. The additive blood pressure lowering effects of exercise intensity on postexercise hypotension. *Am Heart J.* 2010;160:513–520.
- 123. Guimarães GV, Ciolac EG, Carvalho VO, D'Avila VM, Bortolotto LA, Bocchi EA. Effects of continuous vs. interval exercise training on blood pressure and arterial stiffness in treated hypertension. *Hypertens Res.* 2010;33:627–632.
- 124. Molmen-Hansen HE, Stolen T, Tjonna AE, Aamot IL, Ekeberg IS, Tyldum GA, Wisloff U, Ingul CB, Stoylen A. Aerobic interval training reduces blood pressure and improves myocardial function in hypertensive patients. *Eur J Prev Cardiol.* 2012;19:151–160.
- 125. Westhoff TH, Schmidt S, Gross V, Joppke M, Zidek W, van der Giet M, Dimeo F. The cardiovascular effects of upper-limb aerobic exercise in hypertensive patients. *J Hypertens*. 2008;26:1336–1342.
- 126. Pitsavos C, Chrysohoou C, Koutroumbi M, Aggeli C, Kourlaba G, Panagiotakos D, Michaelides A, Stefanadis C. The impact of moderate aerobic physical training on left ventricular mass, exercise capacity and blood pressure response during treadmill testing in borderline and mildly hypertensive males. *Hellenic J Cardiol*. 2011;52:6–14.
- 127. Park S, Rink LD, Wallace JP. Accumulation of physical activity leads to a greater blood pressure reduction than a single continuous session, in prehypertension. *J Hypertens*. 2006;24:1761–1770.
- 128. Leehey DJ, Moinuddin I, Bast JP, Qureshi S, Jelinek CS, Cooper C, Edwards LC, Smith BM, Collins EG. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. *Cardiovasc Diabetol.* 2009;8:62.
- 129. Koh KP, Fassett RG, Sharman JE, Coombes JS, Williams AD. Effect of intradialytic versus home-based aerobic exercise training on physical function and vascular parameters in hemodialysis patients: a randomized pilot study. *Am J Kidney Dis.* 2010;55:88–99.
- 130. Stensvold D, Tjønna AE, Skaug EA, Aspenes S, Stølen T, Wisløff U, Slørdahl SA. Strength training versus aerobic interval training to modify risk factors of metabolic syndrome. J Appl Physiol. 2010;108:804–810.
- 131. Andrews RC, Cooper AR, Montgomery AA, Norcross AJ, Peters TJ, Sharp DJ, Jackson N, Fitzsimons K, Bright J, Coulman K, England CY, Gorton J, McLenaghan A, Paxton E, Polet A, Thompson C, Dayan CM. Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. *Lancet*. 2011;378:129–139.
- 132. Collier SR, Frechette V, Sandberg K, Schafer P, Ji H, Smulyan H, Fernhall B. Sex differences in resting hemodynamics and arterial stiffness following 4 weeks of resistance versus aerobic exercise training in individuals with pre-hypertension to stage 1 hypertension. *Biol Sex Differ*. 2011;2:9.
- 133. Kokkinos P, Myers J, Faselis C, Panagiotakos DB, Doumas M, Pittaras A, Manolis A, Kokkinos JP, Karasik P, Greenberg M, Papademetriou V, Fletcher R. Exercise capacity and mortality in older men: a 20-year follow-up study. *Circulation*. 2010;122:790–797.
- 134. Martins RA, Veríssimo MT, Coelho e Silva MJ, Cumming SP, Teixeira AM. Effects of aerobic and strength-based training on metabolic health indicators in older adults. *Lipids Health Dis*. 2010;9:76.
- Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. *Hypertension*. 2012;60:653–658.
- 136. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. *Hypertension*. 2011;58: 950–958.
- 137. Rossi A, Moullec G, Lavoie KL, Bacon SL. Resistance training, blood pressure, and meta-analyses [comment]. *Hypertension*. 2012;59:e22– e23; author reply e24.
- 138. Moraes MR, Bacurau RF, Simões HG, Campbell CS, Pudo MA, Wasinski F, Pesquero JB, Würtele M, Araujo RC. Effect of 12 weeks of resistance exercise on post-exercise hypotension in stage 1 hypertensive individuals. J Hum Hypertens. 2012;26:533–539.
- 139. Berent R, von Duvillard SP, Crouse SF, Sinzinger H, Green JS, Schmid P. Resistance training dose response in combined endurance-resistance training in patients with cardiovascular disease: a randomized trial. *Arch Phys Med Rehabil*. 2011;92:1527–1533.
- 140. Casey DP, Beck DT, Braith RW. Progressive resistance training without volume increases does not alter arterial stiffness and aortic wave reflection. *Exp Biol Med (Maywood)*. 2007;232:1228–1235.
- 141. Rakobowchuk M, McGowan CL, de Groot PC, Hartman JW, Phillips SM, MacDonald MJ. Endothelial function of young healthy males following whole body resistance training. *J Appl Physiol*. 2005;98:2185–2190.

- 142. Rakobowchuk M, McGowan CL, de Groot PC, Bruinsma D, Hartman JW, Phillips SM, MacDonald MJ. Effect of whole body resistance training on arterial compliance in young men. *Exp Physiol.* 2005;90:645–651.
- 143. Carter JR, Ray CA, Downs EM, Cooke WH. Strength training reduces arterial blood pressure but not sympathetic neural activity in young normotensive subjects. J Appl Physiol. 2003;94:2212–2216.
- 144. Collier SR, Kanaley JA, Carhart R Jr, Frechette V, Tobin MM, Bennett N, Luckenbaugh AN, Fernhall B. Cardiac autonomic function and baroreflex changes following 4 weeks of resistance versus aerobic training in individuals with pre-hypertension. *Acta Physiol (Oxf)*. 2009;195:339–348.
- 145. Cortez-Cooper MY, DeVan AE, Anton MM, Farrar RP, Beckwith KA, Todd JS, Tanaka H. Effects of high intensity resistance training on arterial stiffness and wave reflection in women. *Am J Hypertens*. 2005;18:930–934.
- 146. Kelley GA, Kelley KS. Isometric handgrip exercise and resting blood pressure: a meta-analysis of randomized controlled trials. J Hypertens. 2010;28:411–418.
- 147. Chrysant SG. Current evidence on the hemodynamic and blood pressure effects of isometric exercise in normotensive and hypertensive persons. J Clin Hypertens (Greenwich). 2010;12:721–726.
- Millar PJ, Paashuis A, McCartney N. Isometric handgrip effects on hypertension. *Curr Hypertens Rev.* 2009;5:54–60.
- 149. Millar PJ, Bray SR, MacDonald MJ, McCartney N. The hypotensive effects of isometric handgrip training using an inexpensive spring handgrip training device. J Cardiopulm Rehabil Prev. 2008;28:203–207.
- Devereux GR, Wiles JD, Swaine IL. Reductions in resting blood pressure after 4 weeks of isometric exercise training. *Eur J Appl Physiol*. 2010;109:601–606.
- Wiles JD, Coleman DA, Swaine IL. The effects of performing isometric training at two exercise intensities in healthy young males. *Eur J Appl Physiol.* 2010;108:419–428.
- 152. de Souza Nery S, Gomides RS, da Silva GV, de Moraes Forjaz CL, Mion D Jr, Tinucci T. Intra-arterial blood pressure response in hypertensive subjects during low- and high-intensity resistance exercise. *Clinics (Sao Paulo)*. 2010;65:271–277.
- 153. Symplicity HTN-2 Investigators; Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 trial): a randomised controlled trial. *Lancet*. 2010;376:1903–1909.

- 154. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. *Hypertension*. 2011;57:911–917.
- 155. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol. 2011;58:765–773.
- 156. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. *Hypertension*. 2010;55:619–626.
- Baguet JP, Barone-Rochette G, Pépin JL. Hypertension and obstructive sleep apnoea syndrome: current perspectives. J Hum Hypertens. 2009;23:431–443.
- 158. Lozano L, Tovar JL, Sampol G, Romero O, Jurado MJ, Segarra A, Espinel E, Ríos J, Untoria MD, Lloberes P. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. *J Hypertens.* 2010;28:2161–2168.
- Nahas R. Complementary and alternative medicine approaches to blood pressure reduction: an evidence-based review. *Can Fam Physician*. 2008;54:1529–1533.
- Shiroma EJ, Lee IM. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. *Circulation*. 2010;122:743–752.
- 161. Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. *Circulation*. 2011;124:789–795.
- 162. Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, Caccia C, Johnson J, Waugh R, Sherwood A. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010;170:126–135.
- 163. Nelson M, Reid C, Krum H, McNeil J. A systematic review of predictors of maintenance of normotension after withdrawal of antihypertensive drugs. *Am J Hypertens*. 2001;14:98–105.
- 164. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA. Refractory hypertension: definition, prevalence, and patients characteristics. J Clin Hypertens (Greenwich). 2012;14:7–12.

AMERICAN HEART ASSOCIATION SCIENTIFIC STATEMENT: Beyond Medications and Diet: Alternative Approaches to Lowering Blood Pressure

Online supplement: Methods and Results

ONLINE SUPPLEMENTAL METHODS Systematic Review Search Strategies and Terms

Alternative BP-Lowering Approaches Sections of the document had search strategies using PubMed constructed for human and English language studies published between 1/1/2006 through 10/31/2011. The search strategy consisted of terms for a "HypertensionBase" (defined below) plus a "Clinical Studies (CS)/Systematic Reviews (SR) /Practice Guidelines (PG) base" (defined below). These 2 search bases were next combined with the corresponding search strategy for each treatment modality section (Sections A-C). Medical Subject Heading (MeSH) categories were used in the searches.

Hypertension Base

"Prehypertension"[Mesh] OR "Hypertension"[Mesh] OR "Blood pressure"[Mesh] OR hypertensi* OR prehypertensi* OR prehypertensi* OR "Pre hypertensive" OR "pre hypertension" OR "high blood pressure" OR "elevated blood pressure"

Clinical Queries Therapy/Broad OR Systematic Review

((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) OR **systematic [sb]***

*Systematic Review search limit [sb]

(systematic review [ti] OR meta-analysis [pt] OR meta-analysis [ti] OR systematic literature review [ti] OR (systematic review [tiab] AND review [pt]) OR consensus development conference [pt] OR practice guideline [pt] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol assess [ta] OR evid rep technol assess summ [ta]) OR ((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab])AND (review [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR therapeutics [mh] OR evaluation studies[pt] OR validation studies[pt] OR quideline [pt]))OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection [tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] OR analysis [tiab] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] OR published [tiab] OR unpublished [tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta-analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome [tw])) NOT (letter [pt] OR newspaper article [pt] OR comment [pt])

Section A

Main search method = HypertensionBase AND *Clinical Studies (CS)/Systematic Reviews (SR) /Practice Guidelines (PG) Base* AND BehaviorBase

Yielded = 124 English language human publications on 11/8/2011

Behavior Therapy Base (BehaviorBase)

"Relaxation Therapy"[Mesh] OR "Yoga"[Mesh] OR "Biofeedback, Psychology"[Mesh] OR "Tai Ji"[Mesh] OR "Stress, Psychological/prevention and control"[Mesh] OR "Stress, Psychological/rehabilitation"[Mesh] OR "Stress, Psychological/therapy"[Mesh] OR meditat* OR "tai chi" OR "tai ji" OR "Tai chi" OR yoga

Section B

HypertensionBase AND CS/SR/PG base AND AcuBreathBase Yielded = 105 English language human publications on 11/8/2011

Acupuncture Resperate/Breathing Base (AcuBreathBase)

"Breathing Exercises"[Mesh] OR "Acupuncture Therapy"[Mesh] OR "Acupuncture"[Mesh] OR "Massage"[Mesh] OR "Ultraviolet Rays"[Mesh] OR "Ultraviolet Therapy"[Mesh] OR "Steam Bath"[Mesh] OR acupuncture OR qigong OR "qi gong" OR "ch'i kung" OR "RESPERATE" OR "device-guided breathing" OR ("device-guided" AND "breathing")

Section C

HypertensionBase AND CS/SR/PG base AND ExerciseBase Yielded = 3090 (773 after review) English language human publications on 10/18/2011

Exercise Base

"Exercise"[Mesh] OR "Physical Exertion"[Mesh] OR "Physical Fitness"[Mesh] OR "Exercise Therapy"[Mesh] OR exercise OR **(Exercise subtopics ORed together)**

ONLINE SUPPLEMENTAL RESULTS

BEHAVIORAL THERAPIES

Meditation Techniques

Contemplative meditation has most often been studied as Zen meditation or mindfulness meditation. Transcendental medication is based on meditative practices originating in Indian philosophic traditions and typically involves focused attention on a word, phrase, or concept to allow a state of awareness/consciousness.¹ Mindfulness meditation may be best described inculcating a nonjudgmental awareness characterized by openness, acceptance, and reflection.² Meditation has been practiced for thousands of years and is associated with religious and cultural practices³ such as Hinduism (as part of the Upanishads, part of Hindu scriptures and a treatise on the Vedas, Ashtanga Yoga and Hatha yoga) and Buddhism (i.e., mindfulness is the 7th step of the Noble Eightfold Path). Maharishi Mahesh Yogi popularized a version of meditation called Transcendental Meditation (TM) in the 1950's which is arguably the most studied meditative practice in regards to BP-lowering. Mindfulness meditation has also been incorporated into a group stress management intervention by Jon Kabat-Zinn, when he founded the Mindfulness-based Stress Reduction (MBSR) program at University of Massachusetts-Amherst to treat patients with chronic pain.⁴

Yoga

The term Yoga (Sanskrit meaning "union") originated in Hindu scriptures such as the Upanishads (ca.1500 BCE). In its truest sense, yoga incorporates physical, mental and spiritual elements with the goal of unifying these aspects. Patañjali (fl 150 BC), also the father of Ayurvedic medicine, wrote a treatise called the Yoga Sutras in which he formalized this discipline. Ashtanga yoga (Sanskrit, eight limbs) is the yoga of Patañjali and is composed of eight components: yama and niyama (moral and ethical restraints); asana (postures/positions); pranayama (breath control); pratyahara (internalization of the senses); dharana (concentration); dhyana (meditation); samadhi (mastery over the mind). The eight limbs can be viewed as eight levels of progress, each level providing benefits and laying the foundation for higher levels. Thus, the practice of yoga is intertwined with meditative and contemplative aspects that are inseparable. It is often emphasized that the physical yogic exercises are only a means to get the body ready for mental practices such as meditation. Hatha yoga is the other branch of yoga that in a sense focuses on the more physical aspects of the original eight limbs (asana, pranayama, pratyahara, dharana, dhyana and samādhi) again with ultimate goal of samadhi. Hatha Yoga differs

substantially from the Yoga of Patanjali in that it focuses on the purification of the physical body leading to the purification of the mind ("ha"), and "prana," or vital energy (tha). Compared to the seated asana, or sitting meditation posture of Patanjali's yoga, full body 'postures' are common in Hatha yoga. In the West, the term "yoga" is today typically associated with Hatha Yoga and its asanas (postures) as a form of exercise. In the 1960s, interest in Hindu spirituality grew throughout western nations, giving rise to a great number of schools. Among the teachers of Hatha yoga who were active in the west in this period were B.K.S. Iyengar (Iyengar yoga), K. Pattabhi Jois (Ashtanga- Vinyāsa) and Swami Satchidananda (Integral Yoga). A number of forms of yoga that primarily emphasize the callisthenic aspects of yoga have also gained traction in the west. These include "Power Yoga" which is a more vigorous asana practice and Bikram yoga which is primarily asanas practiced in hot temperature, which is not recommended for those with hypertension, especially individuals taking medications.

ADDITIONAL METHODS

Renal nerve ablation

The key role of the kidney and of the sympathetic system in the pathogenesis and maintenance of hypertension has long been recognized. Renal sympathetic efferent nerves influence the ability of the kidney to handle sodium-volume homeostasis and the afferent outflow promotes the sympathetic stimulation of other systems. Historically, radical sympathectomy was one of the only therapeutic methods for malignant hypertension, but this invasive surgery was fraught with serious adverse effects. More recently, the selective inhibition of the renal sympathetic nerve traffic by percutaneous catheterbased radiofrequency ablation has been explored. In a series of 50 patients with uncontrolled hypertension (systolic BP>160 mm Hg and taking at least 3 medications), BP was lowered by 27/17 mm Hg 12 months after sympathetic ablation.⁵ In a follow-up study involving 153 patients with resistant hypertension the BP-lowering benefits were shown to be maintained over 2 years.⁶ More robust evidence has recently been provided by a randomized controlled trial involving 106 patients with resistant hypertension.⁷ The between-group difference of active treatment versus control in office BP at 6 months was 33/11 mm Hg (P < 0.0001). Thus far, few serious side effects and little evidence for longterm adverse consequences (e.g. renal artery stenosis) have been reported.

We were able to identify at least 15 registered in clinical trials aiming to test the efficacy of renal nerve ablation in hypertension and other disease states (e.g. heart failure).⁸ Other benefits of the treatment reported thus far include improvements in OSA severity as well as insulin sensitivity.⁹ These

findings have illustrated that renal sympathetic percutaneous ablation is a promising procedure to control systemic sympathetic efferent activity and as such may favorably affect other CV and metabolic diseases in addition to lowering BP. The results from ongoing larger clinical trials aiming to establish the efficacy and safety of this procedure over longer follow-up periods are awaited.

Carotid baroreceptor stimulation

Improvements in technology over the past decade have allowed for the programmable stimulation of carotid baroreceptors as a potential novel treatment option for resistant hypertension. The surgically implanted device consists of an internal programmable pulse generator, 2 electrode leads, and 2 field electrodes. The leads are positioned over the carotid sinuses bilaterally where electrical pulses are delivered (bilaterally or unilaterally as required) and intensified as needed to achieve the required BP-lowering. Initial studies showed promising results for this treatment modality termed baroreflex activation therapy (BAT).^{10, 11}

Recently, the BP-lowering efficacy and safety of this device were investigated in a complex multi-center randomized clinical trial (phase III Rheos Pivotal Trial) among 265 patients with resistant hypertension.¹² After device implantation, one set of subjects started active BAT one month later while the second group was randomized to a delayed treatment limb with the device activated after six months. There were 2 BP-related co-primary endpoints. At the six month time point when the acute efficacy endpoint was evaluated, 54% of the participants of the initially-activated group and 46% of the non-active group reached the pre-specified endpoint of a drop of least a 10 mmHg in systolic blood pressure (P = 0.97). On the other hand, the sustained BP-lowering efficacy endpoint determined at month 12 did reach significance. The investigators cited several methodological limitations potentially explaining the negative results of the acute efficacy endpoint (e.g. unexpected reductions in BP after device implantation prior to randomization, larger than expected variability in BP changes and decreases in BP in the delayed BAT group during the first 6 months). Post hoc analyses evaluating the BP reductions in each limb compared to pre-implantation BP levels showed significant reductions in systolic BP at 6 months in the active versus delayed BAT (26 vs 17 mm Hg, p=0.03). However, there were also some concerning treatment-induced adverse events related to lead placement including transient (4.4%) or permanent nerve injury (4.8%), along with a 4.8% surgical complication rate. Overall, the results of this pivotal study were mixed. Future studies are planned that will employ improved technology (device miniaturization) along with a less invasive implantation procedures and

predominately unilateral carotid stimulation (which was shown to be successful for inducing BPlowering among 75% of subjects in the pivot trial).

Continuous Positive Airway Pressure (CPAP)

Obstructive sleep apnea (OSA) has been identified as a risk factor for hypertension in many¹³⁻¹⁵ but not all studies¹⁶. Excess adiposity is a strong risk factor for both hypertension and OSA and could serve as the underlying intermediate mechanism explaining the association between these comorbidities. On the other hand, OSA is a strong and independent risk factor for resistant hypertension^{17, 18} and several animal and human studies have demonstrated a variety of direct mechanistic linkages between the pathophysiology of OSA and elevated BP.^{19, 20}

The use of CPAP as a means to lower BP has been investigated by secondary analysis of various trials testing its efficacy in the treatment of OSA and in a few studies as the primary outcome. A metaanalysis of trials with office BP measurement identified a mean net decrease in systolic BP of 2.5 mm Hg (95% CI: 4.3 to 0.6) in patients treated with CPAP compared with control. The corresponding effect for diastolic BP was 1.8 mm Hg (95% CI: 3.1 to 0.6).²¹ A meta-analysis of trials using ambulatory BP monitoring²² demonstrated a discernable effect of CPAP as well (1.8 mmHg, 95% CI from 3.0 to 0.5 for 24-hour SBP and 1.8 (2.9 to 0.7) for 24-hour DBP).²² A larger and more recent trial with ambulatory BP monitoring confirmed these results.²³ CPAP may also lower BP in patients with prehypertension and masked hypertension.²⁴ In a relatively small trial testing the efficacy of CPAP in patients with resistant hypertension,²⁵ 24 hour diastolic BP decreased significantly in patients treated with CPAP (4.9 ± 6.4 versus 0.1 ± 7.3mmHg in patients from the control group, P = 0.027).

The individual studies and meta-analyses show that though CPAP significantly lowers BP, on average the magnitude of reduction is clinically modest. However, it has been suggested that patients with higher levels of BP, those with refractory hypertension, and those with more severe OSA may derive more robust CPAP-related BP reductions.¹⁹ Since the BP-lowering magnitude produced by CPAP is clearly less than that achieved with anti-hypertensive medications, as demonstrated in a recent randomized trial compared to valsartan therapy, the role of CPAP as a first line or primary method to treat OSA-related hypertension remains unjustified.²⁶ Nonetheless, CPAP is a viable additional modality to consider among patients with OSA and hypertension that may help lower BP modestly, ease hypertension control (particularly among those with resistant hypertension), and/or possibly reduce medication requirements.

Further Approaches

A limited number of studies have investigated the capacity of several additional treatments that could potentially lower BP. These include surgical decompression of the rostral ventral lateral medulla due to vascular contact or a mass lesion,²⁷ chiropractic manipulation of the first cervical vertebrae,²⁸ sauna and hot tub treatments,^{29, 30} whole body ultraviolet light irradiation,³¹ and enhanced external counter-pulsation therapy.³² Each approach may hold some promise, at least among a sub-set of patients; however, practical limitations or a paucity of high quality trials remain limitations.

A wide variety of nutraceuticals, herbal remedies, and dietary vitamins or micronutrients have been touted to have a favorable effect upon BP.^{33, 34} Some of the more widely studied or notable treatments include cocoa products,³⁵ garlic,³⁶ inorganic nitrates,^{37, 38} and lactotripeptides.^{39, 40} Additional agents with some and/or mixed evidence for BP-lowering effects include co-enzyme Q10, fish oil, Larginine, tetrahydrobiopterin, alpha lipoic acid, glutamate, polyphenols, and Vitamin D supplementation.^{33, 34} A complete review is beyond the scope of this scientific statement that focuses on approaches beyond "dietary" treatments. Futures larger or higher quality clinical trials are required to corroborate the clinical usefulness of each of these agents prior to them being recommended as viable approaches.

References

- 1. Birnbaum L, Birnbaum A. In search of inner wisdom: Guided mindfulness meditation in the context of suicide. *ScientificWorldJournal*. 2004;4:216-227
- 2. Kabat-Zinn J. An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: Theoretical considerations and preliminary results. *Gen Hosp Psychiatry*. 1982;4:33-47
- 3. Brown KW, Ryan RM. The benefits of being present: Mindfulness and its role in psychological well-being. *J Pers Soc Psychol*. 2003;84:822-848
- 4. Kabat-Zinn J, University of Massachusetts Medical C. *Full catastrophe living : Using the wisdom of your body and mind to face stress, pain, and illness*. New York, N.Y.: Delta Trade Paperbacks; 2005.
- Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. *Lancet*. 2009;373:1275-1281
- SymplicityHTN-1Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. *Hypertension*. 2011;57:911-917
- 7. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): A randomised controlled trial. *Lancet*. 2010;376:1903-1909
- 8. ClinicalTrials.gov. 2011; Retrieved December 9, 2011, from <u>http://clinicaltrials.gov/ct2/results?term=sympathetic+renal+ablation+OR+denervation+OR+mo</u> <u>dification.</u>
- 9. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. *Hypertension*. 2011;58:559-565
- 10. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. *Hypertension*. 2010;55:619-626
- 11. Wustmann K, Kucera JP, Scheffers I, Mohaupt M, Kroon AA, de Leeuw PW, Schmidli J, Allemann Y, Delacretaz E. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. *Hypertension*. 2009;54:530-536
- Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-773
- 13. Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Leiby BE, Vela-Bueno A, Kales A. Association of hypertension and sleep-disordered breathing. *Arch Intern Med*. 2000;160:2289-2295
- Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep heart health study. *JAMA*. 2000;283:1829-1836
- 15. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleepdisordered breathing and hypertension. *N Engl J Med*. 2000;342:1378-1384

- 16. O'Connor GT, Caffo B, Newman AB, Quan SF, Rapoport DM, Redline S, Resnick HE, Samet J, Shahar E. Prospective study of sleep-disordered breathing and hypertension: The sleep heart health study. *Am J Respir Crit Care Med*. 2009;179:1159-1164
- 17. Goncalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I, Branchi T, Moreira LB, Fuchs SC, de Oliveira AC, Fuchs FD. Obstructive sleep apnea and resistant hypertension: A case-control study. *Chest*. 2007;132:1858-1862
- Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, Amodeo C, Bortolotto LA, Krieger EM, Bradley TD, Lorenzi-Filho G. Obstructive sleep apnea: The most common secondary cause of hypertension associated with resistant hypertension. *Hypertension*. 2011;58:811-817
- 19. Baguet JP, Barone-Rochette G, Pepin JL. Hypertension and obstructive sleep apnoea syndrome: Current perspectives. *J Hum Hypertens*. 2009;23:431-443
- 20. Dopp JM, Reichmuth KJ, Morgan BJ. Obstructive sleep apnea and hypertension: Mechanisms, evaluation, and management. *Curr Hypertens Rep.* 2007;9:529-534
- 21. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. *Hypertension*. 2007;50:417-423
- 22. Haentjens P, Van Meerhaeghe A, Moscariello A, De Weerdt S, Poppe K, Dupont A, Velkeniers B. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: Evidence from a meta-analysis of placebo-controlled randomized trials. *Arch Intern Med*. 2007;167:757-764
- 23. Duran-Cantolla J, Aizpuru F, Montserrat JM, Ballester E, Teran-Santos J, Aguirregomoscorta JI, Gonzalez M, Lloberes P, Masa JF, De La Pena M, Carrizo S, Mayos M, Barbe F. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: Randomised controlled trial. *BMJ*. 2010;341:c5991
- 24. Drager LF, Pedrosa RP, Diniz PM, Diegues-Silva L, Marcondes B, Couto RB, Giorgi DM, Krieger EM, Lorenzi-Filho G. The effects of continuous positive airway pressure on prehypertension and masked hypertension in men with severe obstructive sleep apnea. *Hypertension*. 2011;57:549-555
- 25. Lozano L, Tovar JL, Sampol G, Romero O, Jurado MJ, Segarra A, Espinel E, Rios J, Untoria MD, Lloberes P. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: A randomized, controlled trial. *J Hypertens*. 2010;28:2161-2168
- 26. Pepin JL, Tamisier R, Barone-Rochette G, Launois SH, Levy P, Baguet JP. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. *Am J Respir Crit Care Med*. 2010;182:954-960
- 27. Pickering TG. Neurovascular compression of the medulla: Can it cause neurogenic hypertension? *J Clin Hypertens (Greenwich)*. 2007;9:63-66
- 28. Bakris G, Dickholtz M, Sr., Meyer PM, Kravitz G, Avery E, Miller M, Brown J, Woodfield C, Bell B. Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: A pilot study. *J Hum Hypertens*. 2007;21:347-352
- 29. Hannuksela ML, Ellahham S. Benefits and risks of sauna bathing. *Am J Med*. 2001;110:118-126
- 30. Shin TW, Wilson M, Wilson TW. Are hot tubs safe for people with treated hypertension? *CMAJ*. 2003;169:1265-1268
- Oplander C, Volkmar CM, Paunel-Gorgulu A, van Faassen EE, Heiss C, Kelm M, Halmer D, Murtz M, Pallua N, Suschek CV. Whole body uva irradiation lowers systemic blood pressure by release of nitric oxide from intracutaneous photolabile nitric oxide derivates. *Circ Res*. 2009;105:1031-1040

- 32. Cohen DL, Townsend RR. What's in the works for refractory hypertension beyond drugs and diet? *J Clin Hypertens (Greenwich)*. 2011;13:212-213
- 33. Nahas R. Complementary and alternative medicine approaches to blood pressure reduction: An evidence-based review. *Can Fam Physician*. 2008;54:1529-1533
- 34. Woolf KJ, Bisognano JD. Nondrug interventions for treatment of hypertension. *J Clin Hypertens* (*Greenwich*). 2011;13:829-835
- 35. Desch S, Schmidt J, Kobler D, Sonnabend M, Eitel I, Sareban M, Rahimi K, Schuler G, Thiele H. Effect of cocoa products on blood pressure: Systematic review and meta-analysis. *Am J Hypertens*. 2010;23:97-103
- 36. Ried K, Sullivan T, Fakler P, Frank OR, Stocks NP. Does chocolate reduce blood pressure? A metaanalysis. *BMC Med*. 2010;8:39
- Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F, Rehman F, Arghandawi S, Pearl V, Benjamin N, Loukogeorgakis S, Macallister R, Hobbs AJ, Webb AJ, Ahluwalia A. Inorganic nitrate supplementation lowers blood pressure in humans: Role for nitrite-derived no. *Hypertension*. 2010;56:274-281
- 38. Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, Rashid R, Miall P, Deanfield J, Benjamin N, MacAllister R, Hobbs AJ, Ahluwalia A. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. *Hypertension*. 2008;51:784-790
- 39. Engberink MF, Schouten EG, Kok FJ, van Mierlo LA, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure: Results from a double-blind randomized controlled trial. *Hypertension*. 2008;51:399-405
- 40. van Mierlo LA, Koning MM, van der Zander K, Draijer R. Lactotripeptides do not lower ambulatory blood pressure in untreated whites: Results from 2 controlled multicenter crossover studies. *Am J Clin Nutr*. 2009;89:617-623

PMIDs		URL
	21502567	http://www.ncbi.nlm.nih.gov/pubmed?term=21502567
	21493732	http://www.ncbi.nlm.nih.gov/pubmed?term=21493732
	21487075	http://www.ncbi.nlm.nih.gov/pubmed?term=21487075
	21330697	http://www.ncbi.nlm.nih.gov/pubmed?term=21330697
	21219533	http://www.ncbi.nlm.nih.gov/pubmed?term=21219533
	21212051	http://www.ncbi.nlm.nih.gov/pubmed?term=21212051
	21194669	http://www.ncbi.nlm.nih.gov/pubmed?term=21194669
	21185525	http://www.ncbi.nlm.nih.gov/pubmed?term=21185525
	21168107	http://www.ncbi.nlm.nih.gov/pubmed?term=21168107
	21108620	http://www.ncbi.nlm.nih.gov/pubmed?term=21108620
	21037456	http://www.ncbi.nlm.nih.gov/pubmed?term=21037456
	21035950	http://www.ncbi.nlm.nih.gov/pubmed?term=21035950
	20954960	http://www.ncbi.nlm.nih.gov/pubmed?term=20954960
	20945159	http://www.ncbi.nlm.nih.gov/pubmed?term=20945159
	20857772	http://www.ncbi.nlm.nih.gov/pubmed?term=20857772
	20716839	http://www.ncbi.nlm.nih.gov/pubmed?term=20716839
	20585102	http://www.ncbi.nlm.nih.gov/pubmed?term=20585102
	20583377 20580284	http://www.ncbi.nlm.nih.gov/pubmed?term=20583377
	20580284 20557410	http://www.ncbi.nlm.nih.gov/pubmed?term=20580284 http://www.ncbi.nlm.nih.gov/pubmed?term=20557410
	20537410	http://www.ncbi.nlm.nih.gov/pubmed?term=20537410
	20318223	http://www.ncbi.nlm.nih.gov/pubmed?term=20318223
	20492047	http://www.ncbi.nlm.nih.gov/pubmed?term=20492047
	20404037	http://www.ncbi.nlm.nih.gov/pubmed?term=20417038
	20357497	http://www.ncbi.nlm.nih.gov/pubmed?term=20357497
	20194302	http://www.ncbi.nlm.nih.gov/pubmed?term=20194302
	20158297	http://www.ncbi.nlm.nih.gov/pubmed?term=20158297
	20090553	http://www.ncbi.nlm.nih.gov/pubmed?term=20090553
	20059570	http://www.ncbi.nlm.nih.gov/pubmed?term=20059570
	20047924	http://www.ncbi.nlm.nih.gov/pubmed?term=20047924
	20025832	http://www.ncbi.nlm.nih.gov/pubmed?term=20025832
	19954337	http://www.ncbi.nlm.nih.gov/pubmed?term=19954337
	19949851	http://www.ncbi.nlm.nih.gov/pubmed?term=19949851
	19846273	http://www.ncbi.nlm.nih.gov/pubmed?term=19846273
	19842868	http://www.ncbi.nlm.nih.gov/pubmed?term=19842868
	19822104	http://www.ncbi.nlm.nih.gov/pubmed?term=19822104
	19798037	http://www.ncbi.nlm.nih.gov/pubmed?term=19798037
	19258625	http://www.ncbi.nlm.nih.gov/pubmed?term=19258625
	19715461	http://www.ncbi.nlm.nih.gov/pubmed?term=19715461
	19574102	http://www.ncbi.nlm.nih.gov/pubmed?term=19574102
	19552057	http://www.ncbi.nlm.nih.gov/pubmed?term=19552057
	19534616	http://www.ncbi.nlm.nih.gov/pubmed?term=19534616
	19524848	http://www.ncbi.nlm.nih.gov/pubmed?term=19524848
	19486853 19471133	http://www.ncbi.nlm.nih.gov/pubmed?term=19486853 http://www.ncbi.nlm.nih.gov/pubmed?term=19471133
	19471133 19422285	http://www.ncbi.nlm.nih.gov/pubmed?term=19471133 http://www.ncbi.nlm.nih.gov/pubmed?term=19422285
	1342203	http://www.http://http://www.http://http://www.http://www.http://

19400399	http://www.ncbi.nlm.nih.gov/pubmed?term=19400399
19376750	http://www.ncbi.nlm.nih.gov/pubmed?term=19376750
19370642	http://www.ncbi.nlm.nih.gov/pubmed?term=19370642
19249921	http://www.ncbi.nlm.nih.gov/pubmed?term=19249921
19130860	http://www.ncbi.nlm.nih.gov/pubmed?term=19130860
19130855	http://www.ncbi.nlm.nih.gov/pubmed?term=19130855
19123875	http://www.ncbi.nlm.nih.gov/pubmed?term=19123875
19005120	http://www.ncbi.nlm.nih.gov/pubmed?term=19005120
19002314	http://www.ncbi.nlm.nih.gov/pubmed?term=19002314
18941131	http://www.ncbi.nlm.nih.gov/pubmed?term=18941131
18940711	http://www.ncbi.nlm.nih.gov/pubmed?term=18940711
18804330	http://www.ncbi.nlm.nih.gov/pubmed?term=18804330
18782196	http://www.ncbi.nlm.nih.gov/pubmed?term=18782196
18721084	http://www.ncbi.nlm.nih.gov/pubmed?term=18721084
18711762	http://www.ncbi.nlm.nih.gov/pubmed?term=18711762
18651193	http://www.ncbi.nlm.nih.gov/pubmed?term=18651193
18639628	http://www.ncbi.nlm.nih.gov/pubmed?term=18639628
18618236	http://www.ncbi.nlm.nih.gov/pubmed?term=18618236
18548088	http://www.ncbi.nlm.nih.gov/pubmed?term=18548088
18540144	http://www.ncbi.nlm.nih.gov/pubmed?term=18540144
18477078	http://www.ncbi.nlm.nih.gov/pubmed?term=18477078
18447091	http://www.ncbi.nlm.nih.gov/pubmed?term=18447091
18401235	http://www.ncbi.nlm.nih.gov/pubmed?term=18401235
18390974	http://www.ncbi.nlm.nih.gov/pubmed?term=18390974
18350109	http://www.ncbi.nlm.nih.gov/pubmed?term=18350109
18341229	http://www.ncbi.nlm.nih.gov/pubmed?term=18341229
18317289	http://www.ncbi.nlm.nih.gov/pubmed?term=18317289
18315510	http://www.ncbi.nlm.nih.gov/pubmed?term=18315510
18311126	http://www.ncbi.nlm.nih.gov/pubmed?term=18311126
18254065	http://www.ncbi.nlm.nih.gov/pubmed?term=18254065
18074473	http://www.ncbi.nlm.nih.gov/pubmed?term=18074473
18072392	http://www.ncbi.nlm.nih.gov/pubmed?term=18072392
18072370	http://www.ncbi.nlm.nih.gov/pubmed?term=18072370
18029960	http://www.ncbi.nlm.nih.gov/pubmed?term=18029960
18003209	http://www.ncbi.nlm.nih.gov/pubmed?term=18003209
17726407	http://www.ncbi.nlm.nih.gov/pubmed?term=17726407
17726406	http://www.ncbi.nlm.nih.gov/pubmed?term=17726406
17968296	http://www.ncbi.nlm.nih.gov/pubmed?term=17968296
17965035	http://www.ncbi.nlm.nih.gov/pubmed?term=17965035
17923653	http://www.ncbi.nlm.nih.gov/pubmed?term=17923653
17891560	http://www.ncbi.nlm.nih.gov/pubmed?term=17891560
17881186	http://www.ncbi.nlm.nih.gov/pubmed?term=17881186
17823597	http://www.ncbi.nlm.nih.gov/pubmed?term=17823597
17768459	http://www.ncbi.nlm.nih.gov/pubmed?term=17768459
17764203	http://www.ncbi.nlm.nih.gov/pubmed?term=17764203
17709061	http://www.ncbi.nlm.nih.gov/pubmed?term=17709061
17604559	http://www.ncbi.nlm.nih.gov/pubmed?term=17604559

17597249	http://www.ncbi.nlm.nih.gov/pubmed?term=17597249
17596901	http://www.ncbi.nlm.nih.gov/pubmed?term=17596901
17571741	http://www.ncbi.nlm.nih.gov/pubmed?term=17571741
17541386	http://www.ncbi.nlm.nih.gov/pubmed?term=17541386
17521871	http://www.ncbi.nlm.nih.gov/pubmed?term=17521871
17469937	http://www.ncbi.nlm.nih.gov/pubmed?term=17469937
17435356	http://www.ncbi.nlm.nih.gov/pubmed?term=17435356
17400142	http://www.ncbi.nlm.nih.gov/pubmed?term=17400142
17374121	http://www.ncbi.nlm.nih.gov/pubmed?term=17374121
17324679	http://www.ncbi.nlm.nih.gov/pubmed?term=17324679
17324047	http://www.ncbi.nlm.nih.gov/pubmed?term=17324047
17299006	http://www.ncbi.nlm.nih.gov/pubmed?term=17299006
17210835	http://www.ncbi.nlm.nih.gov/pubmed?term=17210835
17167159	http://www.ncbi.nlm.nih.gov/pubmed?term=17167159
17163086	http://www.ncbi.nlm.nih.gov/pubmed?term=17163086
17107296	http://www.ncbi.nlm.nih.gov/pubmed?term=17107296
16983600	http://www.ncbi.nlm.nih.gov/pubmed?term=16983600
16858219	http://www.ncbi.nlm.nih.gov/pubmed?term=16858219
16806478	http://www.ncbi.nlm.nih.gov/pubmed?term=16806478
16800217	http://www.ncbi.nlm.nih.gov/pubmed?term=16800217
16765850	http://www.ncbi.nlm.nih.gov/pubmed?term=16765850
16755313	http://www.ncbi.nlm.nih.gov/pubmed?term=16755313
16752104	http://www.ncbi.nlm.nih.gov/pubmed?term=16752104
16635593	http://www.ncbi.nlm.nih.gov/pubmed?term=16635593
16581115	http://www.ncbi.nlm.nih.gov/pubmed?term=16581115
16565886	http://www.ncbi.nlm.nih.gov/pubmed?term=16565886
16552946	http://www.ncbi.nlm.nih.gov/pubmed?term=16552946
16541997	http://www.ncbi.nlm.nih.gov/pubmed?term=16541997
16500773	http://www.ncbi.nlm.nih.gov/pubmed?term=16500773
16314148	http://www.ncbi.nlm.nih.gov/pubmed?term=16314148
16199412	http://www.ncbi.nlm.nih.gov/pubmed?term=16199412

PMIDs	URL
21572019	http://www.ncbi.nlm.nih.gov/pubmed?term=21572019
21534920	http://www.ncbi.nlm.nih.gov/pubmed?term=21534920
21532036	http://www.ncbi.nlm.nih.gov/pubmed?term=21532036
21494241	http://www.ncbi.nlm.nih.gov/pubmed?term=21494241
21487075	http://www.ncbi.nlm.nih.gov/pubmed?term=21487075
21410107	http://www.ncbi.nlm.nih.gov/pubmed?term=21410107
21137615	http://www.ncbi.nlm.nih.gov/pubmed?term=21137615
21133928	http://www.ncbi.nlm.nih.gov/pubmed?term=21133928
21062699	http://www.ncbi.nlm.nih.gov/pubmed?term=21062699
21037459	http://www.ncbi.nlm.nih.gov/pubmed?term=21037459
20954960	http://www.ncbi.nlm.nih.gov/pubmed?term=20954960
20921442	http://www.ncbi.nlm.nih.gov/pubmed?term=20921442
20859545	http://www.ncbi.nlm.nih.gov/pubmed?term=20859545
20857772	http://www.ncbi.nlm.nih.gov/pubmed?term=20857772
20828224	http://www.ncbi.nlm.nih.gov/pubmed?term=20828224
20821816	http://www.ncbi.nlm.nih.gov/pubmed?term=20821816
20807278	http://www.ncbi.nlm.nih.gov/pubmed?term=20807278
20798692	http://www.ncbi.nlm.nih.gov/pubmed?term=20798692
20673141	http://www.ncbi.nlm.nih.gov/pubmed?term=20673141
20634749	http://www.ncbi.nlm.nih.gov/pubmed?term=20634749
20633484	http://www.ncbi.nlm.nih.gov/pubmed?term=20633484
20626055	http://www.ncbi.nlm.nih.gov/pubmed?term=20626055
20602794	http://www.ncbi.nlm.nih.gov/pubmed?term=20602794
20590731	http://www.ncbi.nlm.nih.gov/pubmed?term=20590731
20583377	http://www.ncbi.nlm.nih.gov/pubmed?term=20583377
20520613	http://www.ncbi.nlm.nih.gov/pubmed?term=20520613
20518225	http://www.ncbi.nlm.nih.gov/pubmed?term=20518225
20429696	http://www.ncbi.nlm.nih.gov/pubmed?term=20429696
20402578	http://www.ncbi.nlm.nih.gov/pubmed?term=20402578
20369112	http://www.ncbi.nlm.nih.gov/pubmed?term=20369112
20362267	http://www.ncbi.nlm.nih.gov/pubmed?term=20362267
20351978	http://www.ncbi.nlm.nih.gov/pubmed?term=20351978
20346014	http://www.ncbi.nlm.nih.gov/pubmed?term=20346014
20232615	http://www.ncbi.nlm.nih.gov/pubmed?term=20232615
20200548	http://www.ncbi.nlm.nih.gov/pubmed?term=20200548
20184043	http://www.ncbi.nlm.nih.gov/pubmed?term=20184043
20183539	http://www.ncbi.nlm.nih.gov/pubmed?term=20183539
20160655	http://www.ncbi.nlm.nih.gov/pubmed?term=20160655
20091554	http://www.ncbi.nlm.nih.gov/pubmed?term=20091554
19954337 19938212	http://www.ncbi.nlm.nih.gov/pubmed?term=19954337 http://www.ncbi.nlm.nih.gov/pubmed?term=19938212
19938212	http://www.ncbi.nlm.nih.gov/pubmed?term=19958212
19919399	http://www.ncbi.nlm.nih.gov/pubmed?term=19919399
19716133	http://www.ncbi.nlm.nih.gov/pubmed?term=19775538
19687790	http://www.ncbi.nlm.nih.gov/pubmed?term=19710135
19666148	http://www.ncbi.nlm.nih.gov/pubmed?term=19666148
12000140	http://www.http://http://bubilled:term=15000146

19606508	http://www.ncbi.nlm.nih.gov/pubmed?term=19606508
19574102	http://www.ncbi.nlm.nih.gov/pubmed?term=19574102
19546422	http://www.ncbi.nlm.nih.gov/pubmed?term=19546422
19539385	http://www.ncbi.nlm.nih.gov/pubmed?term=19539385
19534616	http://www.ncbi.nlm.nih.gov/pubmed?term=19534616
19524848	http://www.ncbi.nlm.nih.gov/pubmed?term=19524848
19497571	http://www.ncbi.nlm.nih.gov/pubmed?term=19497571
19400528	http://www.ncbi.nlm.nih.gov/pubmed?term=19400528
19376750	http://www.ncbi.nlm.nih.gov/pubmed?term=19376750
19258571	http://www.ncbi.nlm.nih.gov/pubmed?term=19258571
19249921	http://www.ncbi.nlm.nih.gov/pubmed?term=19249921
19161949	http://www.ncbi.nlm.nih.gov/pubmed?term=19161949
19138020	http://www.ncbi.nlm.nih.gov/pubmed?term=19138020
19123875	http://www.ncbi.nlm.nih.gov/pubmed?term=19123875
19008863	http://www.ncbi.nlm.nih.gov/pubmed?term=19008863
19005477	http://www.ncbi.nlm.nih.gov/pubmed?term=19005477
19005120	http://www.ncbi.nlm.nih.gov/pubmed?term=19005120
18522783	http://www.ncbi.nlm.nih.gov/pubmed?term=18522783
18416079	http://www.ncbi.nlm.nih.gov/pubmed?term=18416079
18399759	http://www.ncbi.nlm.nih.gov/pubmed?term=18399759
18309160	http://www.ncbi.nlm.nih.gov/pubmed?term=18309160
18297751	http://www.ncbi.nlm.nih.gov/pubmed?term=18297751
18199012	http://www.ncbi.nlm.nih.gov/pubmed?term=18199012
18195178	http://www.ncbi.nlm.nih.gov/pubmed?term=18195178
18160927	http://www.ncbi.nlm.nih.gov/pubmed?term=18160927
18077936	http://www.ncbi.nlm.nih.gov/pubmed?term=18077936
18018435	http://www.ncbi.nlm.nih.gov/pubmed?term=18018435
18003209	http://www.ncbi.nlm.nih.gov/pubmed?term=18003209
17959591	http://www.ncbi.nlm.nih.gov/pubmed?term=17959591
17950182	http://www.ncbi.nlm.nih.gov/pubmed?term=17950182
17906382	http://www.ncbi.nlm.nih.gov/pubmed?term=17906382
17765644	http://www.ncbi.nlm.nih.gov/pubmed?term=17765644
17764203	http://www.ncbi.nlm.nih.gov/pubmed?term=17764203
17631256	http://www.ncbi.nlm.nih.gov/pubmed?term=17631256
17620944	http://www.ncbi.nlm.nih.gov/pubmed?term=17620944
17595599	http://www.ncbi.nlm.nih.gov/pubmed?term=17595599
17576882	http://www.ncbi.nlm.nih.gov/pubmed?term=17576882
17548730	http://www.ncbi.nlm.nih.gov/pubmed?term=17548730
17433083	http://www.ncbi.nlm.nih.gov/pubmed?term=17433083
17405694	http://www.ncbi.nlm.nih.gov/pubmed?term=17405694
17400142	http://www.ncbi.nlm.nih.gov/pubmed?term=17400142
17361530	http://www.ncbi.nlm.nih.gov/pubmed?term=17361530
17359649	http://www.ncbi.nlm.nih.gov/pubmed?term=17359649
17143197	http://www.ncbi.nlm.nih.gov/pubmed?term=17143197
17143174	http://www.ncbi.nlm.nih.gov/pubmed?term=17143174
17090803	http://www.ncbi.nlm.nih.gov/pubmed?term=17090803
17015785	http://www.ncbi.nlm.nih.gov/pubmed?term=17015785

17015784	http://www.ncbi.nlm.nih.gov/pubmed?term=17015784
16979007	http://www.ncbi.nlm.nih.gov/pubmed?term=16979007
16871826	http://www.ncbi.nlm.nih.gov/pubmed?term=16871826
16819575	http://www.ncbi.nlm.nih.gov/pubmed?term=16819575
16800217	http://www.ncbi.nlm.nih.gov/pubmed?term=16800217
16765850	http://www.ncbi.nlm.nih.gov/pubmed?term=16765850
16755149	http://www.ncbi.nlm.nih.gov/pubmed?term=16755149
16722787	http://www.ncbi.nlm.nih.gov/pubmed?term=16722787
16625616	http://www.ncbi.nlm.nih.gov/pubmed?term=16625616
16546242	http://www.ncbi.nlm.nih.gov/pubmed?term=16546242
16494570	http://www.ncbi.nlm.nih.gov/pubmed?term=16494570
16365322	http://www.ncbi.nlm.nih.gov/pubmed?term=16365322

PMIDs		URL
	22010971	http://www.ncbi.nlm.nih.gov/pubmed?term=22010971
	21972328	http://www.ncbi.nlm.nih.gov/pubmed?term=21972328
	21988649	http://www.ncbi.nlm.nih.gov/pubmed?term=21988649
	21985749	http://www.ncbi.nlm.nih.gov/pubmed?term=21985749
	21967166	http://www.ncbi.nlm.nih.gov/pubmed?term=21967166
	21966218	http://www.ncbi.nlm.nih.gov/pubmed?term=21966218
	21947813	http://www.ncbi.nlm.nih.gov/pubmed?term=21947813
	21946534	http://www.ncbi.nlm.nih.gov/pubmed?term=21946534
	21923735	http://www.ncbi.nlm.nih.gov/pubmed?term=21923735
	21896934	http://www.ncbi.nlm.nih.gov/pubmed?term=21896934
	21884616	http://www.ncbi.nlm.nih.gov/pubmed?term=21884616
	21878135	http://www.ncbi.nlm.nih.gov/pubmed?term=21878135
	21867499	http://www.ncbi.nlm.nih.gov/pubmed?term=21867499
	21833976	http://www.ncbi.nlm.nih.gov/pubmed?term=21833976
	21831004	http://www.ncbi.nlm.nih.gov/pubmed?term=21831004
	21828157	http://www.ncbi.nlm.nih.gov/pubmed?term=21828157
	21800269	http://www.ncbi.nlm.nih.gov/pubmed?term=21800269
	21793327 21791456	http://www.ncbi.nlm.nih.gov/pubmed?term=21793327
	21791456	http://www.ncbi.nlm.nih.gov/pubmed?term=21791456 http://www.ncbi.nlm.nih.gov/pubmed?term=21789889
	21789889	http://www.ncbi.nlm.nih.gov/pubmed?term=21789889
	21789392	http://www.ncbi.nlm.nih.gov/pubmed?term=21789592
	21787904	http://www.ncbi.nlm.nih.gov/pubmed?term=2178256
	21771564	http://www.ncbi.nlm.nih.gov/pubmed?term=21773230
	21751661	http://www.ncbi.nlm.nih.gov/pubmed?term=21751661
	21709071	http://www.ncbi.nlm.nih.gov/pubmed?term=21709071
	21708874	http://www.ncbi.nlm.nih.gov/pubmed?term=21708874
	21668339	http://www.ncbi.nlm.nih.gov/pubmed?term=21668339
	21697894	http://www.ncbi.nlm.nih.gov/pubmed?term=21697894
	21692322	http://www.ncbi.nlm.nih.gov/pubmed?term=21692322
	21690484	http://www.ncbi.nlm.nih.gov/pubmed?term=21690484
	21675668	http://www.ncbi.nlm.nih.gov/pubmed?term=21675668
	21663652	http://www.ncbi.nlm.nih.gov/pubmed?term=21663652
	21649862	http://www.ncbi.nlm.nih.gov/pubmed?term=21649862
	21636016	http://www.ncbi.nlm.nih.gov/pubmed?term=21636016
	21620872	http://www.ncbi.nlm.nih.gov/pubmed?term=21620872
	21608354	http://www.ncbi.nlm.nih.gov/pubmed?term=21608354
	21602474	http://www.ncbi.nlm.nih.gov/pubmed?term=21602474
	21600062	http://www.ncbi.nlm.nih.gov/pubmed?term=21600062
	21586437	http://www.ncbi.nlm.nih.gov/pubmed?term=21586437
	21572019	http://www.ncbi.nlm.nih.gov/pubmed?term=21572019
	21565479	http://www.ncbi.nlm.nih.gov/pubmed?term=21565479
	21549876	http://www.ncbi.nlm.nih.gov/pubmed?term=21549876
	21547656	http://www.ncbi.nlm.nih.gov/pubmed?term=21547656
	21540753	http://www.ncbi.nlm.nih.gov/pubmed?term=21540753
	21516959	http://www.ncbi.nlm.nih.gov/pubmed?term=21516959

21508347	http://www.ncbi.nlm.nih.gov/pubmed?term=21508347
21505612	http://www.ncbi.nlm.nih.gov/pubmed?term=21505612
21500519	http://www.ncbi.nlm.nih.gov/pubmed?term=21500519
21486813	http://www.ncbi.nlm.nih.gov/pubmed?term=21486813
21481265	http://www.ncbi.nlm.nih.gov/pubmed?term=21481265
21478777	http://www.ncbi.nlm.nih.gov/pubmed?term=21478777
21450597	http://www.ncbi.nlm.nih.gov/pubmed?term=21450597
21450580	http://www.ncbi.nlm.nih.gov/pubmed?term=21450580
21389976	http://www.ncbi.nlm.nih.gov/pubmed?term=21389976
21381320	http://www.ncbi.nlm.nih.gov/pubmed?term=21381320
21362526	http://www.ncbi.nlm.nih.gov/pubmed?term=21362526
21361811	http://www.ncbi.nlm.nih.gov/pubmed?term=21361811
21332027	http://www.ncbi.nlm.nih.gov/pubmed?term=21332027
21324150	http://www.ncbi.nlm.nih.gov/pubmed?term=21324150
21317789	http://www.ncbi.nlm.nih.gov/pubmed?term=21317789
21292602	http://www.ncbi.nlm.nih.gov/pubmed?term=21292602
21272417	http://www.ncbi.nlm.nih.gov/pubmed?term=21272417
21272196	http://www.ncbi.nlm.nih.gov/pubmed?term=21272196
21261939	http://www.ncbi.nlm.nih.gov/pubmed?term=21261939
21257979	http://www.ncbi.nlm.nih.gov/pubmed?term=21257979
21252862	http://www.ncbi.nlm.nih.gov/pubmed?term=21252862
21242555	http://www.ncbi.nlm.nih.gov/pubmed?term=21242555
21219582	http://www.ncbi.nlm.nih.gov/pubmed?term=21219582
21214718	http://www.ncbi.nlm.nih.gov/pubmed?term=21214718
21206679 21204963	http://www.ncbi.nlm.nih.gov/pubmed?term=21206679
21204903	http://www.ncbi.nlm.nih.gov/pubmed?term=21204963 http://www.ncbi.nlm.nih.gov/pubmed?term=21183531
21183531	http://www.ncbi.nlm.nih.gov/pubmed?term=21183331
211/65806	http://www.ncbi.nlm.nih.gov/pubmed?term=21178587
21165804	http://www.ncbi.nlm.nih.gov/pubmed?term=21165804
21150005	http://www.ncbi.nlm.nih.gov/pubmed?term=21150005
21143864	http://www.ncbi.nlm.nih.gov/pubmed?term=21143864
21142752	http://www.ncbi.nlm.nih.gov/pubmed?term=21142752
21135297	http://www.ncbi.nlm.nih.gov/pubmed?term=21135297
21119574	http://www.ncbi.nlm.nih.gov/pubmed?term=21119574
21088304	http://www.ncbi.nlm.nih.gov/pubmed?term=21088304
21059991	http://www.ncbi.nlm.nih.gov/pubmed?term=21059991
21059972	http://www.ncbi.nlm.nih.gov/pubmed?term=21059972
21054770	http://www.ncbi.nlm.nih.gov/pubmed?term=21054770
21049244	http://www.ncbi.nlm.nih.gov/pubmed?term=21049244
21039760	http://www.ncbi.nlm.nih.gov/pubmed?term=21039760
21033083	http://www.ncbi.nlm.nih.gov/pubmed?term=21033083
21029425	http://www.ncbi.nlm.nih.gov/pubmed?term=21029425
20979920	http://www.ncbi.nlm.nih.gov/pubmed?term=20979920
20970072	http://www.ncbi.nlm.nih.gov/pubmed?term=20970072
20954778	http://www.ncbi.nlm.nih.gov/pubmed?term=20954778
20937445	http://www.ncbi.nlm.nih.gov/pubmed?term=20937445

20936328	http://www.ncbi.nlm.nih.gov/pubmed?term=20936328
20935337	http://www.ncbi.nlm.nih.gov/pubmed?term=20935337
20929464	http://www.ncbi.nlm.nih.gov/pubmed?term=20929464
20922265	http://www.ncbi.nlm.nih.gov/pubmed?term=20922265
20878176	http://www.ncbi.nlm.nih.gov/pubmed?term=20878176
20876408	http://www.ncbi.nlm.nih.gov/pubmed?term=20876408
20863494	http://www.ncbi.nlm.nih.gov/pubmed?term=20863494
20834187	http://www.ncbi.nlm.nih.gov/pubmed?term=20834187
20826261	http://www.ncbi.nlm.nih.gov/pubmed?term=20826261
20802964	http://www.ncbi.nlm.nih.gov/pubmed?term=20802964
20798154	http://www.ncbi.nlm.nih.gov/pubmed?term=20798154
20795922	http://www.ncbi.nlm.nih.gov/pubmed?term=20795922
20730452	http://www.ncbi.nlm.nih.gov/pubmed?term=20730452
20726383	http://www.ncbi.nlm.nih.gov/pubmed?term=20726383
20720553	http://www.ncbi.nlm.nih.gov/pubmed?term=20720553
20717040	http://www.ncbi.nlm.nih.gov/pubmed?term=20717040
20716839	http://www.ncbi.nlm.nih.gov/pubmed?term=20716839
20714233	http://www.ncbi.nlm.nih.gov/pubmed?term=20714233
20708715	http://www.ncbi.nlm.nih.gov/pubmed?term=20708715
20700054	http://www.ncbi.nlm.nih.gov/pubmed?term=20700054
20663148	http://www.ncbi.nlm.nih.gov/pubmed?term=20663148
20657311	http://www.ncbi.nlm.nih.gov/pubmed?term=20657311
20650652	http://www.ncbi.nlm.nih.gov/pubmed?term=20650652
20646010	http://www.ncbi.nlm.nih.gov/pubmed?term=20646010
20644006	http://www.ncbi.nlm.nih.gov/pubmed?term=20644006
20634749	http://www.ncbi.nlm.nih.gov/pubmed?term=20634749
20634358	http://www.ncbi.nlm.nih.gov/pubmed?term=20634358
20617051	http://www.ncbi.nlm.nih.gov/pubmed?term=20617051
20610361	http://www.ncbi.nlm.nih.gov/pubmed?term=20610361
20609030	http://www.ncbi.nlm.nih.gov/pubmed?term=20609030
20592685	http://www.ncbi.nlm.nih.gov/pubmed?term=20592685
20592655	http://www.ncbi.nlm.nih.gov/pubmed?term=20592655
20574413	http://www.ncbi.nlm.nih.gov/pubmed?term=20574413
20560165	http://www.ncbi.nlm.nih.gov/pubmed?term=20560165
20557410	http://www.ncbi.nlm.nih.gov/pubmed?term=20557410
20546381	http://www.ncbi.nlm.nih.gov/pubmed?term=20546381
20544611	http://www.ncbi.nlm.nih.gov/pubmed?term=20544611
20544489	http://www.ncbi.nlm.nih.gov/pubmed?term=20544489
20530294	http://www.ncbi.nlm.nih.gov/pubmed?term=20530294
20518802	http://www.ncbi.nlm.nih.gov/pubmed?term=20518802
20513738	http://www.ncbi.nlm.nih.gov/pubmed?term=20513738
20498244	http://www.ncbi.nlm.nih.gov/pubmed?term=20498244
20485689	http://www.ncbi.nlm.nih.gov/pubmed?term=20485689
20484759	http://www.ncbi.nlm.nih.gov/pubmed?term=20484759
20467191	http://www.ncbi.nlm.nih.gov/pubmed?term=20467191
20459784	http://www.ncbi.nlm.nih.gov/pubmed?term=20459784
20459467	http://www.ncbi.nlm.nih.gov/pubmed?term=20459467

20456282	http://www.ncbi.nlm.nih.gov/pubmed?term=20456282
20448634	http://www.ncbi.nlm.nih.gov/pubmed?term=20448634
20446585	http://www.ncbi.nlm.nih.gov/pubmed?term=20446585
20437055	http://www.ncbi.nlm.nih.gov/pubmed?term=20437055
20434864	http://www.ncbi.nlm.nih.gov/pubmed?term=20434864
20428722	http://www.ncbi.nlm.nih.gov/pubmed?term=20428722
20424400	http://www.ncbi.nlm.nih.gov/pubmed?term=20424400
20424397	http://www.ncbi.nlm.nih.gov/pubmed?term=20424397
20419359	http://www.ncbi.nlm.nih.gov/pubmed?term=20419359
20416042	http://www.ncbi.nlm.nih.gov/pubmed?term=20416042
20413121	http://www.ncbi.nlm.nih.gov/pubmed?term=20413121
20386125	http://www.ncbi.nlm.nih.gov/pubmed?term=20386125
20385968	http://www.ncbi.nlm.nih.gov/pubmed?term=20385968
20383229	http://www.ncbi.nlm.nih.gov/pubmed?term=20383229
20379194	http://www.ncbi.nlm.nih.gov/pubmed?term=20379194
20375102	http://www.ncbi.nlm.nih.gov/pubmed?term=20375102
20368209	http://www.ncbi.nlm.nih.gov/pubmed?term=20368209
20367220	http://www.ncbi.nlm.nih.gov/pubmed?term=20367220
20363592	http://www.ncbi.nlm.nih.gov/pubmed?term=20363592
20360917	http://www.ncbi.nlm.nih.gov/pubmed?term=20360917
20357497	http://www.ncbi.nlm.nih.gov/pubmed?term=20357497
20332353	http://www.ncbi.nlm.nih.gov/pubmed?term=20332353
20305369	http://www.ncbi.nlm.nih.gov/pubmed?term=20305369
20305128	http://www.ncbi.nlm.nih.gov/pubmed?term=20305128
20304932	http://www.ncbi.nlm.nih.gov/pubmed?term=20304932
20232761	http://www.ncbi.nlm.nih.gov/pubmed?term=20232761
20224555	http://www.ncbi.nlm.nih.gov/pubmed?term=20224555
20216514	http://www.ncbi.nlm.nih.gov/pubmed?term=20216514
20212264	http://www.ncbi.nlm.nih.gov/pubmed?term=20212264
20210907	http://www.ncbi.nlm.nih.gov/pubmed?term=20210907
20210906	http://www.ncbi.nlm.nih.gov/pubmed?term=20210906
20203092	http://www.ncbi.nlm.nih.gov/pubmed?term=20203092
20202135	http://www.ncbi.nlm.nih.gov/pubmed?term=20202135
20200548	http://www.ncbi.nlm.nih.gov/pubmed?term=20200548
20193521	http://www.ncbi.nlm.nih.gov/pubmed?term=20193521
20187285 20185009	http://www.ncbi.nlm.nih.gov/pubmed?term=20187285
20185009	http://www.ncbi.nlm.nih.gov/pubmed?term=20185009
	http://www.ncbi.nlm.nih.gov/pubmed?term=20183539
20182455 20176771	http://www.ncbi.nlm.nih.gov/pubmed?term=20182455
20175771	http://www.ncbi.nlm.nih.gov/pubmed?term=20176771
20175014	http://www.ncbi.nlm.nih.gov/pubmed?term=20175014 http://www.ncbi.nlm.nih.gov/pubmed?term=20169360
20169560	
20167668	http://www.ncbi.nlm.nih.gov/pubmed?term=20167668 http://www.ncbi.nlm.nih.gov/pubmed?term=20165628
20103028	http://www.ncbi.nlm.nih.gov/pubmed?term=20163628
20155487	http://www.ncbi.nlm.nih.gov/pubmed?term=20150293
20130293	http://www.ncbi.nlm.nih.gov/pubmed?term=20130293
20133/30	http://www.http://infl.nifl.gov/publieu/terifi=20139790

20139661	http://www.ncbi.nlm.nih.gov/pubmed?term=20139661
20139168	http://www.ncbi.nlm.nih.gov/pubmed?term=20139168
20136857	http://www.ncbi.nlm.nih.gov/pubmed?term=20136857
20136765	http://www.ncbi.nlm.nih.gov/pubmed?term=20136765
20136764	http://www.ncbi.nlm.nih.gov/pubmed?term=20136764
20125037	http://www.ncbi.nlm.nih.gov/pubmed?term=20125037
20120125	http://www.ncbi.nlm.nih.gov/pubmed?term=20120125
20112887	http://www.ncbi.nlm.nih.gov/pubmed?term=20112887
20101007	http://www.ncbi.nlm.nih.gov/pubmed?term=20101007
20093665	http://www.ncbi.nlm.nih.gov/pubmed?term=20093665
20086201	http://www.ncbi.nlm.nih.gov/pubmed?term=20086201
20084314	http://www.ncbi.nlm.nih.gov/pubmed?term=20084314
20083615	http://www.ncbi.nlm.nih.gov/pubmed?term=20083615
20082930	http://www.ncbi.nlm.nih.gov/pubmed?term=20082930
20075849	http://www.ncbi.nlm.nih.gov/pubmed?term=20075849
20071896	http://www.ncbi.nlm.nih.gov/pubmed?term=20071896
20059368	http://www.ncbi.nlm.nih.gov/pubmed?term=20059368
20052455	http://www.ncbi.nlm.nih.gov/pubmed?term=20052455
20047924	http://www.ncbi.nlm.nih.gov/pubmed?term=20047924
20044222	http://www.ncbi.nlm.nih.gov/pubmed?term=20044222
21718583	http://www.ncbi.nlm.nih.gov/pubmed?term=21718583
20040882	http://www.ncbi.nlm.nih.gov/pubmed?term=20040882
20030546	http://www.ncbi.nlm.nih.gov/pubmed?term=20030546
20019197	http://www.ncbi.nlm.nih.gov/pubmed?term=20019197
20015524	http://www.ncbi.nlm.nih.gov/pubmed?term=20015524
20012885	http://www.ncbi.nlm.nih.gov/pubmed?term=20012885
20010427	http://www.ncbi.nlm.nih.gov/pubmed?term=20010427
20009767	http://www.ncbi.nlm.nih.gov/pubmed?term=20009767
20003224	http://www.ncbi.nlm.nih.gov/pubmed?term=20003224
19997578	http://www.ncbi.nlm.nih.gov/pubmed?term=19997578
19961024	http://www.ncbi.nlm.nih.gov/pubmed?term=19961024
19961023	http://www.ncbi.nlm.nih.gov/pubmed?term=19961023
19954321	http://www.ncbi.nlm.nih.gov/pubmed?term=19954321
19951850	http://www.ncbi.nlm.nih.gov/pubmed?term=19951850
19945929	http://www.ncbi.nlm.nih.gov/pubmed?term=19945929
19936461 19932545	http://www.ncbi.nlm.nih.gov/pubmed?term=19936461
19932343	http://www.ncbi.nlm.nih.gov/pubmed?term=19932545
19929718	http://www.ncbi.nlm.nih.gov/pubmed?term=19929718 http://www.ncbi.nlm.nih.gov/pubmed?term=19926371
19920371	http://www.ncbi.nlm.nih.gov/pubmed?term=1992046
19922040	http://www.ncbi.nlm.nih.gov/pubmed?term=19922034
19922034	http://www.ncbi.nlm.nih.gov/pubmed?term=19920081
19920081	http://www.ncbi.nlm.nih.gov/pubmed?term=19920081
19919395	http://www.ncbi.nlm.nih.gov/pubmed?term=19915859
19910222	http://www.ncbi.nlm.nih.gov/pubmed?term=1991325
19910222	http://www.ncbi.nlm.nih.gov/pubmed?term=19910222
19892055	http://www.ncbi.nlm.nih.gov/pubmed?term=19875555
17072033	neep.//www.neonann.nin.gov/publicu:terin=13632033

19860100	http://www.ncbi.nlm.nih.gov/pubmed?term=19860100
19853389	http://www.ncbi.nlm.nih.gov/pubmed?term=19853389
19844115	http://www.ncbi.nlm.nih.gov/pubmed?term=19844115
19838463	http://www.ncbi.nlm.nih.gov/pubmed?term=19838463
19837534	http://www.ncbi.nlm.nih.gov/pubmed?term=19837534
19834322	http://www.ncbi.nlm.nih.gov/pubmed?term=19834322
19833893	http://www.ncbi.nlm.nih.gov/pubmed?term=19833893
19826291	http://www.ncbi.nlm.nih.gov/pubmed?term=19826291
19819486	http://www.ncbi.nlm.nih.gov/pubmed?term=19819486
19811364	http://www.ncbi.nlm.nih.gov/pubmed?term=19811364
19809331	http://www.ncbi.nlm.nih.gov/pubmed?term=19809331
19808241	http://www.ncbi.nlm.nih.gov/pubmed?term=19808241
19793849	http://www.ncbi.nlm.nih.gov/pubmed?term=19793849
19789064	http://www.ncbi.nlm.nih.gov/pubmed?term=19789064
19786647	http://www.ncbi.nlm.nih.gov/pubmed?term=19786647
19783777	http://www.ncbi.nlm.nih.gov/pubmed?term=19783777
19771797	http://www.ncbi.nlm.nih.gov/pubmed?term=19771797
19258625	http://www.ncbi.nlm.nih.gov/pubmed?term=19258625
19767799	http://www.ncbi.nlm.nih.gov/pubmed?term=19767799
19765488	http://www.ncbi.nlm.nih.gov/pubmed?term=19765488
19762206	http://www.ncbi.nlm.nih.gov/pubmed?term=19762206
19760431	http://www.ncbi.nlm.nih.gov/pubmed?term=19760431
19754634	http://www.ncbi.nlm.nih.gov/pubmed?term=19754634
19741540	http://www.ncbi.nlm.nih.gov/pubmed?term=19741540
19730414	http://www.ncbi.nlm.nih.gov/pubmed?term=19730414
19720810	http://www.ncbi.nlm.nih.gov/pubmed?term=19720810
19713419	http://www.ncbi.nlm.nih.gov/pubmed?term=19713419
19709693	http://www.ncbi.nlm.nih.gov/pubmed?term=19709693
19706375	http://www.ncbi.nlm.nih.gov/pubmed?term=19706375
19701531	http://www.ncbi.nlm.nih.gov/pubmed?term=19701531
19680681	http://www.ncbi.nlm.nih.gov/pubmed?term=19680681
19675378	http://www.ncbi.nlm.nih.gov/pubmed?term=19675378
19654887	http://www.ncbi.nlm.nih.gov/pubmed?term=19654887
19651919	http://www.ncbi.nlm.nih.gov/pubmed?term=19651919
19634087	http://www.ncbi.nlm.nih.gov/pubmed?term=19634087
19633333 19629292	http://www.ncbi.nlm.nih.gov/pubmed?term=19633333 http://www.ncbi.nlm.nih.gov/pubmed?term=19629292
19629292	
19627291	http://www.ncbi.nlm.nih.gov/pubmed?term=19627291 http://www.ncbi.nlm.nih.gov/pubmed?term=19626520
19626520	http://www.ncbi.nlm.nih.gov/pubmed?term=19626320
19606039	http://www.ncbi.nlm.nih.gov/pubmed?term=19606039
19602539	http://www.ncbi.nlm.nih.gov/pubmed?term=19602539
19576927	http://www.ncbi.nlm.nih.gov/pubmed?term=19576927
19576927	http://www.ncbi.nlm.nih.gov/pubmed?term=195763641
19555811	http://www.ncbi.nlm.nih.gov/pubmed?term=19555811
19554346	http://www.ncbi.nlm.nih.gov/pubmed?term=19554346
19554028	http://www.ncbi.nlm.nih.gov/pubmed?term=19554028
19994020	<u>1009-77 www.ncolamin.nin.gov/publicu:tci11-15554020</u>

19552083	http://www.ncbi.nlm.nih.gov/pubmed?term=19552083
19545388	http://www.ncbi.nlm.nih.gov/pubmed?term=19545388
19544106	http://www.ncbi.nlm.nih.gov/pubmed?term=19544106
19543081	http://www.ncbi.nlm.nih.gov/pubmed?term=19543081
19534616	http://www.ncbi.nlm.nih.gov/pubmed?term=19534616
19524243	http://www.ncbi.nlm.nih.gov/pubmed?term=19524243
19523157	http://www.ncbi.nlm.nih.gov/pubmed?term=19523157
19494472	http://www.ncbi.nlm.nih.gov/pubmed?term=19494472
19517596	http://www.ncbi.nlm.nih.gov/pubmed?term=19517596
19509014	http://www.ncbi.nlm.nih.gov/pubmed?term=19509014
19509011	http://www.ncbi.nlm.nih.gov/pubmed?term=19509011
19508653	http://www.ncbi.nlm.nih.gov/pubmed?term=19508653
19505285	http://www.ncbi.nlm.nih.gov/pubmed?term=19505285
19500488	http://www.ncbi.nlm.nih.gov/pubmed?term=19500488
19495557	http://www.ncbi.nlm.nih.gov/pubmed?term=19495557
19494782	http://www.ncbi.nlm.nih.gov/pubmed?term=19494782
19487301	http://www.ncbi.nlm.nih.gov/pubmed?term=19487301
19486853	http://www.ncbi.nlm.nih.gov/pubmed?term=19486853
19486715	http://www.ncbi.nlm.nih.gov/pubmed?term=19486715
19479901	http://www.ncbi.nlm.nih.gov/pubmed?term=19479901
19473823	http://www.ncbi.nlm.nih.gov/pubmed?term=19473823
19471133	http://www.ncbi.nlm.nih.gov/pubmed?term=19471133
19462500	http://www.ncbi.nlm.nih.gov/pubmed?term=19462500
19460478	http://www.ncbi.nlm.nih.gov/pubmed?term=19460478
19454575	http://www.ncbi.nlm.nih.gov/pubmed?term=19454575
19451553	http://www.ncbi.nlm.nih.gov/pubmed?term=19451553
19450141	http://www.ncbi.nlm.nih.gov/pubmed?term=19450141
19442975	http://www.ncbi.nlm.nih.gov/pubmed?term=19442975
19432034	http://www.ncbi.nlm.nih.gov/pubmed?term=19432034
19427502	http://www.ncbi.nlm.nih.gov/pubmed?term=19427502
19417859	http://www.ncbi.nlm.nih.gov/pubmed?term=19417859
19410255	http://www.ncbi.nlm.nih.gov/pubmed?term=19410255
19404196	http://www.ncbi.nlm.nih.gov/pubmed?term=19404196
19403246	http://www.ncbi.nlm.nih.gov/pubmed?term=19403246
19397857	http://www.ncbi.nlm.nih.gov/pubmed?term=19397857
19396644	http://www.ncbi.nlm.nih.gov/pubmed?term=19396644
19390517	http://www.ncbi.nlm.nih.gov/pubmed?term=19390517
19386059	http://www.ncbi.nlm.nih.gov/pubmed?term=19386059
19385461	http://www.ncbi.nlm.nih.gov/pubmed?term=19385461
19369828	http://www.ncbi.nlm.nih.gov/pubmed?term=19369828
19366419	http://www.ncbi.nlm.nih.gov/pubmed?term=19366419
19357051	http://www.ncbi.nlm.nih.gov/pubmed?term=19357051
19353407	http://www.ncbi.nlm.nih.gov/pubmed?term=19353407
19346992	http://www.ncbi.nlm.nih.gov/pubmed?term=19346992
19346192	http://www.ncbi.nlm.nih.gov/pubmed?term=19346192
19304570	http://www.ncbi.nlm.nih.gov/pubmed?term=19304570
19302423	http://www.ncbi.nlm.nih.gov/pubmed?term=19302423

19300110	http://www.ncbi.nlm.nih.gov/pubmed?term=19300110
19290674	http://www.ncbi.nlm.nih.gov/pubmed?term=19290674
19280213	http://www.ncbi.nlm.nih.gov/pubmed?term=19280213
19274027	http://www.ncbi.nlm.nih.gov/pubmed?term=19274027
19264372	http://www.ncbi.nlm.nih.gov/pubmed?term=19264372
19256282	http://www.ncbi.nlm.nih.gov/pubmed?term=19256282
19250574	http://www.ncbi.nlm.nih.gov/pubmed?term=19250574
19245692	http://www.ncbi.nlm.nih.gov/pubmed?term=19245692
19236691	http://www.ncbi.nlm.nih.gov/pubmed?term=19236691
19227387	http://www.ncbi.nlm.nih.gov/pubmed?term=19227387
19216999	http://www.ncbi.nlm.nih.gov/pubmed?term=19216999
19208697	http://www.ncbi.nlm.nih.gov/pubmed?term=19208697
19207416	http://www.ncbi.nlm.nih.gov/pubmed?term=19207416
19204599	http://www.ncbi.nlm.nih.gov/pubmed?term=19204599
19204218	http://www.ncbi.nlm.nih.gov/pubmed?term=19204218
19202718	http://www.ncbi.nlm.nih.gov/pubmed?term=19202718
19192106	http://www.ncbi.nlm.nih.gov/pubmed?term=19192106
19188808	http://www.ncbi.nlm.nih.gov/pubmed?term=19188808
19183462	http://www.ncbi.nlm.nih.gov/pubmed?term=19183462
19178747	http://www.ncbi.nlm.nih.gov/pubmed?term=19178747
19172461	http://www.ncbi.nlm.nih.gov/pubmed?term=19172461
19170860	http://www.ncbi.nlm.nih.gov/pubmed?term=19170860
19161365	http://www.ncbi.nlm.nih.gov/pubmed?term=19161365
19157258	http://www.ncbi.nlm.nih.gov/pubmed?term=19157258
19147407	http://www.ncbi.nlm.nih.gov/pubmed?term=19147407
19145963	http://www.ncbi.nlm.nih.gov/pubmed?term=19145963
19142373	http://www.ncbi.nlm.nih.gov/pubmed?term=19142373
19132882	http://www.ncbi.nlm.nih.gov/pubmed?term=19132882
19130041	http://www.ncbi.nlm.nih.gov/pubmed?term=19130041
19122353	http://www.ncbi.nlm.nih.gov/pubmed?term=19122353
19114874	http://www.ncbi.nlm.nih.gov/pubmed?term=19114874
19114803	http://www.ncbi.nlm.nih.gov/pubmed?term=19114803
19101752 19100282	http://www.ncbi.nlm.nih.gov/pubmed?term=19101752
19100282	http://www.ncbi.nlm.nih.gov/pubmed?term=19100282 http://www.ncbi.nlm.nih.gov/pubmed?term=19098116
19098116	http://www.ncbi.nlm.nih.gov/pubmed?term=19097666
190976137	http://www.ncbi.nlm.nih.gov/pubmed?term=19076137
19062240	http://www.ncbi.nlm.nih.gov/pubmed?term=19062240
19062240	http://www.ncbi.nlm.nih.gov/pubmed?term=190602240
19000990	http://www.ncbi.nlm.nih.gov/pubmed?term=19000550
19043651	http://www.ncbi.nlm.nih.gov/pubmed?term=19043651
19022170	http://www.ncbi.nlm.nih.gov/pubmed?term=19022170
19008688	http://www.ncbi.nlm.nih.gov/pubmed?term=19022170
19005477	http://www.ncbi.nlm.nih.gov/pubmed?term=19005477
19002314	http://www.ncbi.nlm.nih.gov/pubmed?term=19002314
18996856	http://www.ncbi.nlm.nih.gov/pubmed?term=18996856
18995158	http://www.ncbi.nlm.nih.gov/pubmed?term=18995158
10555150	

http://www.ncbi.nlm.nih.gov/pubmed?term=18981938
http://www.ncbi.nlm.nih.gov/pubmed?term=18972748
http://www.ncbi.nlm.nih.gov/pubmed?term=18971545
http://www.ncbi.nlm.nih.gov/pubmed?term=18949104
http://www.ncbi.nlm.nih.gov/pubmed?term=18946484
http://www.ncbi.nlm.nih.gov/pubmed?term=18945274
http://www.ncbi.nlm.nih.gov/pubmed?term=18936731
http://www.ncbi.nlm.nih.gov/pubmed?term=18928127
http://www.ncbi.nlm.nih.gov/pubmed?term=18927266
http://www.ncbi.nlm.nih.gov/pubmed?term=18927168
http://www.ncbi.nlm.nih.gov/pubmed?term=18922983
http://www.ncbi.nlm.nih.gov/pubmed?term=18818240
http://www.ncbi.nlm.nih.gov/pubmed?term=18806611
http://www.ncbi.nlm.nih.gov/pubmed?term=18799983
http://www.ncbi.nlm.nih.gov/pubmed?term=18797405
http://www.ncbi.nlm.nih.gov/pubmed?term=18795893
http://www.ncbi.nlm.nih.gov/pubmed?term=18793562
http://www.ncbi.nlm.nih.gov/pubmed?term=18793247
http://www.ncbi.nlm.nih.gov/pubmed?term=18774947
http://www.ncbi.nlm.nih.gov/pubmed?term=18759755
http://www.ncbi.nlm.nih.gov/pubmed?term=18754275
http://www.ncbi.nlm.nih.gov/pubmed?term=18571267
http://www.ncbi.nlm.nih.gov/pubmed?term=18565222
http://www.ncbi.nlm.nih.gov/pubmed?term=18561517
http://www.ncbi.nlm.nih.gov/pubmed?term=18560801
http://www.ncbi.nlm.nih.gov/pubmed?term=18551087
http://www.ncbi.nlm.nih.gov/pubmed?term=18551008
http://www.ncbi.nlm.nih.gov/pubmed?term=18548143
http://www.ncbi.nlm.nih.gov/pubmed?term=18544158
http://www.ncbi.nlm.nih.gov/pubmed?term=18540180
http://www.ncbi.nlm.nih.gov/pubmed?term=18539917
http://www.ncbi.nlm.nih.gov/pubmed?term=18525382
http://www.ncbi.nlm.nih.gov/pubmed?term=18520719
http://www.ncbi.nlm.nih.gov/pubmed?term=18504873
http://www.ncbi.nlm.nih.gov/pubmed?term=18504447
http://www.ncbi.nlm.nih.gov/pubmed?term=18503221
http://www.ncbi.nlm.nih.gov/pubmed?term=18501444
http://www.ncbi.nlm.nih.gov/pubmed?term=18497473
http://www.ncbi.nlm.nih.gov/pubmed?term=18496321
http://www.ncbi.nlm.nih.gov/pubmed?term=18489809
http://www.ncbi.nlm.nih.gov/pubmed?term=18487001
http://www.pchi.plm.pib.gov/pubmod2torm_10400100
http://www.ncbi.nlm.nih.gov/pubmed?term=18480188
http://www.ncbi.nlm.nih.gov/pubmed?term=18474182
http://www.ncbi.nlm.nih.gov/pubmed?term=18474182 http://www.ncbi.nlm.nih.gov/pubmed?term=18463296
http://www.ncbi.nlm.nih.gov/pubmed?term=18474182 http://www.ncbi.nlm.nih.gov/pubmed?term=18463296 http://www.ncbi.nlm.nih.gov/pubmed?term=18449384
http://www.ncbi.nlm.nih.gov/pubmed?term=18474182 http://www.ncbi.nlm.nih.gov/pubmed?term=18463296

18435772	http://www.ncbi.nlm.nih.gov/pubmed?term=18435772
18434437	http://www.ncbi.nlm.nih.gov/pubmed?term=18434437
18432253	http://www.ncbi.nlm.nih.gov/pubmed?term=18432253
18430048	http://www.ncbi.nlm.nih.gov/pubmed?term=18430048
18408612	http://www.ncbi.nlm.nih.gov/pubmed?term=18408612
18405469	http://www.ncbi.nlm.nih.gov/pubmed?term=18405469
18401235	http://www.ncbi.nlm.nih.gov/pubmed?term=18401235
18401233	http://www.ncbi.nlm.nih.gov/pubmed?term=18401233
18394931	http://www.ncbi.nlm.nih.gov/pubmed?term=18394931
18391640	http://www.ncbi.nlm.nih.gov/pubmed?term=18391640
18390974	http://www.ncbi.nlm.nih.gov/pubmed?term=18390974
18388897	http://www.ncbi.nlm.nih.gov/pubmed?term=18388897
18388406	http://www.ncbi.nlm.nih.gov/pubmed?term=18388406
18379204	http://www.ncbi.nlm.nih.gov/pubmed?term=18379204
18377970	http://www.ncbi.nlm.nih.gov/pubmed?term=18377970
18341225	http://www.ncbi.nlm.nih.gov/pubmed?term=18341225
18338980	http://www.ncbi.nlm.nih.gov/pubmed?term=18338980
18248107	http://www.ncbi.nlm.nih.gov/pubmed?term=18248107
18321791	http://www.ncbi.nlm.nih.gov/pubmed?term=18321791
18319355	http://www.ncbi.nlm.nih.gov/pubmed?term=18319355
18316153	http://www.ncbi.nlm.nih.gov/pubmed?term=18316153
18300861	http://www.ncbi.nlm.nih.gov/pubmed?term=18300861
18297999	http://www.ncbi.nlm.nih.gov/pubmed?term=18297999
18297259	http://www.ncbi.nlm.nih.gov/pubmed?term=18297259
18296568	http://www.ncbi.nlm.nih.gov/pubmed?term=18296568
18254721	http://www.ncbi.nlm.nih.gov/pubmed?term=18254721
18242934	http://www.ncbi.nlm.nih.gov/pubmed?term=18242934
18241753	http://www.ncbi.nlm.nih.gov/pubmed?term=18241753
18239561 18220669	http://www.ncbi.nlm.nih.gov/pubmed?term=18239561
18220669	http://www.ncbi.nlm.nih.gov/pubmed?term=18220669 http://www.ncbi.nlm.nih.gov/pubmed?term=18213518
18209255	http://www.ncbi.nlm.nih.gov/pubmed?term=18209255
18209255	http://www.ncbi.nlm.nih.gov/pubmed?term=18209255
18199012	http://www.ncbi.nlm.nih.gov/pubmed?term=18195012
18191246	http://www.ncbi.nlm.nih.gov/pubmed?term=18197070
18191071	http://www.ncbi.nlm.nih.gov/pubmed?term=18191240
18191057	http://www.ncbi.nlm.nih.gov/pubmed?term=18191071
18175731	http://www.ncbi.nlm.nih.gov/pubmed?term=18175731
18174667	http://www.ncbi.nlm.nih.gov/pubmed?term=18174667
18164894	http://www.ncbi.nlm.nih.gov/pubmed?term=18164894
19337549	http://www.ncbi.nlm.nih.gov/pubmed?term=19337549
18091752	http://www.ncbi.nlm.nih.gov/pubmed?term=18091752
18084160	http://www.ncbi.nlm.nih.gov/pubmed?term=18084160
18079263	http://www.ncbi.nlm.nih.gov/pubmed?term=18079263
18076272	http://www.ncbi.nlm.nih.gov/pubmed?term=18076272
18072367	http://www.ncbi.nlm.nih.gov/pubmed?term=18072367
18071583	http://www.ncbi.nlm.nih.gov/pubmed?term=18071583
	,,,

•	
18070255	http://www.ncbi.nlm.nih.gov/pubmed?term=18070255
18062139	http://www.ncbi.nlm.nih.gov/pubmed?term=18062139
18061292	http://www.ncbi.nlm.nih.gov/pubmed?term=18061292
18055274	http://www.ncbi.nlm.nih.gov/pubmed?term=18055274
18050530	http://www.ncbi.nlm.nih.gov/pubmed?term=18050530
18046181	http://www.ncbi.nlm.nih.gov/pubmed?term=18046181
17968434	http://www.ncbi.nlm.nih.gov/pubmed?term=17968434
18039630	http://www.ncbi.nlm.nih.gov/pubmed?term=18039630
18029834	http://www.ncbi.nlm.nih.gov/pubmed?term=18029834
18005081	http://www.ncbi.nlm.nih.gov/pubmed?term=18005081
18000181	http://www.ncbi.nlm.nih.gov/pubmed?term=18000181
17998270	http://www.ncbi.nlm.nih.gov/pubmed?term=17998270
17992062	http://www.ncbi.nlm.nih.gov/pubmed?term=17992062
17988901	http://www.ncbi.nlm.nih.gov/pubmed?term=17988901
17986900	http://www.ncbi.nlm.nih.gov/pubmed?term=17986900
17985505	http://www.ncbi.nlm.nih.gov/pubmed?term=17985505
17981851	http://www.ncbi.nlm.nih.gov/pubmed?term=17981851
17980217	http://www.ncbi.nlm.nih.gov/pubmed?term=17980217
17978592	http://www.ncbi.nlm.nih.gov/pubmed?term=17978592
17973988	http://www.ncbi.nlm.nih.gov/pubmed?term=17973988
17971616	http://www.ncbi.nlm.nih.gov/pubmed?term=17971616
17965035	http://www.ncbi.nlm.nih.gov/pubmed?term=17965035
17964917	http://www.ncbi.nlm.nih.gov/pubmed?term=17964917
17964911	http://www.ncbi.nlm.nih.gov/pubmed?term=17964911
17947198	http://www.ncbi.nlm.nih.gov/pubmed?term=17947198
17923653	http://www.ncbi.nlm.nih.gov/pubmed?term=17923653
17908726	http://www.ncbi.nlm.nih.gov/pubmed?term=17908726
17895883	http://www.ncbi.nlm.nih.gov/pubmed?term=17895883
17890969	http://www.ncbi.nlm.nih.gov/pubmed?term=17890969
17890759	http://www.ncbi.nlm.nih.gov/pubmed?term=17890759
17885544	http://www.ncbi.nlm.nih.gov/pubmed?term=17885544
17880478	http://www.ncbi.nlm.nih.gov/pubmed?term=17880478
17877832	http://www.ncbi.nlm.nih.gov/pubmed?term=17877832
17876019	http://www.ncbi.nlm.nih.gov/pubmed?term=17876019
17876015	http://www.ncbi.nlm.nih.gov/pubmed?term=17876015
17875180	http://www.ncbi.nlm.nih.gov/pubmed?term=17875180
17872406	http://www.ncbi.nlm.nih.gov/pubmed?term=17872406
17848142	http://www.ncbi.nlm.nih.gov/pubmed?term=17848142
17823440	http://www.ncbi.nlm.nih.gov/pubmed?term=17823440
17763840	http://www.ncbi.nlm.nih.gov/pubmed?term=17763840
17763013	http://www.ncbi.nlm.nih.gov/pubmed?term=17763013
17726041	http://www.ncbi.nlm.nih.gov/pubmed?term=17726041
17711151	http://www.ncbi.nlm.nih.gov/pubmed?term=17711151
17709061	http://www.ncbi.nlm.nih.gov/pubmed?term=17709061
17703369	http://www.ncbi.nlm.nih.gov/pubmed?term=17703369
17686375	http://www.ncbi.nlm.nih.gov/pubmed?term=17686375
17680900	http://www.ncbi.nlm.nih.gov/pubmed?term=17680900

17679805	http://www.ncbi.nlm.nih.gov/pubmed?term=17679805
17679784	http://www.ncbi.nlm.nih.gov/pubmed?term=17679784
17667215	http://www.ncbi.nlm.nih.gov/pubmed?term=17667215
17667016	http://www.ncbi.nlm.nih.gov/pubmed?term=17667016
17655871	http://www.ncbi.nlm.nih.gov/pubmed?term=17655871
17644577	http://www.ncbi.nlm.nih.gov/pubmed?term=17644577
17644507	http://www.ncbi.nlm.nih.gov/pubmed?term=17644507
17643577	http://www.ncbi.nlm.nih.gov/pubmed?term=17643577
17625024	http://www.ncbi.nlm.nih.gov/pubmed?term=17625024
17622289	http://www.ncbi.nlm.nih.gov/pubmed?term=17622289
17622279	http://www.ncbi.nlm.nih.gov/pubmed?term=17622279
17620944	http://www.ncbi.nlm.nih.gov/pubmed?term=17620944
17615478	http://www.ncbi.nlm.nih.gov/pubmed?term=17615478
17606862	http://www.ncbi.nlm.nih.gov/pubmed?term=17606862
17605959	http://www.ncbi.nlm.nih.gov/pubmed?term=17605959
17599444	http://www.ncbi.nlm.nih.gov/pubmed?term=17599444
17598651	http://www.ncbi.nlm.nih.gov/pubmed?term=17598651
17595387	http://www.ncbi.nlm.nih.gov/pubmed?term=17595387
17592073	http://www.ncbi.nlm.nih.gov/pubmed?term=17592073
17589282	http://www.ncbi.nlm.nih.gov/pubmed?term=17589282
17588824	http://www.ncbi.nlm.nih.gov/pubmed?term=17588824
17584423	http://www.ncbi.nlm.nih.gov/pubmed?term=17584423
17582616	http://www.ncbi.nlm.nih.gov/pubmed?term=17582616
17575470	http://www.ncbi.nlm.nih.gov/pubmed?term=17575470
17571741	http://www.ncbi.nlm.nih.gov/pubmed?term=17571741
17568252	http://www.ncbi.nlm.nih.gov/pubmed?term=17568252
17558191	http://www.ncbi.nlm.nih.gov/pubmed?term=17558191
17557919	http://www.ncbi.nlm.nih.gov/pubmed?term=17557919
17555385	http://www.ncbi.nlm.nih.gov/pubmed?term=17555385
17554399	http://www.ncbi.nlm.nih.gov/pubmed?term=17554399
17554161	http://www.ncbi.nlm.nih.gov/pubmed?term=17554161
17545881	http://www.ncbi.nlm.nih.gov/pubmed?term=17545881
17543684 17534460	http://www.ncbi.nlm.nih.gov/pubmed?term=17543684
17534460	http://www.ncbi.nlm.nih.gov/pubmed?term=17534460 http://www.ncbi.nlm.nih.gov/pubmed?term=17531926
17526374	http://www.ncbi.nlm.nih.gov/pubmed?term=17526374
17516849	http://www.ncbi.nlm.nih.gov/pubmed?term=17516849
17513578	http://www.ncbi.nlm.nih.gov/pubmed?term=17513578
17507344	http://www.ncbi.nlm.nih.gov/pubmed?term=17513578
17506866	http://www.ncbi.nlm.nih.gov/pubmed?term=17506866
17505730	http://www.ncbi.nlm.nih.gov/pubmed?term=17505730
17496216	http://www.ncbi.nlm.nih.gov/pubmed?term=17496216
17490210	http://www.ncbi.nlm.nih.gov/pubmed?term=17490962
17490902	http://www.ncbi.nlm.nih.gov/pubmed?term=17490955
17490955	http://www.ncbi.nlm.nih.gov/pubmed?term=17488145
17486167	http://www.ncbi.nlm.nih.gov/pubmed?term=17488145
17483103	http://www.ncbi.nlm.nih.gov/pubmed?term=17483103
1, 103103	http://www.heshininingov/publicu:term=1/405105

17477091	http://www.ncbi.nlm.nih.gov/pubmed?term=17477091
17477082	http://www.ncbi.nlm.nih.gov/pubmed?term=17477082
17475552	http://www.ncbi.nlm.nih.gov/pubmed?term=17475552
17475317	http://www.ncbi.nlm.nih.gov/pubmed?term=17475317
17460713	http://www.ncbi.nlm.nih.gov/pubmed?term=17460713
17455121	http://www.ncbi.nlm.nih.gov/pubmed?term=17455121
17453749	http://www.ncbi.nlm.nih.gov/pubmed?term=17453749
17446819	http://www.ncbi.nlm.nih.gov/pubmed?term=17446819
17445931	http://www.ncbi.nlm.nih.gov/pubmed?term=17445931
17438307	http://www.ncbi.nlm.nih.gov/pubmed?term=17438307
17436821	http://www.ncbi.nlm.nih.gov/pubmed?term=17436821
17425061	http://www.ncbi.nlm.nih.gov/pubmed?term=17425061
17420669	http://www.ncbi.nlm.nih.gov/pubmed?term=17420669
17406886	http://www.ncbi.nlm.nih.gov/pubmed?term=17406886
17405586	http://www.ncbi.nlm.nih.gov/pubmed?term=17405586
17405564	http://www.ncbi.nlm.nih.gov/pubmed?term=17405564
17394732	http://www.ncbi.nlm.nih.gov/pubmed?term=17394732
17394009	http://www.ncbi.nlm.nih.gov/pubmed?term=17394009
17392129	http://www.ncbi.nlm.nih.gov/pubmed?term=17392129
17377073	http://www.ncbi.nlm.nih.gov/pubmed?term=17377073
17371512	http://www.ncbi.nlm.nih.gov/pubmed?term=17371512
17363746	http://www.ncbi.nlm.nih.gov/pubmed?term=17363746
17363049	http://www.ncbi.nlm.nih.gov/pubmed?term=17363049
17353883	http://www.ncbi.nlm.nih.gov/pubmed?term=17353883
17342166	http://www.ncbi.nlm.nih.gov/pubmed?term=17342166
17332789	http://www.ncbi.nlm.nih.gov/pubmed?term=17332789
17330056	http://www.ncbi.nlm.nih.gov/pubmed?term=17330056
17327140	http://www.ncbi.nlm.nih.gov/pubmed?term=17327140
17319488	http://www.ncbi.nlm.nih.gov/pubmed?term=17319488
17319462	http://www.ncbi.nlm.nih.gov/pubmed?term=17319462
17318036	http://www.ncbi.nlm.nih.gov/pubmed?term=17318036
17301622	http://www.ncbi.nlm.nih.gov/pubmed?term=17301622
17277240	http://www.ncbi.nlm.nih.gov/pubmed?term=17277240
17275896	http://www.ncbi.nlm.nih.gov/pubmed?term=17275896
17270528	http://www.ncbi.nlm.nih.gov/pubmed?term=17270528
17268786	http://www.ncbi.nlm.nih.gov/pubmed?term=17268786
17264187	http://www.ncbi.nlm.nih.gov/pubmed?term=17264187
17263714	http://www.ncbi.nlm.nih.gov/pubmed?term=17263714
17263170	http://www.ncbi.nlm.nih.gov/pubmed?term=17263170
17258823	http://www.ncbi.nlm.nih.gov/pubmed?term=17258823
17224469	http://www.ncbi.nlm.nih.gov/pubmed?term=17224469
17223718	http://www.ncbi.nlm.nih.gov/pubmed?term=17223718
17223076	http://www.ncbi.nlm.nih.gov/pubmed?term=17223076
17221105	http://www.ncbi.nlm.nih.gov/pubmed?term=17221105
17220161	http://www.ncbi.nlm.nih.gov/pubmed?term=17220161
17219171	http://www.ncbi.nlm.nih.gov/pubmed?term=17219171
17213880	http://www.ncbi.nlm.nih.gov/pubmed?term=17213880

17211236	http://www.ncbi.nlm.nih.gov/pubmed?term=17211236
17208119	http://www.ncbi.nlm.nih.gov/pubmed?term=17208119
17195607	http://www.ncbi.nlm.nih.gov/pubmed?term=17195607
19454044	http://www.ncbi.nlm.nih.gov/pubmed?term=19454044
19377540	http://www.ncbi.nlm.nih.gov/pubmed?term=19377540
17173503	http://www.ncbi.nlm.nih.gov/pubmed?term=17173503
17171833	http://www.ncbi.nlm.nih.gov/pubmed?term=17171833
17163086	http://www.ncbi.nlm.nih.gov/pubmed?term=17163086
17158411	http://www.ncbi.nlm.nih.gov/pubmed?term=17158411
17156462	http://www.ncbi.nlm.nih.gov/pubmed?term=17156462
17152246	http://www.ncbi.nlm.nih.gov/pubmed?term=17152246
17147514	http://www.ncbi.nlm.nih.gov/pubmed?term=17147514
17144551	http://www.ncbi.nlm.nih.gov/pubmed?term=17144551
17144438	http://www.ncbi.nlm.nih.gov/pubmed?term=17144438
17142523	http://www.ncbi.nlm.nih.gov/pubmed?term=17142523
17140398	http://www.ncbi.nlm.nih.gov/pubmed?term=17140398
17136940	http://www.ncbi.nlm.nih.gov/pubmed?term=17136940
17106718	http://www.ncbi.nlm.nih.gov/pubmed?term=17106718
17090803	http://www.ncbi.nlm.nih.gov/pubmed?term=17090803
17090361	http://www.ncbi.nlm.nih.gov/pubmed?term=17090361
17087300	http://www.ncbi.nlm.nih.gov/pubmed?term=17087300
17084264	http://www.ncbi.nlm.nih.gov/pubmed?term=17084264
17082376	http://www.ncbi.nlm.nih.gov/pubmed?term=17082376
17064330	http://www.ncbi.nlm.nih.gov/pubmed?term=17064330
17059793	http://www.ncbi.nlm.nih.gov/pubmed?term=17059793
17055561	http://www.ncbi.nlm.nih.gov/pubmed?term=17055561
17036183 17036180	http://www.ncbi.nlm.nih.gov/pubmed?term=17036183
	http://www.ncbi.nlm.nih.gov/pubmed?term=17036180
17030958 17017491	http://www.ncbi.nlm.nih.gov/pubmed?term=17030958 http://www.ncbi.nlm.nih.gov/pubmed?term=17017491
17017491	http://www.ncbi.nlm.nih.gov/pubmed?term=17017451
17017423	http://www.ncbi.nlm.nih.gov/pubmed?term=17017423
17013802	http://www.ncbi.nlm.nih.gov/pubmed?term=17013802
17009057	http://www.ncbi.nlm.nih.gov/pubmed?term=17092775
17008598	http://www.ncbi.nlm.nih.gov/pubmed?term=17008598
17008074	http://www.ncbi.nlm.nih.gov/pubmed?term=17008074
17003602	http://www.ncbi.nlm.nih.gov/pubmed?term=17003602
17001223	http://www.ncbi.nlm.nih.gov/pubmed?term=17001223
16990155	http://www.ncbi.nlm.nih.gov/pubmed?term=16990155
16984699	http://www.ncbi.nlm.nih.gov/pubmed?term=16984699
16983780	http://www.ncbi.nlm.nih.gov/pubmed?term=16983780
16983773	http://www.ncbi.nlm.nih.gov/pubmed?term=16983773
16983771	http://www.ncbi.nlm.nih.gov/pubmed?term=16983771
16982941	http://www.ncbi.nlm.nih.gov/pubmed?term=16982941
16981587	http://www.ncbi.nlm.nih.gov/pubmed?term=16981587
16981549	http://www.ncbi.nlm.nih.gov/pubmed?term=16981549
16981545	http://www.ncbi.nlm.nih.gov/pubmed?term=16981545

•	
16981383	http://www.ncbi.nlm.nih.gov/pubmed?term=16981383
16979021	http://www.ncbi.nlm.nih.gov/pubmed?term=16979021
16966927	http://www.ncbi.nlm.nih.gov/pubmed?term=16966927
16966926	http://www.ncbi.nlm.nih.gov/pubmed?term=16966926
16961681	http://www.ncbi.nlm.nih.gov/pubmed?term=16961681
16959725	http://www.ncbi.nlm.nih.gov/pubmed?term=16959725
16951900	http://www.ncbi.nlm.nih.gov/pubmed?term=16951900
16937604	http://www.ncbi.nlm.nih.gov/pubmed?term=16937604
16937603	http://www.ncbi.nlm.nih.gov/pubmed?term=16937603
16926374	http://www.ncbi.nlm.nih.gov/pubmed?term=16926374
16925851	http://www.ncbi.nlm.nih.gov/pubmed?term=16925851
16924526	http://www.ncbi.nlm.nih.gov/pubmed?term=16924526
16922820	http://www.ncbi.nlm.nih.gov/pubmed?term=16922820
16915025	http://www.ncbi.nlm.nih.gov/pubmed?term=16915025
16907703	http://www.ncbi.nlm.nih.gov/pubmed?term=16907703
16906660	http://www.ncbi.nlm.nih.gov/pubmed?term=16906660
16905831	http://www.ncbi.nlm.nih.gov/pubmed?term=16905831
16904861	http://www.ncbi.nlm.nih.gov/pubmed?term=16904861
16896732	http://www.ncbi.nlm.nih.gov/pubmed?term=16896732
16896730	http://www.ncbi.nlm.nih.gov/pubmed?term=16896730
16891758	http://www.ncbi.nlm.nih.gov/pubmed?term=16891758
16884659	http://www.ncbi.nlm.nih.gov/pubmed?term=16884659
16875724	http://www.ncbi.nlm.nih.gov/pubmed?term=16875724
16863667	http://www.ncbi.nlm.nih.gov/pubmed?term=16863667
16861054	http://www.ncbi.nlm.nih.gov/pubmed?term=16861054
16860699	http://www.ncbi.nlm.nih.gov/pubmed?term=16860699
16860272	http://www.ncbi.nlm.nih.gov/pubmed?term=16860272
16858219	http://www.ncbi.nlm.nih.gov/pubmed?term=16858219
16845224	http://www.ncbi.nlm.nih.gov/pubmed?term=16845224
16842977	http://www.ncbi.nlm.nih.gov/pubmed?term=16842977
16840826	http://www.ncbi.nlm.nih.gov/pubmed?term=16840826
16840576	http://www.ncbi.nlm.nih.gov/pubmed?term=16840576
16839841	http://www.ncbi.nlm.nih.gov/pubmed?term=16839841
16823284	http://www.ncbi.nlm.nih.gov/pubmed?term=16823284
16823250	http://www.ncbi.nlm.nih.gov/pubmed?term=16823250
16823240 16814119	http://www.ncbi.nlm.nih.gov/pubmed?term=16823240
16814119	http://www.ncbi.nlm.nih.gov/pubmed?term=16814119 http://www.ncbi.nlm.nih.gov/pubmed?term=16810473
16810473	http://www.ncbi.nlm.nih.gov/pubmed?term=16810475
16810418	http://www.ncbi.nlm.nih.gov/pubmed?term=16810028
16807483	http://www.ncbi.nlm.nih.gov/pubmed?term=16807483
16801564	http://www.ncbi.nlm.nih.gov/pubmed?term=16801564
16798766	http://www.ncbi.nlm.nih.gov/pubmed?term=16798766
16796174	http://www.ncbi.nlm.nih.gov/pubmed?term=16796174
16790207	http://www.ncbi.nlm.nih.gov/pubmed?term=16790207
16788710	http://www.ncbi.nlm.nih.gov/pubmed?term=16788710
16784957	http://www.ncbi.nlm.nih.gov/pubmed?term=16784957
10104001	neep.//www.neonann.nnn.gov/publicu:terin=10/04557

16781245	http://www.ncbi.nlm.nih.gov/pubmed?term=16781245
16772327	http://www.ncbi.nlm.nih.gov/pubmed?term=16772327
16762931	http://www.ncbi.nlm.nih.gov/pubmed?term=16762931
16755313	http://www.ncbi.nlm.nih.gov/pubmed?term=16755313
16755194	http://www.ncbi.nlm.nih.gov/pubmed?term=16755194
16754702	http://www.ncbi.nlm.nih.gov/pubmed?term=16754702
16751820	http://www.ncbi.nlm.nih.gov/pubmed?term=16751820
16732011	http://www.ncbi.nlm.nih.gov/pubmed?term=16732011
16722787	http://www.ncbi.nlm.nih.gov/pubmed?term=16722787
16716211	http://www.ncbi.nlm.nih.gov/pubmed?term=16716211
16706569	http://www.ncbi.nlm.nih.gov/pubmed?term=16706569
16699361	http://www.ncbi.nlm.nih.gov/pubmed?term=16699361
16698320	http://www.ncbi.nlm.nih.gov/pubmed?term=16698320
16687420	http://www.ncbi.nlm.nih.gov/pubmed?term=16687420
16672855	http://www.ncbi.nlm.nih.gov/pubmed?term=16672855
16672837	http://www.ncbi.nlm.nih.gov/pubmed?term=16672837
16672836	http://www.ncbi.nlm.nih.gov/pubmed?term=16672836
16648182	http://www.ncbi.nlm.nih.gov/pubmed?term=16648182
16637784	http://www.ncbi.nlm.nih.gov/pubmed?term=16637784
16635772	http://www.ncbi.nlm.nih.gov/pubmed?term=16635772
16635203	http://www.ncbi.nlm.nih.gov/pubmed?term=16635203
16625645	http://www.ncbi.nlm.nih.gov/pubmed?term=16625645
16625235	http://www.ncbi.nlm.nih.gov/pubmed?term=16625235
16601623	http://www.ncbi.nlm.nih.gov/pubmed?term=16601623
16598537	http://www.ncbi.nlm.nih.gov/pubmed?term=16598537
16585662	http://www.ncbi.nlm.nih.gov/pubmed?term=16585662
16585657	http://www.ncbi.nlm.nih.gov/pubmed?term=16585657
19462544	http://www.ncbi.nlm.nih.gov/pubmed?term=19462544
16567564 16565627	http://www.ncbi.nlm.nih.gov/pubmed?term=16567564
16552288	http://www.ncbi.nlm.nih.gov/pubmed?term=16565627 http://www.ncbi.nlm.nih.gov/pubmed?term=16552288
16552288	http://www.ncbi.nlm.nih.gov/pubmed?term=16552288
16539167	http://www.ncbi.nlm.nih.gov/pubmed?term=16539167
16537099	http://www.ncbi.nlm.nih.gov/pubmed?term=16537099
16531784	http://www.ncbi.nlm.nih.gov/pubmed?term=16531784
16522995	http://www.ncbi.nlm.nih.gov/pubmed?term=16522995
16513674	http://www.ncbi.nlm.nih.gov/pubmed?term=16522555
16509421	http://www.ncbi.nlm.nih.gov/pubmed?term=16509421
16508577	http://www.ncbi.nlm.nih.gov/pubmed?term=16508577
16508562	http://www.ncbi.nlm.nih.gov/pubmed?term=16508562
16506860	http://www.ncbi.nlm.nih.gov/pubmed?term=16506860
16505579	http://www.ncbi.nlm.nih.gov/pubmed?term=16505579
16504463	http://www.ncbi.nlm.nih.gov/pubmed?term=16504463
16500512	http://www.ncbi.nlm.nih.gov/pubmed?term=16500512
16487847	http://www.ncbi.nlm.nih.gov/pubmed?term=16487847
16478899	http://www.ncbi.nlm.nih.gov/pubmed?term=16478899
16468060	http://www.ncbi.nlm.nih.gov/pubmed?term=16468060

16467407	http://www.ncbi.nlm.nih.gov/pubmed?term=16467407
16455437	http://www.ncbi.nlm.nih.gov/pubmed?term=16455437
16453054	http://www.ncbi.nlm.nih.gov/pubmed?term=16453054
16448882	http://www.ncbi.nlm.nih.gov/pubmed?term=16448882
16448881	http://www.ncbi.nlm.nih.gov/pubmed?term=16448881
16431851	http://www.ncbi.nlm.nih.gov/pubmed?term=16431851
16431183	http://www.ncbi.nlm.nih.gov/pubmed?term=16431183
16428924	http://www.ncbi.nlm.nih.gov/pubmed?term=16428924
16413880	http://www.ncbi.nlm.nih.gov/pubmed?term=16413880
16388774	http://www.ncbi.nlm.nih.gov/pubmed?term=16388774
16377300	http://www.ncbi.nlm.nih.gov/pubmed?term=16377300
16376979	http://www.ncbi.nlm.nih.gov/pubmed?term=16376979
16371486	http://www.ncbi.nlm.nih.gov/pubmed?term=16371486
16362400	http://www.ncbi.nlm.nih.gov/pubmed?term=16362400
16356358	http://www.ncbi.nlm.nih.gov/pubmed?term=16356358
16352667	http://www.ncbi.nlm.nih.gov/pubmed?term=16352667
16324931	http://www.ncbi.nlm.nih.gov/pubmed?term=16324931
16314148	http://www.ncbi.nlm.nih.gov/pubmed?term=16314148
16308413	http://www.ncbi.nlm.nih.gov/pubmed?term=16308413
16046219	http://www.ncbi.nlm.nih.gov/pubmed?term=16046219
16005099	http://www.ncbi.nlm.nih.gov/pubmed?term=16005099
15979232	http://www.ncbi.nlm.nih.gov/pubmed?term=15979232